



(51) International Patent Classification:

A61K 39/395 (2006.01) *A61K 9/08* (2006.01)
A61K 9/00 (2006.01) *C07K 16/24* (2006.01)

(21) International Application Number:

PCT/US2017/067723

(22) International Filing Date:

20 December 2017 (20.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/437,640 21 December 2016 (21.12.2016) US

(71) Applicant: AMGEN INC. [US/US]; ONE AMGEN CENTER DRIVE, THOUSAND OAKS, California 91320-1799 (US).

(72) Inventors: CALLAHAN, William J.; 1104 Woodridge Avenue, Thousand Oaks, California 91362 (US). KAUSHIK, Rahul Rajan; 786 Via Donte, Newbury Park, California 91320 (US). BRENNAN, Joy; 467 Erbes Road, Thousand Oaks, California 91362 (US).


(74) Agent: SCOTT, Derek B.; AMGEN INC., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-TNF ALPHA ANTIBODY FORMULATIONS

FIG. 1



(57) Abstract: Stable adalimumab formulations are disclosed.

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

ANTI-TNF ALPHA ANTIBODY FORMULATIONS

REFERENCE TO PRIOR APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62/437,640, filed December 21, 2016, which is hereby incorporated by reference.

[0002] The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled A-2102-WO-PCT_SeqListing_122017.txt, created December 19, 2017, which is 8kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

BACKGROUND

[0003] Elevated levels of tumor necrosis factor alpha (TNF α) have been associated with a number of human disorders such as arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, intestinal Behçet's disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, Pyoderma Gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthma. TNF α inhibitors are frequently used to treat these disorders. One such inhibitor is adalimumab, also known as D2E7, a recombinant human IgG1 monoclonal antibody specific for human TNF α .

SUMMARY

[0004] The present disclosure is directed to stable aqueous adalimumab formulations, to methods of making stable aqueous adalimumab formulations, to use of a formulation as disclosed herein, and to methods of treating a disease comprising administering to a patient a formulation as disclosed herein.

[0005] In one aspect, the disclosure includes a stable aqueous formulation comprising about 180 mg/mL adalimumab, about 20 mM glutamate, and about 160 mM monoethanolamine (MEA), wherein the formulation has a pH of about 5.2, and demonstrates less than about a 2.1-fold increase in acidic species as measured by cation-exchange high-performance liquid chromatography (CEX-HPLC) after storage for 28 days at 40°C.

[0006] In another aspect, the disclosure provides a stable adalimumab formulation as described in the Tables provided herein. In some aspects, the stable adalimumab formulation provided herein demonstrates one or more of the following parameters: (i) less than about a 2.1-fold increase in acidic species, as measured by cation-exchange high-performance liquid chromatography (CEX-HPLC) after storage for 28 days at 40°C; (ii) less than about a 5-fold increase in high molecular weight species (HMWS) species, as measured by size-exclusion chromatography (SE-HPLC) after storage for 28 days at 40°C; and/or (iii) less than about 500 nephelometric turbidity units (NTUs) after stirring at room temperature for 5 days.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] FIG. 1 is a bar graph of stability of adalimumab formulations as determined by cation-exchange high-performance liquid chromatography (CEX-HPLC).

[0008] FIG. 2 is a bar graph of stability of adalimumab formulations as determined by size-exclusion high-performance liquid chromatography (SE-HPLC).

[0009] FIG. 3 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.

[0010] FIG. 4 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.

[0011] FIG. 5 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.

[0012] FIG. 6 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.

[0013] FIG. 7 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.

[0014] FIG. 8 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC. The symbol “...” indicates a value above the maximum shown on the y-axis.

[0015] FIG. 9 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.

[0016] FIG. 10 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.

[0017] FIG. 11 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.

- [0018] FIG. 12 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0019] FIG. 13 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0020] FIG. 14 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0021] FIG. 15 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0022] FIG. 16 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0023] FIG. 17 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0024] FIG. 18 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0025] FIG. 19 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0026] FIG. 20 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0027] FIG. 21 is a bar graph of stability of adalimumab formulations as determined by opalescence measurement.
- [0028] FIG. 22 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0029] FIG. 23 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0030] FIG. 24 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0031] FIG. 25 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0032] FIG. 26 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.

- [0033] FIG. 27 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0034] FIG. 28 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0035] FIG. 29 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0036] FIG. 30 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0037] FIG. 31 is a bar graph of stability of adalimumab formulations as determined by micro-flow imaging (MFI).
- [0038] FIG. 32 is a bar graph of stability of adalimumab formulations as determined by MFI. The symbol “...” indicates a value above the maximum shown on the y-axis.
- [0039] FIG. 33 is a bar graph of stability of adalimumab formulations as determined by MFI.
- [0040] FIG. 34 is a bar graph of stability of adalimumab formulations as determined by MFI. The symbol “...” indicates a value above the maximum shown on the y-axis.
- [0041] FIG. 35 is a bar graph of stability of adalimumab formulations as determined by MFI.
- [0042] FIG. 36 is a bar graph of stability of adalimumab formulations as determined by MFI. The symbol “...” indicates a value above the maximum shown on the y-axis.
- [0043] FIG. 37 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0044] FIG. 38 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0045] FIG. 39 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0046] FIG. 40 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0047] FIG. 41 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0048] FIG. 42 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.

- [0049] FIG. 43 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0050] FIG. 44 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0051] FIG. 45 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0052] FIG. 46 is a bar graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0053] FIG. 47 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0054] FIG. 48 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0055] FIG. 49 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0056] FIG. 50 is a bar graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0057] FIG. 51 is a line graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0058] FIG. 52 is a line graph of stability of adalimumab formulations as determined by CEX-HPLC.
- [0059] FIG. 53 is a line graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0060] FIG. 54 is a line graph of stability of adalimumab formulations as determined by SE-HPLC.
- [0061] FIG. 55 is a bar graph of stability of adalimumab formulations as determined by MFI.
- [0062] FIG. 56 is a bar graph of stability of adalimumab formulations as determined by MFI.
- [0063] FIG. 57 is a bar graph of stability of adalimumab formulations as determined by MFI.
- [0064] FIG. 58 is a bar graph of stability of adalimumab formulations (non-transport at 4°C) as determined by CEX-HPLC.
- [0065] FIG. 59 is a bar graph of stability of adalimumab formulations (transport at 4°C) as determined by CEX-HPLC.

[0066] FIG. 60 is a bar graph of stability of adalimumab formulations (non-transport at 25°C) as determined by CEX-HPLC.

[0067] FIG. 61 is a bar graph of stability of adalimumab formulations (transport at 25°C) as determined by CEX-HPLC.

[0068] FIG. 62 is a bar graph of stability of adalimumab formulations (non-transport at 40°C) as determined by CEX-HPLC.

[0069] FIG. 63 is a bar graph of stability of adalimumab formulations (transport at 40°C) as determined by CEX-HPLC.

[0070] FIG. 64 is a bar graph of stability of adalimumab formulations (non-transport at 4°C) as determined by SE-HPLC.

[0071] FIG. 65 is a bar graph of stability of adalimumab formulations (transport at 4°C) as determined by SE-HPLC.

[0072] FIG. 66 is a bar graph of stability of adalimumab formulations (non-transport at 25°C) as determined by SE-HPLC.

[0073] FIG. 67 is a bar graph of stability of adalimumab formulations (transport at 25°C) as determined by SE-HPLC.

[0074] FIG. 68 is a bar graph of stability of adalimumab formulations (non-transport at 40°C) as determined by SE-HPLC.

[0075] FIG. 69 is a bar graph of stability of adalimumab formulations (transport at 40°C) as determined by SE-HPLC.

[0076] FIGs. 70A-B are a bar graph of stability of adalimumab formulations as determined by MFI. FIG. 70B is the same data presented in FIG. 70A but graphed at a different scale.

[0077] FIGs. 71A-B are a bar graph of stability of adalimumab formulations as determined by MFI. FIG. 71B is the same data presented in FIG. 71A but graphed at a different scale.

[0078] FIGs. 72A-B are a bar graph of stability of adalimumab formulations as determined by determined by MFI. FIG. 72B is the same data presented in FIG. 72A but graphed at a different scale.

[0079] FIG. 73 is a bar graph of stability of adalimumab formulations (non-transport at 4°C) as determined by CEX-HPLC.

[0080] FIG. 74 is a bar graph of stability of adalimumab formulations (transport at 4°C) as determined by CEX-HPLC.

[0081] FIG. 75 is a bar graph of stability of adalimumab formulations (non-transport at 25°C) as determined by CEX-HPLC.

[0082] FIG. 76 is a bar graph of stability of adalimumab formulations (transport at 25°C) as determined by CEX-HPLC.

[0083] FIG. 77 is a bar graph of stability of adalimumab formulations as (non-transport at 40°C) determined by CEX-HPLC.

[0084] FIG. 78 is a bar graph of stability of adalimumab formulations (transport at 40°C) as determined by CEX-HPLC.

[0085] FIG. 79 is a bar graph of stability of adalimumab formulations (non-transport at 4°C) as determined by SE-HPLC.

[0086] FIG. 80 is a bar graph of stability of adalimumab formulations (transport at 4°C) as determined by SE-HPLC.

[0087] FIG. 81 is a bar graph of stability of adalimumab formulations (non-transport at 25°C) as determined by SE-HPLC.

[0088] FIG. 82 is a bar graph of stability of adalimumab formulations (transport at 25°C) as determined by SE-HPLC.

[0089] FIG. 83 is a bar graph of stability of adalimumab formulations (non-transport at 40°C) as determined by SE-HPLC.

[0090] FIG. 84 is a bar graph of stability of adalimumab formulations (transport at 40°C) as determined by SE-HPLC.

[0091] FIG. 85 is a bar graph of stability of adalimumab formulations as determined by MFI.

[0092] FIG. 86 is a bar graph of stability of adalimumab formulations as determined by MFI.

[0093] FIG. 87 is a bar graph of stability of adalimumab formulations as determined by MFI.

DETAILED DESCRIPTION

[0094] The present disclosure provides stable aqueous adalimumab formulations and related methods of making stable aqueous adalimumab formulations. Also provided are lyophilized forms of the aqueous adalimumab formulations disclosed herein. The present disclosure also provides related uses of the formulations disclosed herein and related methods of administering these formulations to treat diseases such as arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel

disease, Crohn's disease, ulcerative colitis, intestinal Behçet's disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, Pyoderma Gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthma.

[0095] The stable aqueous adalimumab formulations include adalimumab and one or more excipients selected such that the formulation demonstrates characteristics suitable for use as a pharmaceutical composition. A formulation suitable for use as a pharmaceutical composition generally exhibits a low amount of high molecular weight species (HMWS), such as aggregates and dimers, and/or also exhibits a low degree of oxidation over time. For example, a suitable adalimumab formulation may exhibit minimal oxidation of residues TRP 53, MET 34, MET 256, and MET 432. A suitable formulation may also exhibit a minimal amount of sub-visible particles (e.g., particles having a diameter of $\geq 10 \mu\text{m}$ or $\geq 25 \mu\text{m}$) and/or non-spherical particles (e.g., particles having an aspect ratio of $\geq 5 \mu\text{m}$). High amounts of HMWS, oxidation, and/or particles may impact the shelf-life, safety and/or potency of a formulation. Stable aqueous adalimumab formulations are described in the embodiments set forth below.

[0096] In some cases, the stable aqueous adalimumab formulations include adalimumab, calcium chloride, and optionally one or more (typically one, two, or three) additional excipients as described herein.

[0097] In some cases, the stable aqueous adalimumab formulations include adalimumab, a buffer, and optionally one or more (typically one, two, or three) additional excipients as described herein. Suitable buffers include glutamate/glutamic acid buffers ("glutamate buffer"), adipate/adipic acid buffers ("adipate buffer"), glucuronate/glucuronic acid buffers ("glucuronate buffer"), acetate/acetic acid buffers ("acetate buffer"), benzoate/benzoic acid buffers ("benzoate buffer"), glycolate/glycolic acid buffers ("glycolate buffer"), lactate/lactic acid buffers ("lactate buffer"), and histidine buffers.

[0098] In some cases, the stable aqueous adalimumab formulations include adalimumab and do not include a buffer. Optionally, these adalimumab formulations additionally include one or more (typically one, two, or three) excipients as described herein.

[0099] In some cases, the stable aqueous adalimumab formulation includes adalimumab, a buffer (e.g., lactate buffer), calcium chloride, and optionally one or more (typically one, two, or three) additional excipients as described herein.

[00100] As used herein, a “stable” formulation demonstrates stability sufficient to permit administration to a patient. For example, a stable formulation may demonstrate long-term stability, such as stability upon storage for 6 months or 1 year. Stability of a formulation may, for example, be assessed by growth of acidic species over time, growth of high molecular weight species over time, or increase in opalescence over time. When stability is assessed by growth of acidic species over time, a stable formulation may demonstrate less than about a 4-fold increase (e.g., less than about a 3.5-fold increase, less than about a 3-fold increase, less than about a 2.5-fold increase, less than about a 2.4-fold increase, less than about a 2.3-fold increase, less than about a 2.25-fold increase, less than about a 2.2-fold increase, less than about a 2.15-fold increase, less than about a 2.1-fold increase, less than about a 2.05-fold increase, or less than about a 2-fold increase) in acidic species as measured by CEX-HPLC after storage for 28 days at 40°C. When stability is assessed by growth of high molecular weight species over time, a stable formulation may demonstrate less than about a 5-fold increase (e.g., less than about a 4.5-fold increase, less than about a 4-fold increase, less than about a 3.9-fold increase, less than about a 3.8-fold increase, less than about a 3.7-fold increase, less than about a 3.6-fold increase, less than about a 3.5-fold increase, less than about a 3.4-fold increase, less than about a 3.3-fold increase, less than about a 3.2-fold increase, less than about a 3.15-fold increase, less than about a 3.1-fold increase, less than about a 3.05-fold increase, less than about a 3-fold increase, less than about a 2.95-fold increase, or less than about a 2.9-fold increase) in HMWS species as measured by SE-HPLC after storage for 28 days at 40°C. When stability is assessed by increase in opalescence over time, a stable formulation may demonstrate less than about 500 nephelometric turbidity units (NTUs) (e.g., less than about 400 NTUs, less than about 350 NTUs, less than about 300 NTUs, less than about 250 NTUs, less than about 200 NTUs, less than about 150 NTUs, less than about 140 NTUs, less than about 130 NTUs, less than about 125 NTUs, less than about 120 NTUs, less than about 115 NTUs, less than about 110 NTUs, less than about 100 NTUs, less than about 90 NTUs, less than about 80 NTUs, or less than about 70 NTUs) after stirring at room temperature for 5 days.

[00101] As used herein, an “aqueous” formulation contains water. Aqueous formulations can be in a liquid state or a frozen state, and preferably are liquid formulations.

[00102] As used herein, an “excipient” is a component of a formulation other than water and the active agent (e.g., adalimumab or biosimilar thereof) added to the formulation. Examples of excipients include buffers; stabilizers such as amino acids and amino acid derivatives, polyethylene glycols and polyethylene glycol derivatives, polyols, acids, amines, polysaccharides or polysaccharide derivatives, salts, and surfactants; and pH-adjusting agents.

[00103] As used herein, a “biosimilar,” particularly an adalimumab biosimilar, is a biological product that is highly similar to HUMIRA (also known as adalimumab or D2E7) notwithstanding minor differences in clinically inactive components; and there are no clinically meaningful differences between the biological product and HUMIRA in terms of safety, purity, and potency of the product.

[00104] As used herein, the term “about,” when used to modify a particular value or range, generally means within 20 percent, e.g., within 10 percent, 5 percent, 4 percent, 3 percent, 2 percent, or 1 percent of the stated value or range.

[00105] Adalimumab is a fully human monoclonal antibody of the immunoglobulin G1 (IgG1) subclass expressed in the Chinese hamster ovary (CHO) cell line and consists of 2 heavy chains (HC), and 2 light chains (LC) of the kappa subclass. Adalimumab contains 32 total cysteine residues involved in both intrachain and interchain disulfide bonds. Each HC contains 451 amino acids with 4 intrachain disulfides. Each LC contains 214 amino acids with 2 intrachain disulfides. Each HC contains an N-linked glycan at the consensus glycosylation site on Asn301. The amino acid sequences of the adalimumab variable LC and variable HC are set out at SEQ ID NO: 1 and 2, respectively and the full length LC and HC are set out as SEQ ID NO: 3 and 4; respectively. In addition, the adalimumab LC CDRs are set out as SEQ ID NO: 5 (LC CDR1), SEQ ID NO: 6 (LC CDR2) and SEQ ID NO: 7 (LC CDR3). Adalimumab HC CDRs are set out as SEQ ID NO: 8 (HC CDR1), SEQ ID No: 9 (HC CDR2), and SEQ ID NO: 10 (HC CDR3). Adalimumab has been described and claimed in U.S. Pat. No. 6,090,382, the disclosure of which is hereby incorporated by reference in its entirety. As used herein, the term “adalimumab” includes biosimilars of adalimumab.

Formulations of Adalimumab With Calcium Chloride

[00106] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 80 to about 120 mg/mL, about 90 to about 110 mg/mL, about 160 to about 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, calcium chloride at a concentration of about 1 to about 150 mM, such as about 5 to about 50 mM, about 5 to about 30 mM, about 10 to about 30 mM, about 12.5 to about 17.5 mM about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, or about 30 mM, and one or more excipients as discussed below. The presence of calcium chloride in the formulations advantageously and unexpectedly provides improved stability over time as compared to other salts, particularly with respect to levels of acidic species at 40°C as detected by cation-exchange high-performance liquid chromatography (CEX-HPLC). Further, the presence of calcium chloride at low concentrations (e.g., about 20 to about 25 mM, about 10 mM to about 20 mM, about 12.5 mM to about 17.5 mM, or about 15 mM) advantageously lowers the rate of growth of acidic species without significantly increasing the growth of high molecular weight species (HMWS) at 40°C as detected by size-exclusion high-performance liquid chromatography (SE-HPLC).

[00107] Increased levels of acidic species over time are generally due to protein deamidation. It is therefore beneficial for the stable aqueous adalimumab formulations to demonstrate minimal growth of acidic species over time. Similarly, it is beneficial for the stable aqueous adalimumab formulations to demonstrate minimal growth over time of HMWS because HMWS provide a measure of soluble aggregation.

[00108] Further still, the presence of calcium chloride at low concentrations (e.g., about 10 mM to about 20 mM, about 12.5 mM to about 17.5 mM or about 15 mM) advantageously minimizes formation of sub-visible and/or non-spherical particles in a formulation, as detected by micro-flow imaging (“MFI”) even if the formulation has been subjected to transport conditions.

[00109] Suitable excipients for combination with the calcium chloride-containing adalimumab formulations include certain buffers, and certain stabilizers such as certain amino acids and amino acid derivatives, certain polyethylene glycols and polyethylene glycol derivatives, certain polyols, certain acids, certain amines, certain polysaccharides or polysaccharide derivatives, and

certain surfactants. Examples of suitable buffers include glutamate (e.g., at a concentration of about 5 mM to about 50 mM, about 10 mM to about 25 mM, about 15 mM to about 20 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), adipate (e.g., at a concentration of about 5 mM to about 50 mM, about 10 mM to about 25 mM, about 15 mM to about 20 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), glucuronate (e.g., at a concentration of about 5 mM to about 50 mM, about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), acetic acid and/or acetate (e.g., at a concentration of about 0.1 mM to about 300 mM, about 2 mM to about 30 mM, about 5 mM to about 50 mM, about 5 mM to about 15 mM, about 10 mM to about 20 mM, about 10 mM to about 30 mM, about 15 mM to about 25 mM, about 30 mM to about 40 mM, about 35 mM to about 45 mM, about 40 mM to about 50 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), benzoate (e.g., at a concentration of about 5 mM to about 50 mM, about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), glycolate (e.g., at a concentration of about 5 mM to about 50 mM, about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), lactic acid and/or lactate (e.g., at a concentration of about 0.1 mM to about 300 mM, about 2 mM to about 30 mM, about 10 mM to about 30 mM, about 5 mM to about 15 mM, about 7 mM to about 12 mM, about 9 mM to about 11 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and histidine (e.g., at a concentration of about 5 mM to about 50 mM, about 5 mM to about 15 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM). Examples of suitable amino acids and amino acid derivatives include proline (e.g., at a concentration of about 0.1 to about 450 mM, about 50 to about 320 mM, and/or about 50 to about 300 mM), N-acetyl arginine (e.g., at a concentration of about 0.1 to about 450 mM or about 90 to about 150 mM), citrulline (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), sarcosine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), N-acetyl proline (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), N-acetyl ornithine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), ornithine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), beta-alanine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), alanine (e.g., at a concentration of about 0.1 to about 450 mM or about 80 to about 120 mM), asparagine (e.g., at a concentration of about 0.1 to about 450 mM or about 80 to about 120 mM),

isoleucine (e.g., at a concentration of about 0.1 to about 450 mM or about 80 to about 120 mM), serine (e.g., at a concentration of about 0.1 to about 450 mM or about 80 to about 120 mM), aspartic acid (e.g., at a concentration of about 0.1 to about 450 mM or about 10 to about 30 mM), creatine (e.g., at a concentration of about 0.1 to about 450 mM or about 15 to about 35 mM), glutamine (e.g., at a concentration of about 0.1 to about 450 mM or about 40 to about 60 mM), phenylalanine (e.g., at a concentration of about 0.1 to about 450 mM or about 40 to about 60 mM), tryptophan (e.g., at a concentration of about 0.1 to about 450 mM or about 15 to about 35 mM), and arginine-HCl (e.g., at a concentration of about 0.1 to about 450 mM or about 80 to about 120 mM). Examples of suitable polyethylene glycols and polyethylene glycol derivatives include PEG 15 hydroxystearate (e.g., at a concentration of about 0.1% (w/v) to about 20% (w/v) or about 3% (w/v) to about 6% (w/v)), PEG 3350 (e.g., at a concentration of about 0.1% (w/v) to about 30% (w/v) or about 1% (w/v) to about 7% (w/v)), PEG 200 (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v) or about 0.6% (w/v) to about 4.8% (w/v)), PEG 600 (e.g., at a concentration of about 0.1% (w/v) to about 30% (w/v) or about 1.2% (w/v) to about 14.5% (w/v)), and PEG 400 (e.g., at a concentration of about 0.1% (w/v) to about 20% (w/v) or about 0.3% (w/v) to about 1.5% (w/v)). Examples of suitable polyols include inositol (e.g., at a concentration of about 0.1 to about 450 mM or about 150 to about 210 mM), glycerol (also referred to as glycerin) (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 0.5% (w/v) to about 1% (w/v)), sucrose (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 4% (w/v) to about 10% (w/v), about 6% (w/v) to about 8.5% (w/v), about 6.2% (w/v) to about 7.3% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 7.4% (w/v), or about 9% (w/v)), and sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)). Examples of suitable acids include glycolic acid (e.g., at a concentration of about 0.1 to about 300 mM or about 50 to about 70 mM), pyrrolidone carboxylic acid (PCA) (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 0.05% (w/v) to about 2% (w/v)), medronic acid (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), benzene sulfonic acid (e.g., at a concentration of about 0.1 to about 300 mM or about 60 to about 90 mM), and methane sulfonic acid (MSA) (e.g., at a concentration of about 0.1 to about 150 mM, about 0.1 to about 50 mM, and/or about 10 to about 30 mM). Examples of suitable amines include monoethanolamine hydrochloride (MEA-HCl)

(e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 40 mM), monoethanolamine (MEA) (e.g., at a concentration of about 0.1 to about 300 mM, about 0.1 to about 50 mM, and/or about 30 to about 160 mM), and triethanolamine (TEA) (e.g., at a concentration of about 0.1 to about 170 mM or about 30 to about 150 mM). Examples of suitable polysaccharides or polysaccharide derivatives include hyaluronic acid (e.g., at a concentration of about 0.05% (w/v) to about 2.5% (w/v) or about 0.1% (w/v) to about 0.05% (w/v)), sodium carboxymethylcellulose (NaCMC) (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 0.1% (w/v) to about 2% (w/v)), and dextran (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 8% (w/v) to about 12% (w/v)). Examples of suitable surfactants include Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v) to about 0.2% (w/v), about 0.03% (w/v) to about 0.06% (w/v), about 0.01% (w/v), about 0.05% (w/v), about 0.06% (w/v), and/or about 0.1% (w/v)), Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)), Docusate sodium (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.005% (w/v) to about 0.05% (w/v)), benzalkonium chloride (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.05% (w/v) to about 0.5% (w/v)), Span 40 (sorbitan monopalmitate) (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.05% (w/v) to about 0.5% (w/v)), and Triton X-100 (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)). Examples of other suitable excipients include imidazole (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 0.5% (w/v) to about 2% (w/v)), taurine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), betaine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), gelatin (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 0.5% (w/v) to about 2% (w/v)), niacinamide (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 120 mM), polyvinylpyrrolidone (PVP), for example, 10K PVP, (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v) or about 0.05% (w/v) to about 2% (w/v)), guanidine

hydrochloride (GnHCl) (e.g., at a concentration of about 0.1 to about 150 mM or about 10 to about 30 mM), and ethanol (e.g., at a concentration of about 0.05% (w/v) to about 2.5% (w/v) or about 0.25% (w/v) to about 1% (w/v)). Optionally, the calcium chloride-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00110] Suitable excipients for combination with the calcium chloride-containing adalimumab formulations also include, but are not limited to, glutamate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 25 mM, about 15 mM to about 20 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), adipate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 25 mM, about 15 mM to about 20 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), glucuronate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), acetic acid and/or acetate at a concentration of about 0.1 mM to about 300 mM (e.g., about 2 mM to about 30 mM, about 5 mM to about 50 mM, about 5 mM to about 15 mM, about 10 mM to about 20 mM, about 10 mM to about 30 mM, about 15 mM to about 25 mM, about 30 mM to about 40 mM, about 35 mM to about 45 mM, about 40 mM to about 50 mM, about 10 mM, about 15 mM, about 20 mM, and/or 25 mM), benzoate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), glycolate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), lactic acid and/or lactate at a concentration of about 0.1 mM to about 300 mM (e.g., about 2 mM to about 30 mM, about 10 mM to about 30 mM, about 5 mM to about 15 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), histidine at a concentration of about 5 mM to about 50 mM (e.g., about 5 mM to about 15 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), proline at a concentration of about 0.1 to about 450 mM (e.g., about 50 to about 320 mM and/or about 50 to about 300 mM), N-acetyl arginine at a concentration of about 0.1 to about 450 mM (e.g., about 90 to about 150 mM), citruline at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM),

sarcosine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), N-acetyl proline at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), N-acetyl ornithine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), ornithine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), beta-alanine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), alanine at a concentration of about 0.1 to about 450 mM (e.g., about 80 to about 120 mM), asparagine at a concentration of about 0.1 to about 450 mM (e.g., about 80 to about 120 mM), isoleucine at a concentration of about 0.1 to about 450 mM (e.g., about 80 to about 120 mM), serine at a concentration of about 0.1 to about 450 mM (e.g., about 80 to about 120 mM), aspartic acid at a concentration of about 0.1 to about 450 mM (e.g., about 10 to about 30 mM), creatine at a concentration of about 0.1 to about 450 mM (e.g., about 15 to about 35 mM), glutamine at a concentration of about 0.1 to about 450 mM (e.g., about 40 to about 60 mM), phenylalanine at a concentration of about 0.1 to about 450 mM (e.g., about 40 to about 60 mM), tryptophan at a concentration of about 0.1 to about 450 mM (e.g., about 15 to about 35 mM), arginine-HCl at a concentration of about 0.1 to about 450 mM (e.g., about 80 to about 120 mM), PEG 15 hydroxystearate at a concentration of about 0.1% (w/v) to about 20% (w/v) (e.g., about 3% (w/v) to about 6% (w/v)), PEG 3350 at a concentration of about 0.1% (w/v) to about 30% (w/v) (e.g., about 1% (w/v) to about 7% (w/v)), PEG 200 at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 0.6% (w/v) to about 4.8% (w/v)), PEG 600 at a concentration of about 0.1% (w/v) to about 30% (w/v) (e.g., about 1.2% (w/v) to about 14.5% (w/v)), PEG 400 at a concentration of about 0.1% (w/v) to about 20% (w/v) (e.g., about 0.3% (w/v) to about 1.5% (w/v)), inositol at a concentration of about 0.1 to about 450 mM (e.g., about 150 to about 210 mM), glycerol (also referred to as glycerin) at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 0.5% (w/v) to about 1% (w/v)), sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 10% (w/v), about 6.2% (w/v) to about 7.3% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), or about 9% (w/v)), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v) and/or about 4% (w/v)), glycolic acid at a concentration of about 0.1 to about 300 mM (e.g., about 50 to about 70 mM), PCA at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 0.05% (w/v) to about 2% (w/v)), medronic acid at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), benzene sulfonic

acid at a concentration of about 0.1 to about 300 mM (e.g., about 60 to about 90 mM), methane sulfonic acid (MSA) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM and/or about 10 to about 30 mM), monoethanolamine hydrochloride (MEA-HCl) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM), monoethanolamine (MEA) at a concentration of about 0.1 to about 300 mM (e.g., about 0.1 to about 50 mM and/or about 30 to about 160 mM), triethanolamine (TEA) at a concentration of about 0.1 to about 170 mM (e.g., about 30 to about 150 mM), hyaluronic acid at a concentration of about 0.05% (w/v) to about 2.5% (w/v) (e.g., about 0.1% (w/v) to about 0.05% (w/v)), sodium carboxymethylcellulose (NaCMC) at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 0.1% (w/v) to about 2% (w/v)), dextran at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 8% (w/v) to about 12% (w/v)), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), Docusate sodium at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.005% (w/v) to about 0.05% (w/v)), benzalkonium chloride at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.05% (w/v) to about 0.5% (w/v)), Span 40 (sorbitan monopalmitate) at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.05% (w/v) to about 0.5% (w/v)), Triton X-100 at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), imidazole at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 0.5% (w/v) to about 2% (w/v)), taurine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), betaine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), gelatin at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 0.5% (w/v) to about 2% (w/v)), niacinamide at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 120 mM), polyvinylpyrrolidone (PVP), for example, 10K PVP, at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.05% (w/v) to about 2% (w/v)), guanidine hydrochloride (GnHCl) at a concentration of about

0.1 to about 150 mM (e.g., about 10 to about 30 mM), and ethanol at a concentration of about 0.05% (w/v) to about 2.5% (w/v) (e.g., about 0.25% (w/v) to about 1% (w/v)). Optionally, the calcium chloride-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2.

Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00111] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 5% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00112] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 140 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, dextran at a concentration of about 5% (w/v) to about 15% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00113] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 200 at a concentration of about 0.5% (w/v) to about 2% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00114] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 600 at a concentration of about 1.5% (w/v) to about 4% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00115] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, calcium chloride at a concentration of about 50 mM to about 100 mM, proline at a concentration of about 50 mM to about 150 mM, and has a pH of about 5.0 to about 5.5.

[00116] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM

to about 25 mM, ethanol at a concentration of about 0.3% (w/v) to about 0.8% (w/v), calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00117] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.3% (w/v) to about 0.8% (w/v), PEG 3350 at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00118] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, TEA at a concentration of about 100 mM to about 200 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00119] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, TEA at a concentration of about 20 mM to about 40 mM, calcium chloride at a concentration of about 60 mM to about 90 mM, and has a pH of about 5.0 to about 5.5.

[00120] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, alanine at a concentration of about 80 mM to about 120 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00121] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, asparagine at a concentration of about 80 mM to about 120 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00122] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, isoleucine at a concentration of about 80 mM to about 120 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00123] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, serine at a concentration of about 80 mM to about 120 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00124] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, aspartic acid at a concentration of about 10 mM to about 30 mM, proline at a concentration of about 60 mM to about 100 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00125] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, creatine at a concentration of about 15 mM to about 35 mM, proline at a concentration of about 60 mM to about 90 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00126] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, glutamine at a concentration of about 40 mM to about 60 mM, proline at a concentration of about 40 mM to about 60 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00127] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, leucine at a concentration of about 40 mM to about 60 mM, proline at a concentration of about 40 mM to about 60 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00128] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, phenylalanine at a concentration of about 40 mM to about 60 mM, proline at a concentration of about 40 mM to about 60 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00129] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM

to about 25 mM, tryptophan at a concentration of about 10 mM to about 40 mM, proline at a concentration of about 60 mM to about 90 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00130] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00131] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, proline at a concentration of about 80 to about 120 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00132] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 15 hydroxystearate at a concentration of about 3% (w/v) to about 8% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00133] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 15 hydroxystearate at a concentration of about 3% (w/v) to about 8% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, proline at a concentration of about 80 to about 120 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00134] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, imidazole at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a

concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00135] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, N-acetyl arginine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00136] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, inositol at a concentration of about 200 to about 300 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00137] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00138] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, taurine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00139] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, citruline at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of

about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00140] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, betaine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00141] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, sarcosine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00142] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, glycolic acid at a concentration of about 40 to about 80 mM, calcium chloride at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00143] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PCA at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00144] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, gelatin at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a

concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00145] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, hyaluronic acid at a concentration of about 0.1% (w/v) to about 0.5% (w/v), calcium chloride at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00146] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, N-acetyl proline at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00147] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, N-acetyl ornithine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00148] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ornithine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00149] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, beta-alanine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of

about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00150] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, niacinamide at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00151] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, medronic acid at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00152] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 200 at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00153] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 600 at a concentration of about 1.5% (w/v) to about 4% (w/v), and calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00154] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, niacinamide at a concentration of about 80 to about 120 mM, calcium chloride at a concentration of about 60 to about 100 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00155] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, benzene sulfonic acid at a concentration of about 60 to about 90 mM, calcium chloride at a concentration of about 25 to about 75 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00156] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 400 at a concentration of about 0.25% (w/v) to about 0.75% (w/v), calcium chloride at a concentration of about 40 to about 80 mM, glycerin at a concentration of about 0.5% (w/v) to about 1% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00157] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, N-acetyl arginine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 50 mM, and MSA at a concentration of about 10 to about 30 mM, and has a pH of about 5.0 to about 5.5.

[00158] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, calcium chloride at a concentration of about 60 to about 90 mM, PEG 400 at a concentration of about 0.1% (w/v) to about 0.5% (w/v), and 10K PVP at a concentration of about 0.5% (w/v) to about 2% (w/v), and has a pH of about 5.0 to about 5.5.

[00159] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, PEG 400 at a concentration of about 0.5% (w/v) to about 2% (w/v), and calcium chloride at a concentration of about 30 to about 50 mM, and has a pH of about 5.0 to about 5.5.

[00160] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 0.5% (w/v) to about 2% (w/v), and

calcium chloride at a concentration of about 60 to about 90 mM, and has a pH of about 5.0 to about 5.5.

[00161] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 0.5% (w/v) to about 2% (w/v), PEG 400 at a concentration of about 1% (w/v) to about 3% (w/v), and calcium chloride at a concentration of about 10 to about 30 mM, and has a pH of about 5.0 to about 5.5.

[00162] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 0.5% (w/v) to about 2% (w/v), PEG 400 at a concentration of about 0.5% (w/v) to about 2% (w/v), and calcium chloride at a concentration of about 30 to about 50 mM, and has a pH of about 5.0 to about 5.5.

[00163] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00164] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00165] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00166] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl

at a concentration of about 80 to about 120 mM, and Docusate sodium at a concentration of about 0.005% (w/v) to about 0.05% (w/v), and has a pH of about 5.1 to 5.3.

[00167] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and benzalkonium chloride at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00168] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Span 40 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00169] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Triton X-100 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00170] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, and arginine-HCl at a concentration of about 80 to about 120 mM, and has a pH of about 5.1 to 5.3.

[00171] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 80 at a concentration of about 0.0025% (w/v) to about 0.025% (w/v), and has a pH of about 5.1 to 5.3.

[00172] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.05% (w/v), and has a pH of about 5.1 to 5.3.

[00173] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 80 at a concentration of about 0.025% (w/v) to about 0.25% (w/v), and has a pH of about 5.1 to 5.3.

[00174] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 20 at a concentration of about 0.0025% (w/v) to about 0.025% (w/v), and has a pH of about 5.1 to 5.3.

[00175] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 20 at a concentration of about 0.005% (w/v) to about 0.05% (w/v), and has a pH of about 5.1 to 5.3.

[00176] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 20 at a concentration of about 0.025% (w/v) to about 0.25% (w/v), and has a pH of about 5.1 to 5.3.

[00177] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Triton X-100 at a concentration of about 0.0025% (w/v) to about 0.025% (w/v), and has a pH of about 5.1 to 5.3.

[00178] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Triton X-100 at a concentration of about 0.005% (w/v) to about 0.05% (w/v), and has a pH of about 5.1 to 5.3.

[00179] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Triton X-100 at a concentration of about 0.025% (w/v) to about 0.25% (w/v), and has a pH of about 5.1 to 5.3.

[00180] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Pluronic F68 at a concentration of about 0.025% (w/v) to about 0.25% (w/v), and has a pH of about 5.1 to 5.3.

[00181] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00182] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Pluronic F68 at a concentration of about 0.2% (w/v) to about 0.6% (w/v), and has a pH of about 5.1 to 5.3.

[00183] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 50 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.1% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00184] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 50 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.0% (w/v) to about 6.5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00185] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 50 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.7% (w/v) to about 7.3% (w/v), calcium chloride at a concentration of about 5 to about 15 mM, guanidine hydrochloride (GnHCl) at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00186] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 50 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.7% (w/v) to about 7.3% (w/v), calcium chloride at a concentration of about 5 to about 15 mM, NaCMC at a concentration of about 0.2% (w/v) to about 1% (w/v), and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00187] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.4% (w/v) to about 7.2% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, and/or Ca(OH)₂.

[00188] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, and/or Ca(OH)₂.

[00189] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.4% (w/v) to about 7.2% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, and/or Ca(OH)₂.

[00190] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.6% (w/v) to about 7% (w/v), calcium chloride at a concentration of about 20 to about 30 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.2% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, and/or Ca(OH)₂.

[00191] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, and/or Ca(OH)₂.

[00192] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.4% (w/v) to about 7.2% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, and/or Ca(OH)₂.

[00193] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, and/or Ca(OH)₂.

[00194] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 240 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00195] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 200 to about 250 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00196] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 11% (w/v) to about 15% (w/v), calcium chloride at a concentration of about 20 to about 40 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00197] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 11% (w/v) to about 15% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00198] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 8% (w/v) to about 9% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00199] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 3% (w/v) to about 5% (w/v), PEG 200 at a concentration of about 1.2% (w/v) to about 2% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00200] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 200 at a concentration of about 3.5% (w/v) to about 4.2% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00201] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 5% (w/v) to about 5.7% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, proline at a concentration of about 90 to about 130 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00202] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, calcium chloride at a concentration of about 10 to about 30 mM, proline at a concentration of about 190 to about 250 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00203] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, calcium chloride at a concentration of about 15 to about 35 mM, proline at a concentration of about 190 to about 250 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, and/or Ca(OH)₂.

[00204] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, histidine at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 270 to about 370 mM, and calcium chloride at a concentration of about 10 to about 30 mM, and has a pH of about 6.7 to 6.9. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00205] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 8% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00206] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 6.5% (w/v) to about 7.3% (w/v), PEG 200 at a concentration of about 0.3% (w/v) to about 1% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00207] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 4% (w/v) to about 5% (w/v), PEG 200 at a concentration of about 1.5% (w/v) to about 2.1% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00208] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 0.9% (w/v) to about 1.5% (w/v), PEG 200 at a concentration of about 2.5% (w/v) to about 3.5% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00209] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 200 at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00210] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 6.9% (w/v) to about 7.7% (w/v), proline at a concentration of about 40 to about 80 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00211] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 5% (w/v) to about 6% (w/v), proline at a concentration of about 90 to about 150 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00212] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 2% (w/v) to about 3% (w/v), proline at a concentration of about 150 to about 210 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00213] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, proline at a concentration of about 200 to about 300 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00214] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sorbitol at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl and/or NaOH.

[00215] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 5% (w/v) to about 8% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic

F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00216] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, proline at a concentration of about 200 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00217] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 11% (w/v) to about 15% (w/v), calcium chloride at a concentration of about 20 to about 40 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00218] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, sucrose at a concentration of about 5% (w/v) to about 8% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00219] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 6.9% (w/v) to about 7.7% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00220] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 200 at a concentration of about 4.5% (w/v) to about 5.1% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00221] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sorbitol at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl.

[00222] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 13% (w/v) to about 16% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00223] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 3% (w/v) to about 3.6% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, proline at a concentration of about 150 to about 210 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00224] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, PEG 600 at a concentration of about 8% (w/v) to about 9% (w/v), and calcium chloride at a concentration of about 15 to about 35 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00225] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, PEG 600 at a concentration of about 6% (w/v) to about 7% (w/v), and calcium chloride at a concentration of about 40 to about 60 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00226] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, PEG 600 at a concentration of about 3.4% (w/v) to about 4% (w/v), and calcium chloride at a concentration of about 65 to about 85 mM,

and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00227] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL and calcium chloride at a concentration of about 80 to about 120 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00228] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, proline at a concentration of about 200 to about 250 mM, and calcium chloride at a concentration of about 15 to about 35 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00229] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, proline at a concentration of about 120 to about 180 mM, and calcium chloride at a concentration of about 40 to about 60 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00230] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, proline at a concentration of about 60 to about 90 mM, and calcium chloride at a concentration of about 65 to about 85 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00231] In an embodiment, a lyophilized form of any one of the foregoing calcium chloride-containing adalimumab formulations is provided.

[00232] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 mg/ml to about 200 mg/ml, or about 160 mg/ml to about 190 mg/mL, or about 80 mg/ml to about 120 mg/ml, or about 90 mg/ml to about 110 mg/ml, or about 95 mg/ml to about 105 mg/ml, or about 40 mg/ml, or about 45 mg/ml, or about 50 mg/ml, or about 55 mg/ml, or about 60 mg/ml, or about 65 mg/ml, or about 70 mg/ml, or about 75 mg/ml, or about 80 mg/ml, or about 85 mg/ml, or about 90 mg/ml, or about 95 mg/ml, or about 100 mg/ml, or about 105 mg/ml, or about 110 mg/ml, or about 115 mg/ml, or about 120 mg/ml, or about 125 mg/ml, or about 130 mg/ml, or about 135 mg/ml, or about 140 mg/ml, or about 145

mg/ml, or about 150 mg/ml, or about 155 mg/ml, or about 160 mg/ml, or about 165 mg/ml, or about 170 mg/ml, or about 175 mg/ml, or about 180 mg/ml, or about 185 mg/ml, or about 190 mg/mL, with the following excipients:

(a) lactate buffer at a concentration of about 5 mM to about 15 mM, or about 7 mM to about 12 mM, or about 9 mM to about 11 mM, or about 5 mM, or about 6 mM, or about 7 mM, or about 8 mM, or about 8 mM, or about 9 mM, or about 10 mM, or about 11 mM, or about 12 mM, or about 13 mM, or about 14 mM, or about 15 mM;

(b) calcium chloride at a concentration of about 5 to about 30 mM, about 10 to about 20 mM, or about 12.5 mM to about 17.5 mM, or about 14 mM to about 16 mM, or about 10 mM, or about 10.5 mM, or about 11 mM, or about 11.5 mM, or about 12 mM, or about 12.5 mM, or about 13 mM, or about 13.5 mM, or about 14 mM, or about 14.5 mM, or about 15 mM, or about 15.5 mM, or about 16 mM, or about 16.5 mM, or about 17 mM, or about 17.5 mM, or about 18 mM, or about 18.5 mM, or about 19 mM, or about 19.5 mM, or about 20 mM;

(c) sucrose at a concentration of about 4% (w/v) to about 10% (w/v), or about 6% (w/v) to about 8.5% (w/v), or about 4% (w/v), or about 4.5% (w/v), or about 5% (w/v), or about 5.5% (w/v), or about 6% (w/v), or about 6.5% (w/v), or about 7% (w/v), or about 7.1% (w/v), or about 7.2% (w/v), or about 7.3% (w/v), or about 7.4% (w/v), or about 7.5% (w/v), or about 7.6% (w/v), or about 7.7% (w/v), or about 7.8% (w/v), or about 8% (w/v), or about 8.5% (w/v);

(d) Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.09% (w/v), or about 0.03% (w/v) to about 0.06% (w/v), about 0.01% (w/v) to about 0.2% (w/v), about 0.01% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), or about 0.05% (w/v) to about 0.07% (w/v), or about 0.03% (w/v), or about 0.04% (w/v), or about 0.05% (w/v), or about 0.06% (w/v), or about 0.07% (w/v), or about 0.08% (w/v), about 0.09% (w/v), or about 0.1% (w/v); and

(e) has a pH of about 3.5 to about 8, or about 4 to about 7, or about 4.5 to about 6, or about 5 to about 5.5, or about 3.5, or about 4, or about 4.5, or about 4.6, or about 4.7, or about 4.8, or about 4.9, or about 5.0, or about 5.1, or about 5.2, or about 5.3, or about 5.4, or about 5.5, or about 5.6, or about 5.7, or about 5.8, or about 5.9, or about 6.0, or about 6.5, or about 7.0, or about 7.5, or about 8.0.

[00233] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration or about 40 mg/ml to 200 mg/ml, lactate buffer at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 4% (w/v) to about 10% (w/v), calcium

chloride at a concentration of about 5 to about 30 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 3.5 to 8.

[00234] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 mg/ml to 200 mg/ml, lactate buffer at a concentration of about 1 mM to about 15 mM, sucrose at a concentration of about 4% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 10 to about 20 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 3.5 to 8.

[00235] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 mg/ml to about 120 mg/mL, lactate buffer at a concentration of about 7 mM to about 12 mM, sucrose at a concentration of about 4% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 12.5 to about 17.5 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.07% (w/v), and a pH of about 4 to about 7.

[00236] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 mg/ml to about 110 mg/mL, lactate buffer at a concentration of about 9 mM to about 11 mM, sucrose at a concentration of about 6% (w/v) to about 8.5% (w/v), calcium chloride at a concentration of about 14 to about 16 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.07% (w/v), and a pH of about 5.0 to about 5.5.

[00237] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 100 mg/mL, lactate buffer at a concentration of about 10 mM, sucrose at a concentration of about 7.4% (w/v), calcium chloride at a concentration of about 15 mM, and Pluronic F68 at a concentration of about 0.06% (w/v), and a pH of about 5.2.

[00238] In an embodiment, the stable aqueous adalimumab formulation is one of the lactate buffer formulations described in Tables G, H, I, 1, 11, 12, 13, 15, 16 or 17 provided herein.

[00239] In an embodiment, the stable aqueous adalimumab formulations described above, which include lactate buffer, calcium chloride, and Pluronic F68, are in lyophilized form. In an embodiment, the stable aqueous adalimumab formulations described above, which include lactate, calcium chloride, and Pluronic F68, are not in lyophilized form (e.g., are hydrated).

[00240] In an embodiment, the pH of the stable aqueous adalimumab formulations described above, which include lactate buffer, calcium chloride, and Pluronic F68, can be adjusted using HCl/Ca(OH)₂. In an embodiment, the pH of the stable aqueous adalimumab formulations

described above, which include lactate buffer, calcium chloride, and Pluronic F68, is not adjusted using a pH adjusting agent.

[00241] The stable aqueous adalimumab formulations described above, which include lactate buffer, calcium chloride, and Pluronic F68, exhibit a conductivity of less than about 4 mS/cm, or less than about 3.5 mS/cm, or less than about 3 mS/cm, or less than about 2.5 mS/cm, or less than about 2 mS/cm, or less than about 1.5 mS/cm, or less than about 1 mS/cm, or less than about 0.5 mS/cm, or about 0.5 mS/cm to about 3.5 mS/cm at ambient room temperature.

[00242] The stable aqueous adalimumab formulations described above, which include lactate buffer, calcium chloride, and Pluronic F68, exhibit an osmolality of 270-330 mOsM, or about 300 mOsM.

[00243] Aqueous adalimumab formulations having the specific combination of about 5 to about 30 mM (e.g., 12.5 mM to about 17.5 mM, or about 15 mM) calcium chloride, about 5 mM to about 15 mM (e.g., about 7 mM to about 12 mM, or about 9 mM to about 11 mM, or about 10 mM) lactate buffer, and Pluronic F68 surfactant (e.g., about 0.03% (w/v) to about 0.1% (w/v); about 0.03% (w/v) or about 0.06% (w/v)), advantageously exhibit a lowered growth rate of acidic species, as detected by CEX-HPLC), a lowered growth rate of HMWS, as detected by SE-HPLC, and a minimal amount of sub-visible and/or non-spherical particles, as detected by MFI. *See, e.g.,* Examples 15-17 below.

Formulations of Adalimumab With Glutamate Buffer

[00244] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 160 to about 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, glutamate at a concentration of about 5 mM to about 50 mM (e.g., about 5 mM to about 30 mM, about 10 mM to about 25 mM, about 15 mM to about 20 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients. Suitable excipients include certain stabilizers such as certain amino acids and amino acid derivatives, certain polyethylene glycols and polyethylene glycol derivatives, certain polyols, certain acids, certain amines, certain polysaccharides or polysaccharide derivatives, certain salts, and certain surfactants. Examples of suitable amino acids and amino acid derivatives include proline (e.g., at a concentration of about 0.1 to about 450 mM or about 50 to about 300 mM), arginine (e.g., at a concentration of about 0.1 to about 450 mM or about 60 to about 90 mM), N-acetyl arginine

(e.g., at a concentration of about 0.1 to about 450 mM or about 90 to about 150 mM), citruline (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), sarcosine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), N-acetyl proline (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), N-acetyl ornithine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), ornithine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), beta-alanine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), alanine (e.g., at a concentration of about 0.1 to about 450 mM or about 80 to about 120 mM), asparagine (e.g., at a concentration of about 0.1 to about 450 mM or about 80 to about 120 mM), isoleucine (e.g., at a concentration of about 0.1 to about 450 mM or about 80 to about 120 mM), serine (e.g., at a concentration of about 0.1 to about 450 mM or about 80 to about 120 mM), aspartic acid (e.g., at a concentration of about 0.1 to about 450 mM or about 10 to about 30 mM), creatine (e.g., at a concentration of about 0.1 to about 450 mM or about 15 to about 35 mM), glutamine (e.g., at a concentration of about 0.1 to about 450 mM or about 40 to about 60 mM), leucine (e.g., at a concentration of about 0.1 to about 450 mM or about 40 to about 60 mM), phenylalanine (e.g., at a concentration of about 0.1 to about 450 mM or about 40 to about 60 mM), and tryptophan (e.g., at a concentration of about 0.1 to about 450 mM or about 15 to about 35 mM). Examples of suitable polyethylene glycols and polyethylene glycol derivatives include PEG 15 hydroxystearate (e.g., at a concentration of about 0.1% (w/v) to about 20% (w/v) or about 2.5% (w/v) to about 5% (w/v)), PEG 3350 (e.g., at a concentration of about 0.1% (w/v) to about 30% (w/v), about 0.5% (w/v) to about 2% (w/v), about 1% (w/v) to about 7% (w/v), about 5% (w/v) to about 10% (w/v), and/or about 6% (w/v) to about 8% (w/v)), PEG 600 (e.g., at a concentration of about 0.1% (w/v) to about 30% (w/v), about 1% (w/v) to about 4% (w/v), and/or about 1% (w/v) to about 2% (w/v)), PEG 400 (e.g., at a concentration of about 0.1% (w/v) to about 20% (w/v), about 0.5% (w/v) to about 10% (w/v), about 0.2% (w/v) to about 2% (w/v), and/or about 6% (w/v) to about 12% (w/v)), and PEG 200 (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 1% (w/v) to about 4% (w/v), and/or about 0.05% (w/v) to about 5% (w/v)). Examples of suitable polyols include glycerol (also referred to as glycerin) (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 0.7% (w/v) to about 2.5% (w/v), and/or about 0.5% (w/v) to about 4% (w/v)), inositol (e.g., at a concentration of about 0.1 to about 450 mM or about 180 to about 250 mM), sucrose

(e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), or about 9% (w/v)), and sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)). Examples of suitable acids include glycolic acid (e.g., at a concentration of about 0.1 to about 300 mM or about 50 to about 70 mM), PCA (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 0.05% (w/v) to about 2% (w/v)), medronic acid (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), methane sulfonic acid (MSA) (e.g., at a concentration of about 0.1 to about 150 mM, about 0.1 to about 50 mM, and/or about 20 to about 125 mM), benzene sulfonic acid (e.g., at a concentration of about 0.1 to about 300 mM or about 75 to about 150 mM), and adipic acid (e.g., at a concentration of about 0.1 to about 300 mM or about 120 to about 180 mM). Examples of suitable amines include triethanolamine (TEA) (e.g., at a concentration of about 0.1 to about 170 mM or about 30 to about 150 mM), monoethanolamine hydrochloride (MEA-HCl) (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 40 mM), monoethanolamide (MEA) (e.g., at a concentration of about 0.1 to about 300 mM, about 0.1 to about 50 mM, about 0.1 to about 170 mM, and/or about 30 to about 160 mM). Examples of suitable polysaccharides or polysaccharide derivatives include dextran (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 2% (w/v) to about 10% (w/v)) and hyaluronic acid (e.g., at a concentration of about 0.05% (w/v) to about 2.5% (w/v) or about 0.1% (w/v) to about 0.05% (w/v)). Examples of suitable salts include calcium chloride (e.g., at a concentration of about 1 to about 150 mM, about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM), sodium borate (e.g., at a concentration of about 0.1 to about 150 mM or about 60 to about 90 mM), sodium bicarbonate (e.g., at a concentration of about 0.1 to about 150 mM or about 60 to about 90 mM), sodium sulfate (e.g., at a concentration of about 0.1 to about 150 mM or about 60 to about 90 mM), calcium sulfate (e.g., at a concentration of about 0.1 to about 150 mM or about 10 to about 30 mM), ammonium sulfate (e.g., at a concentration of about 0.1 to about 150 mM or about 60 to about 90 mM), sodium chloride (e.g., at a concentration of about 10 to about 100 mM, about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), and magnesium chloride (e.g., at a concentration of about 0.1 to about 150 mM or about 60 to about 90 mM). Examples of suitable surfactants include benzalkonium

chloride (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.005% (w/v) to about 0.05% (w/v)), guanidine HCl (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.005% (w/v) to about 0.05% (w/v)), lecithin (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.005% (w/v) to about 0.05% (w/v)), oleic acid (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.005% (w/v) to about 0.05% (w/v)), Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)), Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)), polyvinyl alcohol, for example, 31K or 205 K polyvinyl alcohol, (e.g., at a concentration of about 0.01% (w/v) to about 10% (w/v) or about 0.05% (w/v) to about 0.5% (w/v)), polyvinylpyrrolidone (PVP), for example, 10K PVP, (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.01% (w/v) to about 1% (w/v), and/or about 0.005% (w/v) to about 2% (w/v)), and protamine sulfate (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.05% (w/v)). Examples of other suitable excipients include imidazole (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 1% (w/v) to about 2% (w/v)), taurine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), betaine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM), gelatin (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 0.5% (w/v) to about 2% (w/v)), niacinamide (e.g., at a concentration of about 0.1 to about 450 mM, about 100 to about 270 mM, and/or about 100 to about 150 mM), and ethanol (e.g., at a concentration of about 0.05% (w/v) to about 2.5% (w/v) or about 0.25% (w/v) to about 1.4% (w/v)). Optionally, the glutamate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base

including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00245] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 160 to about 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, glutamate at a concentration of about 5 mM to about 50 mM (e.g., about 5 mM to about 30 mM, about 10 mM to about 25 mM, about 15 mM to about 20 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients selected from the group consisting of PEG 3350 at a concentration of about 0.1% (w/v) to about 30% (w/v) (e.g., about 0.5% (w/v) to about 2% (w/v), about 1% (w/v) to about 7% (w/v), about 5% (w/v) to about 10% (w/v), and/or about 6% (w/v) to about 8% (w/v)), PEG 600 at a concentration of about 0.1% (w/v) to about 30% (w/v) (e.g., about 1% (w/v) to about 4% (w/v) and/or about 1% (w/v) to about 2% (w/v)), PEG 400 at a concentration of about 0.1% (w/v) to about 20% (w/v) (e.g., about 0.5% (w/v) to about 10% (w/v), about 0.2% (w/v) to about 2% (w/v) and/or about 6% (w/v) to about 12% (w/v)), PEG 200 at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 1% (w/v) to about 4% (w/v) and/or about 0.05% (w/v) to about 5% (w/v)), glycerol (also referred to as glycerin) at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 0.7% (w/v) to about 2.5% (w/v) and/or about 0.5% (w/v) to about 4% (w/v)), polyvinylpyrrolidone (PVP), for example, 10K PVP, at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.01% (w/v) to about 1% (w/v) and/or about 0.005% (w/v) to about 2% (w/v)), calcium chloride at a concentration of about 1 to about 150 mM (e.g., about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM), proline at a concentration of about 0.1 to about 450 mM (e.g., about 50 to about 300 mM), PEG 15 hydroxystearate at a concentration of about 0.1% (w/v) to about 20% (w/v) (e.g., about 2.5% (w/v) to about 5% (w/v)), arginine at a concentration of about 0.1 to about 450 mM (e.g., about 60 to about 90 mM), dextran at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 2% (w/v) to about 10% (w/v)), imidazole at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 1% (w/v) to about 2% (w/v)), N-acetyl arginine at a concentration of about 0.1 to about 450 mM (e.g., about 90 to about 150 mM), inositol at a concentration of about 0.1 to about 450 mM (e.g., about 180 to about 250 mM), taurine at a concentration of about 0.1

to about 450 mM (e.g., about 100 to about 150 mM), citruline at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), betaine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), sarcosine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), glycolic acid at a concentration of about 0.1 to about 300 mM (e.g., about 50 to about 70 mM), PCA at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 0.05% (w/v) to about 2% (w/v)), gelatin at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 0.5% (w/v) to about 2% (w/v)), hyaluronic acid at a concentration of about 0.05% (w/v) to about 2.5% (w/v) (e.g., about 0.1% (w/v) to about 0.05% (w/v)), N-acetyl proline at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), N-acetyl ornithine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), ornithine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), beta-alanine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), niacinamide at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 270 mM and/or about 100 to about 150 mM), medronic acid at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), methane sulfonic acid (MSA) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM and/or about 20 to about 125 mM), triethanolamine (TEA) at a concentration of about 0.1 to about 170 mM (e.g., about 30 to about 150 mM), monoethanolamide hydrochloride (MEA-HCl) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM), monoethanolamide (MEA) at a concentration of about 0.1 to about 300 mM (e.g., about 0.1 to about 50 mM, about 0.1 to about 170 mM, and/or about 30 to about 160 mM), ethanol at a concentration of about 0.05% (w/v) to about 2.5% (w/v) (e.g., about 0.25% (w/v) to about 1.4% (w/v)), benzene sulfonic acid at a concentration of about 0.1 to about 300 mM (e.g., about 75 to about 150 mM), adipic acid at a concentration of about 0.1 to about 300 mM (e.g., about 120 to about 180 mM), sodium borate at a concentration of about 0.1 to about 150 mM (e.g., about 60 to about 90 mM), sodium bicarbonate at a concentration of about 0.1 to about 150 mM (e.g., about 60 to about 90 mM), sodium sulfate at a concentration of about 0.1 to about 150 mM (e.g., about 60 to about 90 mM), calcium sulfate at a concentration of about 0.1 to about 150 mM (e.g., about 10 to about 30 mM), ammonium sulfate at a concentration of about 0.1 to about 150 mM (e.g., about 60 to about 90 mM), sodium chloride at a concentration of about 10 to about 100 mM (e.g., about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), magnesium chloride at a concentration

of about 0.1 to about 150 mM (e.g., about 60 to about 90 mM), alanine at a concentration of about 0.1 to about 450 mM (e.g., about 80 to about 120 mM), asparagine at a concentration of about 0.1 to about 450 mM (e.g., about 80 to about 120 mM), isoleucine at a concentration of about 0.1 to about 450 mM (e.g., about 80 to about 120 mM), serine at a concentration of about 0.1 to about 450 mM (e.g., about 80 to about 120 mM), aspartic acid at a concentration of about 0.1 to about 450 mM (e.g., about 10 to about 30 mM), creatine at a concentration of about 0.1 to about 450 mM (e.g., about 15 to about 35 mM), glutamine at a concentration of about 0.1 to about 450 mM (e.g., about 40 to about 60 mM), leucine at a concentration of about 0.1 to about 450 mM (e.g., about 40 to about 60 mM), phenylalanine at a concentration of about 0.1 to about 450 mM (e.g., about 40 to about 60 mM), tryptophan at a concentration of about 0.1 to about 450 mM (e.g., about 15 to about 35 mM), benzalkonium chloride at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.005% (w/v) to about 0.05% (w/v)), guanidine HCl at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.005% (w/v) to about 0.05% (w/v)), lecithin at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.005% (w/v) to about 0.05% (w/v)), oleic acid at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.005% (w/v) to about 0.05% (w/v)), sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), or about 9% (w/v)), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v) and/or about 4% (w/v)), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)), polyvinyl alcohol, for example, 31K or 205 K polyvinyl alcohol, at a concentration of about 0.01% (w/v) to about 10% (w/v) (e.g., about 0.05% (w/v) to about 0.5% (w/v)), and protamine sulfate at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.05% (w/v)). Optionally, the glutamate-containing stable aqueous adalimumab formulation has

a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00246] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted within this range with MEA or sodium hydroxide.

[00247] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 5% (w/v) to about 10% (w/v), and has a pH of about 5.0 to about 5.5.

[00248] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 5% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00249] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 140 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, dextran at a concentration of about 5% (w/v) to about 15% (w/v), and has a pH of about 5.0 to about 5.5.

[00250] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 140 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, dextran at a concentration of about 5% (w/v) to about 15% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00251] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 200 at a concentration of about 0.5% (w/v) to about 2% (w/v), and has a pH of about 5.0 to about 5.5.

[00252] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 200 at a concentration of about 0.5% (w/v) to about 2% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00253] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 600 at a concentration of about 1.5% (w/v) to about 4% (w/v), and has a pH of about 5.0 to about 5.5.

[00254] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 600 at a concentration of about 1.5% (w/v) to about 4% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00255] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 140 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, proline at a concentration of about 200 to about 300 mM, and has a pH of about 5.0 to about 5.5.

[00256] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 0.5% (w/v) to about 2% (w/v), and has a pH of about 5.0 to about 5.5.

[00257] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, MSA at a concentration of about 50 mM to about 150 mM, TEA at a concentration of about 25 mM to about 75 mM, and has a pH of about 5.0 to about 5.5.

[00258] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, sodium borate at a concentration of about 50 mM to about 100 mM, proline at a concentration of about 50 mM to about 150 mM, and has a pH of about 5.0 to about 5.5.

[00259] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10

mM to about 25 mM, sodium bicarbonate at a concentration of about 50 mM to about 100 mM, proline at a concentration of about 50 mM to about 150 mM, and has a pH of about 5.0 to about 5.5.

[00260] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, sodium sulfate at a concentration of about 50 mM to about 100 mM, proline at a concentration of about 50 mM to about 150 mM, and has a pH of about 5.0 to about 5.5.

[00261] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, calcium sulfate at a concentration of about 10 mM to about 30 mM, proline at a concentration of about 50 mM to about 150 mM, and has a pH of about 5.0 to about 5.5.

[00262] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ammonium sulfate at a concentration of about 50 mM to about 100 mM, proline at a concentration of about 50 mM to about 150 mM, and has a pH of about 5.0 to about 5.5.

[00263] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, calcium chloride at a concentration of about 50 mM to about 100 mM, proline at a concentration of about 50 mM to about 150 mM, and has a pH of about 5.0 to about 5.5.

[00264] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, sodium chloride at a concentration of about 50 mM to about 100 mM, proline at a concentration of about 50 mM to about 150 mM, and has a pH of about 5.0 to about 5.5.

[00265] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 200 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, magnesium chloride at a concentration of about 50 mM to about 100 mM,

proline at a concentration of about 50 mM to about 150 mM, and has a pH of about 5.0 to about 5.5.

[00266] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, MEA at a concentration of about 20 mM to about 50 mM, and has a pH of about 5.0 to about 5.5.

[00267] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, MEA at a concentration of about 70 mM to about 90 mM, and has a pH of about 5.0 to about 5.5.

[00268] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, MEA at a concentration of about 100 mM to about 130 mM, and has a pH of about 5.0 to about 5.5.

[00269] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 1% (w/v) to about 2% (w/v), and has a pH of about 5.0 to about 5.5.

[00270] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.3% (w/v) to about 0.8% (w/v), calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00271] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.3% (w/v) to about 0.8% (w/v), PEG 3350 at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00272] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM

to about 25 mM, TEA at a concentration of about 100 mM to about 200 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00273] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, TEA at a concentration of about 20 mM to about 40 mM, calcium chloride at a concentration of about 60 mM to about 90 mM, and has a pH of about 5.0 to about 5.5.

[00274] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.3% (w/v) to about 0.8% (w/v), and has a pH of about 5.0 to about 5.5.

[00275] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.3% (w/v) to about 0.8% (w/v), PEG 200 at a concentration of about 1.5% (w/v) to about 4% (w/v), and has a pH of about 5.0 to about 5.5.

[00276] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.1% (w/v) to about 0.4% (w/v), PEG 200 at a concentration of about 1.5% (w/v) to about 4% (w/v), and has a pH of about 5.0 to about 5.5.

[00277] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.3% (w/v) to about 0.8% (w/v), MSA at a concentration of about 80 mM to about 120 mM, and has a pH of about 5.0 to about 5.5.

[00278] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.3% (w/v) to about 0.8% (w/v), 10K PVP at a concentration of about 0.3% (w/v) to about 0.8% (w/v), MSA at a concentration of about 80 mM to about 120 mM, and has a pH of about 5.0 to about 5.5.

[00279] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.3% (w/v) to about 0.8% (w/v), MEA at a concentration of about 80 mM to about 120 mM, and has a pH of about 5.0 to about 5.5.

[00280] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, alanine at a concentration of about 80 mM to about 120 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00281] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, asparagine at a concentration of about 80 mM to about 120 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00282] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, isoleucine at a concentration of about 80 mM to about 120 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00283] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, serine at a concentration of about 80 mM to about 120 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00284] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, aspartic acid at a concentration of about 10 mM to about 30 mM, proline at a concentration of about 60 mM to about 100 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00285] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, creatine at a concentration of about 15 mM to about 35 mM, proline at a concentration of about 60 mM to about 90 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00286] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, glutamine at a concentration of about 40 mM to about 60 mM, proline at a

concentration of about 40 mM to about 60 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00287] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, leucine at a concentration of about 40 mM to about 60 mM, proline at a concentration of about 40 mM to about 60 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00288] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, phenylalanine at a concentration of about 40 mM to about 60 mM, proline at a concentration of about 40 mM to about 60 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00289] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, tryptophan at a concentration of about 10 mM to about 40 mM, proline at a concentration of about 60 mM to about 90 mM, calcium chloride at a concentration of about 30 mM to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00290] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, benzalkonium chloride at a concentration of about 0.005% (w/v) to about 0.05% (w/v), proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00291] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, guanidine HCl at a concentration of about 0.005% (w/v) to about 0.05% (w/v), proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00292] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, lecithin at a concentration of about 0.005% (w/v) to about 0.05% (w/v), proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00293] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, oleic acid at a concentration of about 0.005% (w/v) to about 0.05% (w/v), proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00294] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.05% (w/v), proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00295] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, polyvinyl alcohol 205K at a concentration of about 0.05% (w/v) to about 0.5% (w/v), proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00296] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, polyvinyl alcohol 31K at a concentration of about 0.05% (w/v) to about 0.5% (w/v), proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00297] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PVP at a concentration of about 0.005% (w/v) to about 0.05% (w/v), proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00298] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, protamine sulfate at a concentration of about 0.005% (w/v) to about 0.05% (w/v), proline at a concentration of about 250 mM to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00299] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM

to about 25 mM, PEG 400 at a concentration of about 5% (w/v) to about 12% (w/v), glycerol at a concentration of about 0.7% (w/v) to about 1.5% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00300] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 400 at a concentration of about 2% (w/v) to about 6% (w/v), glycerol at a concentration of about 0.7% (w/v) to about 1.5% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00301] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 400 at a concentration of about 0.5% (w/v) to about 2% (w/v), glycerol at a concentration of about 1.5% (w/v) to about 4% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00302] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 400 at a concentration of about 8% (w/v) to about 12% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00303] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PVP at a concentration of about 0.7% (w/v) to about 1.5% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00304] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally

Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00305] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, proline at a concentration of about 80 to about 120 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00306] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 15 hydroxystearate at a concentration of about 1.5% (w/v) to about 4% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00307] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 15 hydroxystearate at a concentration of about 1.5% (w/v) to about 4% (w/v), arginine at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00308] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 15 hydroxystearate at a concentration of about 3% (w/v) to about 8% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00309] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 15 hydroxystearate at a concentration of about 3% (w/v) to about 8% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, proline at a concentration of about 80 to about 120 mM, and optionally Pluronic F68 at a concentration of about 0.05%

(w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00310] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, dextran at a concentration of about 1.5% (w/v) to about 4% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00311] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, imidazole at a concentration of about 1.5% (w/v) to about 4% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00312] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, imidazole at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00313] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, N-acetyl arginine at a concentration of about 100 to about 150 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00314] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, N-acetyl arginine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a

concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00315] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, inositol at a concentration of about 200 to about 300 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00316] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, inositol at a concentration of about 200 to about 300 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00317] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00318] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, taurine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00319] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, citruline at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00320] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, betaine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00321] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, sarcosine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00322] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 400 at a concentration of about 1% (w/v) to about 1.5% (w/v), glycolic acid at a concentration of about 40 to about 80 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00323] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, glycolic acid at a concentration of about 40 to about 80 mM, calcium chloride at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00324] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PCA at a concentration of about 0.7% (w/v) to about 1.5% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00325] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PCA at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00326] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, gelatin at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00327] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, hyaluronic acid at a concentration of about 0.1% (w/v) to about 0.5% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00328] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, hyaluronic acid at a concentration of about 0.1% (w/v) to about 0.5% (w/v), calcium chloride at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00329] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, N-acetyl proline at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00330] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, N-acetyl ornithine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00331] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ornithine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00332] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, beta-alanine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00333] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, niacinamide at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00334] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, medronic acid at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00335] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 200 at a concentration of about 0.7% (w/v) to about 1.5% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00336] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 200 at a concentration of about 0.7% (w/v) to about 1.5% (w/v), calcium chloride at a concentration of about 30 to about 60 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00337] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 600 at a concentration of about 1.5% (w/v) to about 4% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00338] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 600 at a concentration of about 1.5% (w/v) to about 4% (w/v), and calcium chloride at a concentration of about 30 to about 60 mM, and has a pH of about 5.0 to about 5.5.

[00339] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, MSA at a concentration of about 80 to about 120 mM, TEA at a concentration of about 30 to about 70 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00340] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM

to about 25 mM, MSA at a concentration of about 110 to about 140 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00341] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, niacinamide at a concentration of about 250 to about 300 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00342] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, niacinamide at a concentration of about 80 to about 120 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00343] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, niacinamide at a concentration of about 80 to about 120 mM, calcium chloride at a concentration of about 60 to about 100 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00344] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, niacinamide at a concentration of about 80 to about 120 mM, MSA at a concentration of about 60 to about 100 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00345] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, niacinamide at a concentration of about 80 to about 120 mM, PEG 200 at a concentration of about 0.7% (w/v) to about 1.5% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00346] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.25% (w/v) to about 0.75% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00347] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.25% (w/v) to about 0.75% (w/v), PEG 200 at a concentration of about 1.5% (w/v) to about 4% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00348] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.1% (w/v) to about 0.4% (w/v), PEG 200 at a concentration of about 1.5% (w/v) to about 4% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00349] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.1% (w/v) to about 0.4% (w/v), PEG 200 at a concentration of about 1.5% (w/v) to about 4% (w/v), MSA at a concentration of about 80 to about 120 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00350] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.25% (w/v) to about 0.75% (w/v), MSA at a concentration of about 80 to about 120 mM, 10K PVP at a concentration of about 0.25% (w/v) to about 0.75% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to

about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00351] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, ethanol at a concentration of about 0.25% (w/v) to about 0.75% (w/v), MEA at a concentration of about 80 to about 120 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00352] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, benzene sulfonic acid at a concentration of about 100 to about 200 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5. Optionally, the pH of the formulation is adjusted within this range with sodium hydroxide or calcium hydroxide.

[00353] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, benzene sulfonic acid at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00354] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, benzene sulfonic acid at a concentration of about 60 to about 90 mM, calcium chloride at a concentration of about 25 to about 75 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00355] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, benzene sulfonic acid at a concentration of about 60 to about 90 mM, MEA at a concentration of about 60 to about 90 mM, and optionally Pluronic F68 at a concentration of

about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00356] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, adipic acid at a concentration of about 100 to about 200 mM, and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00357] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, glutamate at a concentration of about 10 mM to about 25 mM, PEG 400 at a concentration of about 0.25% (w/v) to about 0.75% (w/v), calcium chloride at a concentration of about 40 to about 80 mM, glycerin at a concentration of about 0.5% (w/v) to about 1% (w/v), and optionally Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.4% (w/v) or Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.1% (w/v), and has a pH of about 5.0 to about 5.5.

[00358] Exemplary aqueous adalimumab formulations are provided in Table A. Each formulation in Table A may optionally include Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), or Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Each formulation in Table A has a pH of about 5.0 to about 5.5, e.g., about 5.1 to about 5.3 and/or about 5.2. Optionally, the pH of each formulation in Table A is adjusted using a strong acid and/or strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

Table A

Protein conc.	Buffer	Excipient(s)¹
100 mg/mL	15 mM glutamate	8% PEG 400 1% glycerol
100 mg/mL	15 mM glutamate	4% PEG 200 1% glycerol
100 mg/mL	15 mM glutamate	1% PEG 400

Protein conc.	Buffer	Excipient(s) ¹
		2.5% glycerol
100 mg/mL	15 mM glutamate	10% PEG 400
100 mg/mL	15 mM glutamate	1% PVP
110 mg/mL	20 mM glutamate	45 mM CaCl ₂
110 mg/mL	20 mM glutamate	45 mM CaCl ₂ 100 mM proline
110 mg/mL	20 mM glutamate	2.5% PEG 15 hydroxystearate
110 mg/mL	20 mM glutamate	2.5% PEG 15 hydroxystearate 75 mM arginine
110 mg/mL	20 mM glutamate	5% PEG 15 hydroxystearate 45 mM CaCl ₂
110 mg/mL	20 mM glutamate	5% PEG 15 hydroxystearate 45 mM CaCl ₂ 100 mM proline
110 mg/mL	20 mM glutamate	2% dextran
110 mg/mL	20 mM glutamate	2% imidazole
110 mg/mL	20 mM glutamate	1% imidazole 45 mM CaCl ₂
110 mg/mL	20 mM glutamate	120 mM N-acetyl arginine
110 mg/mL	20 mM glutamate	120 mM N-acetyl arginine 45 mM CaCl ₂
105 mg/mL	20 mM glutamic acid	250 mM inositol
105 mg/mL	20 mM glutamic acid	180 mM inositol 40 mM CaCl ₂
105 mg/mL	20 mM glutamic acid	1% PEG 3350 40 mM CaCl ₂
105 mg/mL	20 mM glutamic acid	120 mM taurine 40 mM CaCl ₂
105 mg/mL	20 mM glutamic acid	120 mM citrulline 40 mM CaCl ₂
105 mg/mL	20 mM glutamic acid	120 mM betaine 40 mM CaCl ₂
105 mg/mL	20 mM glutamic acid	120 mM sarcosine 40 mM CaCl ₂
105 mg/mL	20 mM glutamic acid	1.2% PEG 400 60 mM glycolic acid
105 mg/mL	20 mM glutamic acid	60 mM glycolic acid 75 mM CaCl ₂
105 mg/mL	20 mM glutamic acid	1% PCA
105 mg/mL	20 mM glutamic acid	1% PCA 75 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	1% Type B gelatin 75 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	0.25% hyaluronic acid
110 mg/mL	20 mM glutamic acid	0.25% hyaluronic acid

Protein conc.	Buffer	Excipient(s) ¹
		75 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	120 mM N-acetyl proline 40 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	120 mM N-acetyl ornithine 40 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	120 mM ornithine 40 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	120 mM beta-alanine 40 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	120 mM niacinamide 40 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	120 mM medronic acid 40 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	1% PEG 200
110 mg/mL	20 mM glutamic acid	1% PEG 200 40 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	2% PEG 600
110 mg/mL	20 mM glutamic acid	2% PEG 600 40 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	100 mM MSA 50 mM TEA
110 mg/mL	20 mM glutamic acid	125 mM MSA
110 mg/mL	20 mM glutamic acid	270 mM niacinamide
110 mg/mL	20 mM glutamic acid	100 mM niacinamide
110 mg/mL	20 mM glutamic acid	100 mM niacinamide 80 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	100 mM niacinamide 80 mM MSA
110 mg/mL	20 mM glutamic acid	100 mM niacinamide 1% PEG 200
110 mg/mL	20 mM glutamic acid	0.5% ethanol
110 mg/mL	20 mM glutamic acid	0.5% ethanol 2% PEG 200
110 mg/mL	20 mM glutamic acid	0.25% ethanol 2% PEG 200
110 mg/mL	20 mM glutamic acid	0.25% ethanol 2% PEG 200 100 mM MSA
110 mg/mL	20 mM glutamic acid	0.5% ethanol 100 mM MSA 0.5% 10K PVP
110 mg/mL	20 mM glutamic acid	0.5% ethanol 100 mM MEA
110 mg/mL	20 mM glutamic acid	150 mM benzene sulfonic acid (adjust pH with NaOH)

Protein conc.	Buffer	Excipient(s) ¹
110 mg/mL	20 mM glutamic acid	150 mM benzene sulfonic acid (adjust pH with Ca(OH) ₂)
110 mg/mL	20 mM glutamic acid	75 mM benzene sulfonic acid
110 mg/mL	20 mM glutamic acid	75 mM benzene sulfonic acid 50 mM CaCl ₂
110 mg/mL	20 mM glutamic acid	75 mM benzene sulfonic acid 75 mM MEA
110 mg/mL	20 mM glutamic acid	150 mM adipic acid
180 mg/mL	20 mM glutamic acid	0.5% PEG 400 60 mM CaCl ₂ 0.7% glycerin

¹All percentages are (w/v).

[00359] In an embodiment, a lyophilized form of any one of the foregoing glutamate-containing adalimumab formulations is provided.

Formulations of Adalimumab With Adipate Buffer

[00360] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 170 to about 190 mg/mL, about 90 to about 120 mg/mL, about 160 to about 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, adipate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 25 mM, about 15 mM to about 20 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients. Suitable excipients include certain stabilizers such as certain amino acids and amino acid derivatives, certain polyethylene glycols and polyethylene glycol derivatives, certain polyols, certain acids, certain amines, certain salts, and certain surfactants. Examples of suitable amino acids and amino acid derivatives include proline (e.g., at a concentration of about 0.1 to about 450 mM or about 50 to about 300 mM) and N-acetyl arginine (e.g., at a concentration of about 0.1 to about 450 mM or about 100 to about 150 mM). Examples of suitable polyethylene glycols and polyethylene glycol derivatives include PEG 400 (e.g., at a concentration of about 0.1% (w/v) to about 20% (w/v) or about 0.3% (w/v) to about 1.5% (w/v)) and PEG 3350 (e.g., at a concentration of about 0.1% (w/v) to about 30% (w/v) or about 0.5% (w/v) to about 2% (w/v)). Examples of suitable polyols include glycerol (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 1% (w/v) to about 2% (w/v)), sucrose (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about

9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), or about 9% (w/v)), and sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)). Examples of suitable acids include MSA (e.g., at a concentration of about 0.1 to about 150 mM, about 0.1 to about 50 mM, and/or about 10 to about 40 mM). Examples of suitable amines include monoethanolamine hydrochloride (MEA-HCl) (e.g., at a concentration of about 0.1 to about 150 mM, about 0.1 to about 40 mM, or about 50 to about 100 mM) and methanolamine (MEA) (e.g., at a concentration of about 0.1 to about 150 mM, about 0.1 to about 50 mM, or about 50 to about 100 mM). Examples of suitable salts include calcium chloride (e.g., at a concentration of about 1 to about 150 mM, about 20 to about 75 mM, about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM) and sodium chloride (e.g., at a concentration of about 10 to about 100 mM, about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM). Examples of suitable surfactants Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Examples of other suitable excipients include imidazole (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v) or about 1% (w/v) to about 1.5% (w/v)) and PVP, for example, 10K PVP, (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v) or about 0.5% (w/v) to about 2% (w/v)). Optionally, the adipate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00361] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 170 to about 190 mg/mL,

about 90 to about 120 mg/mL, about 160 to about 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, adipate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 25 mM, about 15 mM to about 20 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients selected from the group consisting of N-acetyl arginine at a concentration of about 0.1 to about 450 mM (e.g., about 100 to about 150 mM), PEG 400 at a concentration of about 0.1% (w/v) to about 20% (w/v) (e.g., about 0.3% (w/v) to about 1.5% (w/v)), MSA at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM and/or about 10 to about 40 mM), calcium chloride at a concentration of about 1 to about 150 mM (e.g., about 20 to about 75 mM, about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM), monoethanolamide hydrochloride (MEA-HCl) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM or about 50 to about 100 mM), monoethanolamide (MEA) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM or about 50 to about 100 mM), glycerol at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 1% (w/v) to about 2% (w/v)), imidazole at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 1% (w/v) to about 1.5% (w/v)), PVP, for example, 10K PVP, at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 0.5% (w/v) to about 2% (w/v)), PEG 3350 at a concentration of about 0.1% (w/v) to about 30% (w/v) (e.g., about 0.5% (w/v) to about 2% (w/v)), sodium chloride at a concentration of about 10 to about 100 mM (e.g., about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), proline at a concentration of about 0.1 to about 450 mM (e.g., about 50 to about 300 mM), sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), or about 9% (w/v)), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v) and/or about 4% (w/v)), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to

about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the adipate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00362] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, N-acetyl arginine at a concentration of about 100 to about 150 mM, PEG 400 at a concentration of about 0.5% (w/v) to about 1% (w/v), and MSA at a concentration of about 10 to about 30 mM, and has a pH of about 5.0 to about 5.5.

[00363] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, N-acetyl arginine at a concentration of about 100 to about 150 mM, calcium chloride at a concentration of about 30 to about 50 mM, and MSA at a concentration of about 10 to about 30 mM, and has a pH of about 5.0 to about 5.5.

[00364] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, N-acetyl arginine at a concentration of about 100 to about 150 mM, MEA-HCl at a concentration of about 30 to about 70 mM, and MSA at a concentration of about 5 to about 15 mM, and has a pH of about 5.0 to about 5.5.

[00365] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, glycerol at a concentration of about 1% (w/v) to about 2% (w/v), and MSA at a concentration of about 30 to about 50 mM, and has a pH of about 5.0 to about 5.5.

[00366] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, PEG 400 at a concentration of about 0.5% (w/v) to about 2% (w/v), and MSA at a concentration of about 30 to about 50 mM, and has a pH of about 5.0 to about 5.5.

[00367] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, and imidazole at a concentration of about 1% (w/v) to about 1.5% (w/v), and has a pH of about 5.0 to about 5.5.

[00368] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, calcium chloride at a concentration of about 60 to about 90 mM, PEG 400 at a concentration of about 0.1% (w/v) to about 0.5% (w/v), and 10K PVP at a concentration of about 0.5% (w/v) to about 2% (w/v), and has a pH of about 5.0 to about 5.5.

[00369] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, MEA-HCl at a concentration of about 80 to about 120 mM, PEG 400 at a concentration of about 0.1% (w/v) to about 0.5% (w/v), and 10K PVP at a concentration of about 0.5% (w/v) to about 2% (w/v), and has a pH of about 5.0 to about 5.5.

[00370] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, PEG 400 at a concentration of about 0.5% (w/v) to about 2% (w/v), and calcium chloride at a concentration of about 30 to about 50 mM, and has a pH of about 5.0 to about 5.5.

[00371] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 0.5% (w/v) to about 2% (w/v), and calcium chloride at a concentration of about 60 to about 90 mM, and has a pH of about 5.0 to about 5.5.

[00372] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM to about 25 mM, PEG 3350 at a concentration of about 0.5% (w/v) to about 2% (w/v), PEG 400 at a concentration of about 1% (w/v) to about 3% (w/v), and calcium chloride at a concentration of about 10 to about 30 mM, and has a pH of about 5.0 to about 5.5.

[00373] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 170 to about 190 mg/mL, adipate at a concentration of about 10 mM

to about 25 mM, PEG 3350 at a concentration of about 0.5% (w/v) to about 2% (w/v), PEG 400 at a concentration of about 0.5% (w/v) to about 2% (w/v), and calcium chloride at a concentration of about 30 to about 50 mM, and has a pH of about 5.0 to about 5.5.

[00374] Exemplary aqueous adalimumab formulations are provided in Table B. Each formulation in Table B may optionally include Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), or Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Each formulation in Table B has a pH of about 5.0 to about 5.5, e.g., about 5.1 to about 5.3 and/or about 5.2. Optionally, the pH of each formulation in Table B is adjusted using a strong acid and/or strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

Table B

Protein conc.	Buffer	Excipient(s)
180 mg/mL	15 mM adipate	120 mM N-acetyl arginine 0.7% PEG 400 20 mM MSA
180 mg/mL	15 mM adipate	120 mM N-acetyl arginine 40 mM CaCl ₂ 20 mM MSA
180 mg/mL	15 mM adipate	120 mM N-acetyl arginine 50 mM MEA-HCl 10 mM MSA
180 mg/mL	15 mM adipate	1.4% glycerol 40 mM MSA
180 mg/mL	15 mM adipate	1% PEG 400 40 mM MSA
180 mg/mL	15 mM adipate	1.2% imidazole
180 mg/mL	20 mM adipate	75 mM CaCl ₂ 0.3% PEG 400 1% PVP 10K
180 mg/mL	20 mM adipate	100 mM MEA-HCl 0.3% PEG 400 1% PVP 10K
180 mg/mL	20 mM adipate	1% PEG 400 40 mM CaCl ₂

Protein conc.	Buffer	Excipient(s)
180 mg/mL	20 mM adipate	1% PEG 3350 75 mM CaCl ₂
180 mg/mL	20 mM adipate	1% PEG 3350 1.5% PEG 400 20 mM CaCl ₂
180 mg/mL	20 mM adipate	1% PEG 3350 1% PEG 400 40 mM CaCl ₂

[00375] In an embodiment, a lyophilized form of any one of the foregoing adipate-containing adalimumab formulations is provided.

Formulations of Adalimumab With Glucuronate Buffer

[00376] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 170 to about 190 mg/mL, about 90 to about 120 mg/mL, about 160 to about 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, glucuronate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients. Suitable excipients include certain stabilizers such as certain amino acids and amino acid derivatives, certain polyols, certain acids, certain amines, certain salts, and certain surfactants. Examples of suitable amino acids and amino acid derivatives include proline (e.g., at a concentration of about 0.1 to about 450 mM, about 250 to about 350 mM, or about 50 to about 300 mM). Examples of suitable polyols include sucrose (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), or about 9% (w/v)) and sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)). Examples of suitable acids include methane sulfonic acid (MSA) (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 50 mM). Examples of suitable amines include monoethanolamide hydrochloride (MEA-HCl) (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 40 mM) and monoethanolamide (MEA) (e.g., at a concentration of about 0.1 to about 300 mM or about 0.1 to about 50 mM). Examples of suitable salts include sodium chloride (e.g., at a concentration of about 10 to about 100 mM, about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM) and calcium chloride (e.g., at a concentration of about 1 to about 150 mM,

about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM). Examples of suitable surfactants include Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the glucuronate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00377] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 170 to about 190 mg/mL, about 90 to about 120 mg/mL, about 160 to about 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, glucuronate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients selected from the group consisting of proline at a concentration of about 0.1 to about 450 mM (e.g., about 250 to about 350 mM or about 50 to about 300 mM), sodium chloride at a concentration of about 10 to about 100 mM (e.g., about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), calcium chloride at a concentration of about 1 to about 150 mM (e.g., about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM), sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), or about 9% (w/v)), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v))

and/or about 4% (w/v)), methane sulfonic acid (MSA) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM), monoethanolamide hydrochloride (MEA-HCl) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM), monoethanolamide (MEA) at a concentration of about 0.1 to about 300 mM (e.g., about 0.1 to about 50 mM), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the glucuronate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00378] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glucuronate at a concentration of about 10 mM to about 30 mM, and proline at a concentration of about 250 to about 350 mM, and has a pH of about 5.0 to about 5.5.

[00379] Exemplary aqueous adalimumab formulations are provided in Table C. Each formulation in Table C may optionally include Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), or Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Each formulation in Table C has a

pH of about 5.0 to about 5.5, e.g., about 5.1 to about 5.3 and/or about 5.2. Optionally, the pH of each formulation in Table C is adjusted using a strong acid and/or strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

Table C

Protein conc.	Buffer	Excipient(s)
105 mg/mL	20 mM MEA glucuronate	300 mM proline
105 mg/mL	20 mM Na glucuronate	300 mM proline

[00380] In an embodiment, a lyophilized form of any one of the foregoing glucuronate-containing adalimumab formulations is provided.

Formulations of Adalimumab With Acetate Buffer

[00381] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 90 to about 110 mg/mL, about 100 to about 110 mg/mL, about 120 to about 160 mg/mL, about 130 to about 150 mg/mL, about 160 to about 190 mg/mL, about 160 to about 180 mg/mL, about 170 to about 180 mg/mL, about 40 to about 60 mg/mL, about 40 to about 50 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, acetic acid and/or acetate at a concentration of about 0.1 mM to about 300 mM (e.g., about 2 mM to about 30 mM, about 5 mM to about 50 mM, about 5 mM to about 15 mM, about 10 mM to about 20 mM, about 10 mM to about 30 mM, about 15 mM to about 25 mM, about 30 mM to about 40 mM, about 35 mM to about 45 mM, about 40 mM to about 50 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients. Suitable excipients include certain stabilizers such as certain amino acids and amino acid derivatives, certain polyols, certain acids, certain amines, certain salts, certain polysaccharides or polysaccharide derivatives, and certain surfactants. Examples of suitable amino acids and amino acid derivatives include arginine-HCl (e.g., at a concentration of about 0.1 to about 450 mM, about 20 to about 200 mM, about 50 to about 150 mM, about 80 to about 120 mM, and/or about 100 mM) and proline (e.g., at a concentration of about 0.1 to about 450 mM, about 20 to about 400 mM, about 50 to about 350 mM, about 50 to about 300 mM, about 80 to about 300 mM, about 100 to about 250 mM, about 150 to about 230 mM, about 100 to about 140 mM, about 130 to about 170 mM, about 160 to about 200 mM, about 190 to about 230 mM, about 220 to about 260 mM, about 250 to about 290 mM and/or about 220 mM). Examples of suitable polyols include sucrose (e.g., at a concentration of about 0.1% (w/v) to

about 15% (w/v) about 4% (w/v) to about 12% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 5% (w/v) to about 10% (w/v), about 6% (w/v) to about 8% (w/v), about 8% (w/v) to about 10% (w/v), about 8.5% (w/v) to about 9.5% (w/v), about 9% (w/v), about 5.8% (w/v) to about 6.6% (w/v), about 6% (w/v) to about 6.4% (w/v), about 6.2% (w/v), about 6.1% (w/v) to about 6.9% (w/v), about 6.3% (w/v) to about 6.7% (w/v), about 6.5% (w/v), about 6.4% (w/v) to about 7.2% (w/v), about 6.6% (w/v) to about 7% (w/v), about 6.8% (w/v), about 6.5% (w/v) to about 7.3% (w/v), about 6.7% (w/v) to about 7.1% (w/v), about 6.9% (w/v), about 6.6% (w/v) to about 7.4% (w/v), about 6.8% (w/v) to about 7.2% (w/v), about 7% (w/v), about 6.9% (w/v) to about 7.7% (w/v), about 7.1% (w/v) to about 7.5% (w/v), and/or about 7.3% (w/v)) and sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)). Examples of suitable acids include MSA (e.g., at a concentration of about 0.1 to about 150 mM, about 0.1 to about 50 mM, about 10 to about 50 mM, about 20 to about 40 mM, about 30 mM, about 30 to about 50 mM, about 40 to about 60 mM, about 50 to about 70 mM, about 60 to about 80 mM, about 70 to about 90 mM, and/or about 80 to about 100 mM). Examples of suitable amines include MEA-HCl (e.g., at a concentration of about 0.1 to about 150 mM, about 0.1 to about 40 mM, about 10 to about 50 mM, about 20 to about 40 mM, about 30 mM, about 30 to about 50 mM, about 40 to about 60 mM, about 50 to about 70 mM, about 60 to about 80 mM, about 70 to about 90 mM, and/or about 80 to about 100 mM) and MEA (e.g., at a concentration of about 0.1 to about 300 mM, about 0.1 to about 50 mM, about 10 to about 50 mM, about 20 to about 40 mM, about 30 mM, about 30 to about 50 mM, about 40 to about 60 mM, about 50 to about 70 mM, about 60 to about 80 mM, about 70 to about 90 mM, and/or about 80 to about 100 mM). Examples of suitable salts include calcium chloride (e.g., at a concentration of about 1 to about 150 mM, about 5 to about 50 mM, about 5 to about 15 mM, about 10 to about 40 mM, about 10 to about 30 mM, about 15 to about 35 mM, about 20 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 50 mM, about 40 to about 60 mM, about 40 to about 80 mM, about 50 to about 100 mM, about 10 mM, about 25 mM, and/or about 45 mM) and sodium chloride (e.g., at a concentration of about 10 to about 100 mM, about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM). Examples of suitable polysaccharides or polysaccharide derivatives include sodium carboxymethylcellulose (NaCMC) (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 0.1% (w/v) to about 5% (w/v), about 0.1% (w/v) to about 2% (w/v),

about 0.1% (w/v) to about 1% (w/v), and/or about 0.1% (w/v) to about 0.5% (w/v)). Examples of suitable surfactants include guanidine hydrochloride (GnHCl) (e.g., at a concentration of about 0.1 to about 150 mM, 5 to about 50 mM, about 10 to about 40 mM, about 15 to about 30 mM, and/or 20 mM), Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.01% (w/v) to about 0.1% (w/v), about 0.01% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.5% (w/v), about 0.1% (w/v) to about 2% (w/v), about 0.2% (w/v) to about 1% (w/v), about 0.01% (w/v), about 0.05% (w/v), about 0.1% (w/v), and/or about 0.4% (w/v)), Docusate sodium (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.005% (w/v) to about 0.05% (w/v)), benzalkonium chloride (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.05% (w/v) to about 0.5% (w/v)), Span 40 (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v) or about 0.05% (w/v) to about 0.5% (w/v)), Triton X-100 (e.g., at a concentration of about 0.001% (w/v) to about 1% (w/v), about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.02% (w/v) to about 0.1% (w/v), and/or about 0.05% (w/v) to about 0.2% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.02% (w/v) to about 0.1% (w/v), and/or about 0.05% (w/v) to about 0.2% (w/v)), and Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.02% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), 0.04% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.2% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the acetate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00382] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about

90 to about 110 mg/mL, about 100 to about 110 mg/mL, about 120 to about 160 mg/mL, about 130 to about 150 mg/mL, about 160 to about 190 mg/mL, about 160 to about 180 mg/mL, about 170 to about 180 mg/mL, about 40 to about 60 mg/mL, about 40 to about 50 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, acetic acid and/or acetate at a concentration of about 0.1 mM to about 300 mM (e.g., about 2 mM to about 30 mM, about 5 mM to about 50 mM, about 5 mM to about 15 mM, about 10 mM to about 20 mM, about 10 mM to about 30 mM, about 15 mM to about 25 mM, about 30 mM to about 40 mM, about 35 mM to about 45 mM, about 40 mM to about 50 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients selected from the group consisting of sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 12% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 5% (w/v) to about 10% (w/v), about 6% (w/v) to about 8% (w/v), about 8% (w/v) to about 10% (w/v), about 8.5% (w/v) to about 9.5% (w/v), about 9% (w/v), about 5.8% (w/v) to about 6.6% (w/v), about 6% (w/v) to about 6.4% (w/v), about 6.2% (w/v), about 6.1% (w/v) to about 6.9% (w/v), about 6.3% (w/v) to about 6.7% (w/v), about 6.5% (w/v), about 6.4% (w/v) to about 7.2% (w/v), about 6.6% (w/v) to about 7% (w/v), about 6.8% (w/v), about 6.5% (w/v) to about 7.3% (w/v), about 6.7% (w/v) to about 7.1% (w/v), about 6.9% (w/v), about 6.6% (w/v) to about 7.4% (w/v), about 6.8% (w/v) to about 7.2% (w/v), about 7% (w/v), about 6.9% (w/v) to about 7.7% (w/v), about 7.1% (w/v) to about 7.5% (w/v), and/or about 7.3% (w/v)), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v) and/or about 4% (w/v)), calcium chloride at a concentration of about 1 to about 150 mM (e.g., about 5 to about 50 mM, about 5 to about 15 mM, about 10 to about 40 mM, about 10 to about 30 mM, about 15 to about 35 mM, about 20 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 50 mM, about 40 to about 60 mM, about 40 to about 80 mM, about 50 to about 100 mM, about 10 mM, about 25 mM, and/or about 45 mM), sodium chloride at a concentration of about 10 to about 100 mM (e.g., about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), MSA at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM, about 10 to about 50 mM, about 20 to about 40 mM, about 30 mM, about 30 to about 50 mM, about 40 to about 60 mM, about 50 to about 70 mM, about 60 to about 80 mM, about 70 to about 90 mM, and/or about 80 to about 100 mM), MEA-HCl at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM, about 10 to about 50 mM, about 20 to about 40

mM, about 30 mM, about 30 to about 50 mM, about 40 to about 60 mM, about 50 to about 70 mM, about 60 to about 80 mM, about 70 to about 90 mM, and/or about 80 to about 100 mM), MEA at a concentration of about 0.1 to about 300 mM (e.g., about 0.1 to about 50 mM, about 10 to about 50 mM, about 20 to about 40 mM, about 30 mM, about 30 to about 50 mM, about 40 to about 60 mM, about 50 to about 70 mM, about 60 to about 80 mM, about 70 to about 90 mM, and/or about 80 to about 100 mM), guanidine hydrochloride (GnHCl) at a concentration of about 0.1 to about 150 mM (e.g., 5 to about 50 mM, about 10 to about 40 mM, about 15 to about 30 mM, and/or 20 mM), sodium carboxymethylcellulose (NaCMC) at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 0.1% (w/v) to about 5% (w/v), about 0.1% (w/v) to about 2% (w/v), about 0.1% (w/v) to about 1% (w/v), and/or about 0.1% (w/v) to about 0.5% (w/v)), arginine-HCl at a concentration of about 0.1 to about 450 mM (e.g., about 20 to about 200 mM, about 50 to about 150 mM, about 80 to about 120 mM, and/or about 100 mM), proline at a concentration of about 0.1 to about 450 mM (e.g., about 20 to about 400 mM, about 50 to about 350 mM, about 50 to about 300 mM, about 80 to about 300 mM, about 100 to about 250 mM, about 150 to about 230 mM, about 100 to about 140 mM, about 130 to about 170 mM, about 160 to about 200 mM, about 190 to about 230 mM, about 220 to about 260 mM, about 250 to about 290 mM and/or about 220 mM), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.01% (w/v) to about 0.1% (w/v), about 0.01% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.5% (w/v), about 0.1% (w/v) to about 2% (w/v), about 0.2% (w/v) to about 1% (w/v), about 0.01% (w/v), about 0.05% (w/v), about 0.1% (w/v), and/or about 0.4% (w/v)), Docusate sodium at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.005% (w/v) to about 0.05% (w/v)), benzalkonium chloride at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.05% (w/v) to about 0.5% (w/v)), Span 40 at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.05% (w/v) to about 0.5% (w/v)), Triton X-100 at a concentration of about 0.001% (w/v) to about 1% (w/v) (e.g., about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.02% (w/v) to about 0.1% (w/v), and/or about 0.05% (w/v) to about 0.2% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.02% (w/v) to about 0.1% (w/v), and/or about 0.05% (w/v) to

about 0.2% (w/v)), and Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.02% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), 0.04% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.2% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the acetate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00383] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00384] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00385] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00386] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Docusate sodium at a concentration of about 0.005% (w/v) to about 0.05% (w/v), and has a pH of about 5.1 to 5.3.

[00387] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and benzalkonium chloride at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00388] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Span 40 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00389] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Triton X-100 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00390] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, and arginine-HCl at a concentration of about 80 to about 120 mM, and has a pH of about 5.1 to 5.3.

[00391] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 80 at a concentration of about 0.0025% (w/v) to about 0.025% (w/v), and has a pH of about 5.1 to 5.3.

[00392] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 80 at a concentration of about 0.005% (w/v) to about 0.05% (w/v), and has a pH of about 5.1 to 5.3.

[00393] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM

to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 80 at a concentration of about 0.025% (w/v) to about 0.25% (w/v), and has a pH of about 5.1 to 5.3.

[00394] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 20 at a concentration of about 0.0025% (w/v) to about 0.025% (w/v), and has a pH of about 5.1 to 5.3.

[00395] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 20 at a concentration of about 0.005% (w/v) to about 0.05% (w/v), and has a pH of about 5.1 to 5.3.

[00396] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Polysorbate 20 at a concentration of about 0.025% (w/v) to about 0.25% (w/v), and has a pH of about 5.1 to 5.3.

[00397] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Triton X-100 at a concentration of about 0.0025% (w/v) to about 0.025% (w/v), and has a pH of about 5.1 to 5.3.

[00398] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Triton X-100 at a concentration of about 0.005% (w/v) to about 0.05% (w/v), and has a pH of about 5.1 to 5.3.

[00399] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl

at a concentration of about 80 to about 120 mM, and Triton X-100 at a concentration of about 0.025% (w/v) to about 0.25% (w/v), and has a pH of about 5.1 to 5.3.

[00400] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Pluronic F68 at a concentration of about 0.025% (w/v) to about 0.25% (w/v), and has a pH of about 5.1 to 5.3.

[00401] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00402] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 120 to about 160 mg/mL, acetate at a concentration of about 15 mM to about 25 mM, calcium chloride at a concentration of about 30 to about 60 mM, arginine-HCl at a concentration of about 80 to about 120 mM, and Pluronic F68 at a concentration of about 0.2% (w/v) to about 0.6% (w/v), and has a pH of about 5.1 to 5.3.

[00403] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 150 to about 180 mg/mL, acetate at a concentration of about 5 mM to about 10 mM, sucrose at a concentration of about 7% (w/v) to about 10% (w/v), and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.2% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00404] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 50 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.1% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00405] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 50 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.0% (w/v) to about 6.5% (w/v), calcium

chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00406] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 50 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.6% (w/v) to about 7.2% (w/v), MEA-HCl at a concentration of about 20 to about 40 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00407] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 50 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.7% (w/v) to about 7.3% (w/v), calcium chloride at a concentration of about 5 to about 15 mM, guanidine hydrochloride (GnHCl) at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00408] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 50 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.7% (w/v) to about 7.3% (w/v), calcium chloride at a concentration of about 5 to about 15 mM, NaCMC at a concentration of about 0.2% (w/v) to about 1% (w/v), and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00409] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, and sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl and/or NaOH.

[00410] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00411] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8.5% (w/v) to about 9.5% (w/v), and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.2% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00412] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00413] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8.5% (w/v) to about 9.5% (w/v), and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.2% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00414] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.4% (w/v) to about 7.2% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00415] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00416] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), MEA-HCl at a concentration of about 20 to about 40 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00417] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.9% (w/v) to about 7.7% (w/v), MSA at a concentration of about 20 to about 40 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with NaOH, Ca(OH)₂, or MEA.

[00418] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), sodium chloride at a concentration of about 20 to about 45 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00419] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Pluronic F68 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00420] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8.5% (w/v) to about 9.5% (w/v), and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00421] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.4% (w/v) to about 7.2% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00422] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00423] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), MEA-HCl at a concentration of about 20 to about 40 mM, and Pluronic F68 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00424] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.9% (w/v) to about 7.7% (w/v), MSA at a concentration of about 20 to about 40 mM, and Pluronic F68 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with NaOH, Ca(OH)₂, or MEA.

[00425] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), sodium chloride at a concentration of about 20 to about 45 mM, and Pluronic F68 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00426] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00427] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.4% (w/v) to about 7.2% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00428] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00429] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), MEA-HCl at a concentration of about 20 to about 40 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00430] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.9% (w/v) to about 7.7% (w/v), MSA at a concentration of about 20 to about 40 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with NaOH, Ca(OH)₂, or MEA.

[00431] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), sodium chloride at a concentration of about 20 to about 45 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00432] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00433] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8.5% (w/v) to about 9.5% (w/v), and Polysorbate 80 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00434] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.4% (w/v) to about 7.2% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00435] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.6% (w/v) to about 7 % (w/v), calcium chloride at a concentration of about 20 to about 30 mM, and Polysorbate 80 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00436] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00437] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), MEA-HCl at a concentration of about 20 to about 40 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00438] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.9% (w/v) to about 7.7% (w/v), MSA at a concentration of about 20 to about 40 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with NaOH, Ca(OH)₂, or MEA.

[00439] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), sodium chloride at a concentration of about 20 to about 45 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00440] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.7% (w/v) to about 7.1% (w/v), sodium chloride at a concentration of about 25 to about 40 mM, and Polysorbate 80 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00441] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00442] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.4% (w/v) to about 7.2% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00443] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00444] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), MEA-HCl at a concentration of about 20 to about 40 mM, and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00445] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.9% (w/v) to about 7.7% (w/v), MSA at a concentration of about 20 to about 40 mM, and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with NaOH, Ca(OH)₂, or MEA.

[00446] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), sodium chloride at a concentration of about 20 to about 45 mM, and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00447] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00448] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.4% (w/v) to about 7.2% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00449] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00450] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), MEA-HCl at a concentration of about 20 to about 40 mM, and Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00451] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.9% (w/v) to about 7.7% (w/v), MSA at a concentration of about 20 to about 40 mM, and Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with NaOH, Ca(OH)₂, or MEA.

[00452] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, acetate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 6.5% (w/v) to about 7.3% (w/v), sodium chloride at a concentration of about 20 to about 45 mM, and Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00453] Exemplary aqueous adalimumab formulations are provided in Table D. Each formulation in Table D may optionally include Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.01% (w/v) to about 0.1% (w/v), about 0.01% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.5% (w/v), about 0.1% (w/v) to about 2% (w/v), about 0.2% (w/v) to about 1% (w/v), about 0.01% (w/v), about 0.05% (w/v), about 0.1% (w/v), and/or about 0.4% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.02% (w/v) to about 0.1% (w/v), and/or about 0.05% (w/v) to about 0.2% (w/v)), or Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.02% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), 0.04% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.2% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Each formulation in Table D has a pH of about 5.0 to about 5.5, e.g., about 5.1 to about 5.3 and/or about 5.2. Optionally, the pH of each formulation in Table D is adjusted using a strong acid and/or strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

Table D

Protein conc.	Buffer	Excipient(s)
50 mg/mL	10 mM sodium acetate	6.8% (w/v) sucrose 25 mM CaCl ₂
50 mg/mL	10 mM calcium acetate	6.2% (w/v) sucrose 25 mM CaCl ₂
50 mg/mL	10 mM sodium acetate	6.9% (w/v) sucrose 30 mM MEA-HCl
50 mg/mL	10 mM sodium acetate	7% (w/v) sucrose 10 mM CaCl ₂ 20 mM GnHCl
50 mg/mL	10 mM sodium acetate	7% (w/v) sucrose 10 mM CaCl ₂ 0.5% NaCMC
50 mg/mL	10 mM acetate	9% (w/v) sucrose
100 mg/mL	10 mM acetate	9% (w/v) sucrose
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl

[00454] Exemplary aqueous adalimumab formulations are provided in Table E. Each formulation in Table E has a pH of about 5.0 to about 5.5, e.g., about 5.1 to about 5.3 and/or about 5.2. Optionally, the pH of each formulation in Table E is adjusted using a strong acid and/or strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

Table E

Protein conc.	Buffer	Excipient(s)	Surfactant
50 mg/mL	10 mM sodium acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	0.1% (w/v) Pluronic F68
50 mg/mL	10 mM calcium acetate	6.2% (w/v) sucrose 25 mM CaCl ₂	0.1% (w/v) Pluronic F68
50 mg/mL	10 mM sodium acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	0.1% (w/v) Pluronic F68
50 mg/mL	10 mM sodium acetate	7% (w/v) sucrose 10 mM CaCl ₂ 20 mM GnHCl	0.1% (w/v) Pluronic F68

Protein conc.	Buffer	Excipient(s)	Surfactant
50 mg/mL	10 mM sodium acetate	7% (w/v) sucrose 10 mM CaCl ₂ 0.5% NaCMC	0.1% (w/v) Pluronic F68
50 mg/mL	10 mM acetate	9% (w/v) sucrose	0.1% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	9% (w/v) sucrose	0.1% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	0.1% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	0.1% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	0.1% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	0.1% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	0.1% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	9% (w/v) sucrose	0.05% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	0.05% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	0.05% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	0.05% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	0.05% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	0.05% (w/v) Pluronic F68
100 mg/mL	10 mM acetate	9% (w/v) sucrose	0.1% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	0.1% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	0.1% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	0.1% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	0.1% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	0.1% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	9% (w/v) sucrose	0.05% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	0.05% (w/v) Polysorbate 80

Protein conc.	Buffer	Excipient(s)	Surfactant
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	0.05% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	0.05% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	0.05% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	0.05% (w/v) Polysorbate 80
100 mg/mL	10 mM acetate	9% (w/v) sucrose	0.1% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	0.1% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	0.1% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	0.1% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	0.1% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	0.1% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	9% (w/v) sucrose	0.05% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	0.05% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	0.05% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	0.05% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	0.05% (w/v) Polysorbate 20
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	0.05% (w/v) Polysorbate 20

[00455] Exemplary aqueous adalimumab formulations are provided in Table F.

Table F

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	Surfactant	pH
50 mg/mL	10 mM sodium acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	Surfactant	pH
50 mg/mL	10 mM calcium acetate	6.2% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
50 mg/mL	10 mM sodium acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
50 mg/mL	10 mM sodium acetate	7% (w/v) sucrose 10 mM CaCl ₂ 20 mM GnHCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
50 mg/mL	10 mM sodium acetate	7% (w/v) sucrose 10 mM CaCl ₂ 0.5% NaCMC	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
50 mg/mL	10 mM acetate	9% (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	9% (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ ,	0.1% (w/v) Pluronic F68	5.2

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	Surfactant	pH
			HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA		
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	NaOH, Ca(OH) ₂ , or MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	9% (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Pluronic F68	5.2

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	Surfactant	pH
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	NaOH, Ca(OH) ₂ , or MEA	0.05% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM acetate	9% (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	NaOH, Ca(OH) ₂ , or MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	9% (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ ,	0.05% (w/v) Polysorbate 80	5.2

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	Surfactant	pH
			HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA		
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	NaOH, Ca(OH) ₂ , or MEA	0.05% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	9% (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.04% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.04% (w/v) Polysorbate 80	5.2

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	Surfactant	pH
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.04% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.04% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	NaOH, Ca(OH) ₂ , or MEA	0.04% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.04% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	9% (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.03% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.03% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.03% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂	0.03% (w/v) Polysorbate 80	5.2

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	Surfactant	pH
			2, or MSA/MEA		
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	NaOH, Ca(OH) ₂ , or MEA	0.03% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.03% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM acetate	9% (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	NaOH, Ca(OH) ₂ , or MEA	0.1% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 20	5.2

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	Surfactant	pH
100 mg/mL	10 mM acetate	9% (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	6.8% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 30 mM MEA-HCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	7.3% (w/v) sucrose 30 mM MSA	NaOH, Ca(OH) ₂ , or MEA	0.05% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM acetate	6.9% (w/v) sucrose 35 mM NaCl	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 20	5.2

[00456] Exemplary aqueous adalimumab formulations are also provided in Tables 8, 9, 12, 14 and 15. In an embodiment, the stable aqueous adalimumab formulation is one of the acetate formulations described in Tables D, E, F, 8, 9, 12, 14 or 15 provided herein.

[00457] In an embodiment, a lyophilized form of any one of the foregoing acetate-containing adalimumab formulations is provided.

Formulations of Adalimumab With Benzoate Buffer

[00458] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 170 to about 190, about 160 to about 190 mg/mL, about 60 to about 90 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, benzoate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients. Suitable excipients include certain stabilizers such as certain amino acids and amino acid derivatives, certain polyols, certain acids, certain amines, certain salts, and certain surfactants. Examples of suitable amino acids and amino acid derivatives include proline (e.g., at a concentration of about 0.1 to about 450 mM, about 50 to about 300 mM, or about 250 mM to about 350 mM). Examples of suitable polyols include sucrose (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)) and sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)). Examples of suitable acids include methane sulfonic acid (MSA) (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 50 mM). Examples of suitable amines include MEA-HCl (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 40 mM) and MEA (e.g., at a concentration of about 0.1 to about 300 mM or about 0.1 to about 50 mM). Examples of suitable salts include sodium chloride (e.g., at a concentration of about 10 to about 100 mM, about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM) and calcium chloride (e.g., at a concentration of about 1 to about 150 mM, about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM). Examples of suitable surfactants include Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1%

(w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the benzoate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00459] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 170 to about 190, about 160 to about 190 mg/mL, about 60 to about 90 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, benzoate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients selected from the group consisting of proline at a concentration of about 0.1 to about 450 mM (e.g., about 50 to about 300 mM or about 250 mM to about 350 mM), sodium chloride at a concentration of about 10 to about 100 mM (e.g., about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), calcium chloride at a concentration of about 1 to about 150 mM (e.g., about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM), sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v) and/or about 4% (w/v)), methane sulfonic acid (MSA) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM), MEA-HCl at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM), MEA at a concentration of about 0.1 to about 300 mM (e.g., about 0.1 to about 50 mM), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.01% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1%

(w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the benzoate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00460] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 60 to about 90 mg/mL, benzoate at a concentration of about 10 mM to about 30 mM, and proline at a concentration of about 250 to about 350 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA.

[00461] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, benzoate at a concentration of about 10 mM to about 30 mM, and proline at a concentration of about 250 to about 350 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with NaOH.

[00462] In an embodiment, a lyophilized form of any one of the foregoing benzoate-containing adalimumab formulations is provided.

Formulations of Adalimumab With Glycolate Buffer

[00463] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 170 to about 190, about 160 to about 190 mg/mL, about 60 to about 90 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, glycolate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients. Suitable excipients include certain stabilizers such as certain amino acids and amino acid derivatives, certain polyols, certain acids, certain amines, certain salts, and certain surfactants. Examples of suitable amino acids and amino acid derivatives include proline (e.g., at a concentration of about 0.1 to about 450 mM, about 250 mM to about 350 mM, or about 50 to about 300 mM). Examples of suitable polyols include sucrose (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about

6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)) and sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)). Examples of suitable acids include methane sulfonic acid (MSA) (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 50 mM). Examples of suitable amines include MEA-HCl (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 40 mM) and MEA (e.g., at a concentration of about 0.1 to about 300 mM or about 0.1 to about 50 mM). Examples of suitable salts include sodium chloride (e.g., at a concentration of about 10 to about 100 mM, about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM) and calcium chloride (e.g., at a concentration of about 1 to about 150 mM, about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM). Examples of suitable surfactants include Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the glycolate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00464] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 170 to about 190, about 160 to about 190 mg/mL, about 60 to about 90 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, glycolate at a concentration of about 5 mM to about 50 mM (e.g., about 10 mM to about 30 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients selected

from the group consisting of proline at a concentration of about 0.1 to about 450 mM (e.g., about 250 mM to about 350 mM or about 50 to about 300 mM), sodium chloride at a concentration of about 10 to about 100 mM (e.g., about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), calcium chloride at a concentration of about 1 to about 150 mM (e.g., about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM), sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v) and/or about 4% (w/v)), methane sulfonic acid (MSA) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM), MEA-HCl at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM), MEA at a concentration of about 0.1 to about 300 mM (e.g., about 0.1 to about 50 mM), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the glycolate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00465] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, glycolate at a concentration of about 10 mM to about 30 mM, and proline at a concentration of about 250 to about 350 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA or NaOH.

[00466] In an embodiment, a lyophilized form of any one of the foregoing glycolate-containing adalimumab formulations is provided.

Formulations of Adalimumab With Lactate Buffer

[00467] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 160 to 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, lactic acid and/or lactate at a concentration of about 0.1 mM to about 300 mM (e.g., about 2 mM to about 30 mM, about 10 mM to about 30 mM, about 5 mM to about 15 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients. Suitable excipients include certain stabilizers such as certain amino acids and amino acid derivatives, certain polyethylene glycols and polyethylene glycol derivatives, certain salts, certain polyols, certain acids, certain amines, and certain surfactants. Examples of suitable amino acids include proline (e.g., at a concentration of about 0.1 to about 450 mM, about 50 to about 300 mM, about 110 to about 300 mM, about 250 to about 350 mM, about 190 to about 250 mM, and/or about 220 mM). Examples of suitable polyethylene glycols include PEG 600 (e.g., at a concentration of about 0.1% (w/v) to about 30% (w/v) or about 4% (w/v) to about 13% (w/v)), PEG 400 (e.g., at a concentration of about 0.1% (w/v) to about 20% (w/v) or about 0.5% (w/v) to about 2% (w/v)), and PEG 200 (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v) or about 1.6% (w/v) to about 3.8% (w/v)). Examples of suitable salts include calcium chloride (e.g., at a concentration of about 1 to about 150 mM, about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM) and sodium chloride (e.g., at a concentration of about 10 to about 100 mM, about 60 to about 90 mM, about 15 to about 50 mM, or about 35 mM). Examples of suitable polyols include sucrose (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)) and sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)). Examples of suitable acids include methane sulfonic acid (MSA) (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 50 mM). Examples of suitable amines include monoethanolamide hydrochloride (MEA-HCl) (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 40 mM).

and monoethanolamide (MEA) (e.g., at a concentration of about 0.1 to about 300 mM or about 0.1 to about 50 mM). Examples of suitable surfactants include Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.5% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), 0.04% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the lactate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00468] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 160 to 190 mg/mL, or about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, lactic acid and/or lactate at a concentration of about 0.1 mM to about 300 mM (e.g., about 2 mM to about 30 mM, about 10 mM to about 30 mM, about 5 mM to about 15 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients selected from the group consisting of proline at a concentration of about 0.1 to about 450 mM (e.g., about 50 to about 300 mM, about 110 to about 300 mM, about 250 to about 350 mM, about 190 to about 250 mM, and/or about 220 mM), PEG 600 at a concentration of about 0.1% (w/v) to about 30% (w/v) (e.g., about 4% (w/v) to about 13% (w/v)), PEG 400 at a concentration of about 0.1% (w/v) to about 20% (w/v) (e.g., about 0.5% (w/v) to about 2% (w/v)), PEG 200 at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 1.6% (w/v) to about 3.8% (w/v)), calcium chloride at a concentration of about 1 to about 150 mM (e.g., about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM), sodium

chloride at a concentration of about 10 to about 100 mM (e.g., about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v) and/or about 4% (w/v)), methane sulfonic acid (MSA) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM), monoethanolamide hydrochloride (MEA-HCl) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM), monoethanolamide (MEA) at a concentration of about 0.1 to about 300 mM (e.g., about 0.1 to about 50 mM), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.5% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), 0.04% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the lactate-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00469] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 10 mM to about 30 mM, and proline at a concentration of about 250 to about 350 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA or NaOH.

[00470] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 8% (w/v) to about 9% (w/v), and Pluronic

F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00471] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 3% (w/v) to about 5% (w/v), PEG 200 at a concentration of about 1.2% (w/v) to about 2% (w/v), and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00472] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 8% (w/v) to about 9% (w/v), and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00473] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 3% (w/v) to about 5% (w/v), PEG 200 at a concentration of about 1.2% (w/v) to about 2% (w/v), and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00474] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 200 at a concentration of about 3.5% (w/v) to about 4.2% (w/v), and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00475] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 250 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3.

[00476] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 190 to about 240 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05%

(w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00477] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 200 to about 250 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00478] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 11% (w/v) to about 15% (w/v), calcium chloride at a concentration of about 20 to about 40 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00479] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 11% (w/v) to about 15% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00480] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 8% (w/v) to about 9% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00481] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 3% (w/v) to about 5% (w/v), PEG 200 at a concentration of about 1.2% (w/v) to about 2% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about

0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00482] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 200 at a concentration of about 3.5% (w/v) to about 4.2% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00483] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, PEG 600 at a concentration of about 5% (w/v) to about 5.7% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, proline at a concentration of about 90 to about 130 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00484] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, calcium chloride at a concentration of about 10 to about 30 mM, proline at a concentration of about 190 to about 250 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MSA and/or MEA.

[00485] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, calcium chloride at a concentration of about 15 to about 35 mM, proline at a concentration of about 190 to about 250 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00486] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, calcium chloride at a concentration of about 15 to about 35 mM, proline at a concentration of about 190 to about 250 mM, and Pluronic F68 at a concentration of about

0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00487] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00488] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Pluronic F68 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00489] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8.5% (w/v) to about 9.5% (w/v), and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00490] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 15 mM to about 35 mM, and Pluronic F68 at a concentration of about 0.005% (w/v) to about 0.05% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00491] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 15 mM to about 35 mM, and Pluronic F68 at a concentration of about

0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00492] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, calcium chloride at a concentration of about 15 to about 35 mM, proline at a concentration of about 190 to about 250 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00493] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, calcium chloride at a concentration of about 15 to about 35 mM, proline at a concentration of about 190 to about 250 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00494] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00495] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00496] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, calcium chloride at a concentration of about 15 to about 35 mM, proline at a concentration of about 190 to about 250 mM, and Polysorbate 20 at a concentration of about

0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00497] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, calcium chloride at a concentration of about 15 to about 35 mM, proline at a concentration of about 190 to about 250 mM, and Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00498] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00499] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, lactate at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 8% (w/v) to about 10% (w/v), and Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, Ca(OH)₂, MEA, and/or MSA.

[00500] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 mg/ml to about 200 mg/ml, or about 160 mg/ml to about 190 mg/mL, or about 80 mg/ml to about 120 mg/ml, or about 90 mg/ml to about 110 mg/ml, or about 95 mg/ml to about 105 mg/ml, or about 40 mg/ml, or about 45 mg/ml, or about 50 mg/ml, or about 55 mg/ml, or about 60 mg/ml, or about 65 mg/ml, or about 70 mg/ml, or about 75 mg/ml, or about 80 mg/ml, or about 85 mg/ml, or about 90 mg/ml, or about 95 mg/ml, or about 100 mg/ml, or about 105 mg/ml, or about 110 mg/ml, or about 115 mg/ml, or about 120 mg/ml, or about 125 mg/ml, or about 130 mg/ml, or about 135 mg/ml, or about 140 mg/ml, or about 145 mg/ml, or about 150 mg/ml, or about 155 mg/ml, or about 160 mg/ml, or about 165 mg/ml, or about 170 mg/ml, or about 175 mg/ml, or about 180 mg/ml, or about 185 mg/ml, or about 190 mg/mL, with the following excipients:

- (a) lactate buffer at a concentration of about 5 mM to about 15 mM, or about 7 mM to about 12 mM, or about 9 mM to about 11 mM, or about 5 mM, or about 6 mM, or about 7 mM, or about 8 mM, or about 8 mM, or about 9 mM, or about 10 mM, or about 11 mM, or about 12 mM, or about 13 mM, or about 14 mM, or about 15 mM;
- (b) calcium chloride at a concentration of about 5 to about 30 mM, about 10 to about 20 mM, or about 12.5 mM to about 17.5 mM, or about 14 mM to about 16 mM, or about 10 mM, or about 10.5 mM, or about 11 mM, or about 11.5 mM, or about 12 mM, or about 12.5 mM, or about 13 mM, or about 13.5 mM, or about 14 mM, or about 14.5 mM, or about 15 mM, or about 15.5 mM, or about 16 mM, or about 16.5 mM, or about 17 mM, or about 17.5 mM, or about 18 mM, or about 18.5 mM, or about 19 mM, or about 19.5 mM, or about 20 mM;
- (c) sucrose at a concentration of about 4% (w/v) to about 10% (w/v), or about 6% (w/v) to about 8.5% (w/v), or about 4% (w/v), or about 4.5% (w/v), or about 5% (w/v), or about 5.5% (w/v), or about 6% (w/v), or about 6.5% (w/v), or about 7% (w/v), or about 7.1% (w/v), or about 7.2% (w/v), or about 7.3% (w/v), or about 7.4% (w/v), or about 7.5% (w/v), or about 7.6% (w/v), or about 7.7% (w/v), or about 7.8% (w/v), or about 8% (w/v), or about 8.5% (w/v);
- (d) Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.09% (w/v), or about 0.03% (w/v) to about 0.06% (w/v), about 0.01% (w/v) to about 0.2% (w/v), about 0.01% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), or about 0.05% (w/v) to about 0.07% (w/v), or about 0.03% (w/v), or about 0.04% (w/v), or about 0.05% (w/v), or about 0.06% (w/v), or about 0.07% (w/v), or about 0.08% (w/v), about 0.09% (w/v), or about 0.1% (w/v); and
- (e) has a pH of about 3.5 to about 8, or about 4 to about 7, or about 4.5 to about 6, or about 5 to about 5.5, or about 3.5, or about 4, or about 4.5, or about 4.6, or about 4.7, or about 4.8, or about 4.9, or about 5.0, or about 5.1, or about 5.2, or about 5.3, or about 5.4, or about 5.5, or about 5.6, or about 5.7, or about 5.8, or about 5.9, or about 6.0, or about 6.5, or about 7.0, or about 7.5, or about 8.0.

[00501] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration or about 40 mg/ml to 200 mg/ml, lactate buffer at a concentration of about 5 mM to about 15 mM, sucrose at a concentration of about 4% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 5 to about 30 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 3.5 to 8.

[00502] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 mg/ml to 200 mg/ml, lactate buffer at a concentration of about 1 mM to about 15 mM, sucrose at a concentration of about 4% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 10 to about 20 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 3.5 to 8.

[00503] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 80 mg/ml to about 120 mg/mL, lactate buffer at a concentration of about 7 mM to about 12 mM, sucrose at a concentration of about 4% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 12.5 to about 17.5 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.07% (w/v), and a pH of about 4 to about 7.

[00504] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 mg/ml to about 110 mg/mL, lactate buffer at a concentration of about 9 mM to about 11 mM, sucrose at a concentration of about 6% (w/v) to about 8.5% (w/v), calcium chloride at a concentration of about 14 to about 16 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.07% (w/v), and a pH of about 5.0 to about 5.5.

[00505] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 100 mg/mL, lactate buffer at a concentration of about 10 mM, sucrose at a concentration of about 7.4% (w/v), calcium chloride at a concentration of about 15 mM, and Pluronic F68 at a concentration of about 0.06% (w/v), and a pH of about 5.2.

[00506] Exemplary aqueous adalimumab formulations are provided in Table G. Each formulation in Table G may optionally include Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.01% (w/v) to about 0.1% (w/v), about 0.01% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.01% (w/v), about 0.05% (w/v) to about 0.5% (w/v), about 0.1% (w/v) to about 2% (w/v), about 0.2% (w/v) to about 1% (w/v), about 0.05% (w/v), about 0.1% (w/v), and/or about 0.4% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.02% (w/v) to about 0.1% (w/v), and/or about 0.05% (w/v) to about 0.2% (w/v)), or Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05%

(w/v), about 0.02% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), 0.04% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.2% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Each formulation in Table G has a pH of about 5.0 to about 5.5, e.g., about 5.1 to about 5.3 and/or about 5.2. Optionally, the pH of each formulation in Table G is adjusted using a strong acid and/or strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

Table G

Protein conc.	Buffer	Excipient(s)
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂
100 mg/mL	10 mM lactate	9 % (w/v) sucrose
100 mg/mL	10 mM lactate	9 % (w/v) sucrose 25 mM CaCl ₂

[00507] Exemplary aqueous adalimumab formulations are provided in Table H. Each formulation in Table H has a pH of about 5.0 to about 5.5, e.g., about 5.1 to about 5.3 and/or about 5.2. Optionally, the pH of each formulation in Table H is adjusted using a strong acid and/or strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

Table H

Protein conc.	Buffer	Excipient(s)	Surfactant
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	0.1% (w/v) Pluronic F68
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	0.1% (w/v) Pluronic F68
100 mg/mL	10 mM lactate	9 % (w/v) sucrose 25 mM CaCl ₂	0.1% (w/v) Pluronic F68
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	0.05% (w/v) Pluronic F68
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	0.05% (w/v) Pluronic F68
100 mg/mL	10 mM lactate	9 % (w/v) sucrose 25 mM CaCl ₂	0.05% (w/v) Pluronic F68
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	0.01% (w/v) Pluronic F68
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	0.01% (w/v) Pluronic F68
100 mg/mL	10 mM lactate	9 % (w/v) sucrose 25 mM CaCl ₂	0.01% (w/v) Pluronic F68
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	0.1% (w/v) Polysorbate 80
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	0.1% (w/v) Polysorbate 80
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	0.05% (w/v) Polysorbate 80

100 mg/mL	10 mM lactate	9 % (w/v) sucrose	0.05% (w/v) Polysorbate 80
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	0.1% (w/v) Polysorbate 20
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	0.1% (w/v) Polysorbate 20
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	0.05% (w/v) Polysorbate 20
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	0.05% (w/v) Polysorbate 20

[00508] Exemplary aqueous adalimumab formulations are provided in Table I.

Table I

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	Surfactant	pH
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA,	0.05% (w/v) Pluronic F68	5.2

			MSA/Ca(OH) ₂ , or MSA/MEA		
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.01% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.01% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.01% (w/v) Pluronic F68	5.2
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 80	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 80	5.2

100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM lactate	220 mM proline 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 20	5.2
100 mg/mL	10 mM lactate	9 % (w/v) sucrose	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 20	5.2

[00509] Exemplary aqueous adalimumab lactate formulations are also provided in Tables 1, 11, 12, 13, 15, 16 and 17. In an embodiment, the stable aqueous adalimumab formulation is one of the lactate buffer formulations described in Tables G, H, I, 1, 11, 12, 13, 15, 16 or 17 provided herein.

[00510] In an embodiment, a lyophilized form of any one of the foregoing lactate-containing adalimumab formulations is provided.

Formulations of Adalimumab With Histidine Buffer

[00511] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 160 to 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, histidine at a concentration of about 5 mM to about 50 mM (e.g., about 5 mM to about 15 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients. Suitable excipients include certain stabilizers such as certain amino acids and amino acid derivatives, certain salts, certain polyols, certain acids, certain amines, and certain

surfactants. Examples of suitable amino acids and amino acid derivatives include proline (e.g., at a concentration of about 0.1 to about 450 mM, about 50 to about 300 mM, or about 270 to about 370 mM). Examples of suitable salts include calcium chloride (e.g., at a concentration of about 1 to about 150 mM, about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM) and sodium chloride (e.g., at a concentration of about 10 to about 100 mM, about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM). Examples of suitable polyols include sucrose (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)) and sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)). Examples of suitable acids include methane sulfonic acid (MSA) (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 50 mM). Examples of suitable amines include MEA-HCl (e.g., at a concentration of about 0.1 to about 150 mM or about 0.1 to about 40 mM) and MEA (e.g., at a concentration of about 0.1 to about 300 mM or about 0.1 to about 50 mM). Examples of suitable surfactants include Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the histidine-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, about 6.4 to about 7.2, about 6.5 to about 7.1, about 6.6 to about 7.0, about 6.7 to about 6.9, about 6.7 to about 6.8, about 6.8 to about 6.9, about 5.2, and/or about 6.8. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00512] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 160 to 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, histidine at a concentration of about 5 mM to about 50 mM (e.g., about 5 mM to about 15 mM, about 10 mM, about 15 mM, about 20 mM, and/or about 25 mM), and one or more excipients selected from the group consisting of proline at a concentration of about 0.1 to about 450 mM (e.g., about 50 to about 300 mM or about 270 to about 370 mM), calcium chloride at a concentration of about 1 to about 150 mM (e.g., about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 50 to about 100 mM, or about 25 mM), sodium chloride at a concentration of about 10 to about 100 mM (e.g., about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v) and/or about 4% (w/v)), methane sulfonic acid (MSA) at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM), MEA-HCl at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM), MEA at a concentration of about 0.1 to about 300 mM (e.g., about 0.1 to about 50 mM), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), about 0.04% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the histidine-containing stable aqueous adalimumab formulation has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, about 6.4 to about 7.2, about 6.5 to about 7.1, about 6.6 to about 7.0, about 6.7 to about 6.9, about 6.7 to about 6.8, about 6.8 to about 6.9, about 5.2, and/or about 6.8. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid

and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00513] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, histidine at a concentration of about 5 mM to about 15 mM, proline at a concentration of about 270 to about 370 mM, and calcium chloride at a concentration of about 10 to about 30 mM, and has a pH of about 6.7 to 6.9. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00514] Exemplary aqueous adalimumab formulations are provided in Table J.

Table J

Protein conc.	Buffer	Excipient(s)	pH Adjusting Agent	pH
100 mg/mL	10 mM histidine	320 mM proline 20 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	5.2

[00515] In an embodiment, a lyophilized form of any one of the foregoing histidine-containing adalimumab formulations is provided.

Formulations of Adalimumab Without Buffer

[00516] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 160 to 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, and one or more excipients. Suitable excipients include certain stabilizers such as certain amino acids and amino acid derivatives, certain polyethylene glycols and polyethylene glycol derivatives, certain salts, certain polyols, certain acids, certain amines, and certain surfactants. Examples of suitable amino acids and amino acid derivatives include proline (e.g., at a concentration of about 0.1 to about 450 mM, about 50 to about 300 mM, or about 60 to about 300 mM). Examples of suitable polyethylene glycols and polyethylene glycol derivatives include PEG 600 (e.g., at a concentration of about 0.1% (w/v) to about 30% (w/v) or about 1.2% (w/v) to about 14.5% (w/v)) and PEG 200 (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v) or about 0.6% (w/v) to about 4.8% (w/v)). Examples of suitable salts include calcium chloride (e.g., at a concentration of about 1 to about 150 mM, about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM,

about 20 to about 100 mM, about 50 to about 100 mM, or about 25 mM) and sodium chloride (e.g., at a concentration of about 10 to about 100 mM, about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM). Examples of suitable polyols include sorbitol (e.g., at a concentration of about 0.1% (w/v) to about 10% (w/v), about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)) and sucrose (e.g., at a concentration of about 0.1% (w/v) to about 15% (w/v), about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v) to about 7.3% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)). Examples of suitable acids include MSA (e.g., at a concentration of about 0.1 to about 150 mM, about 0.1 to about 50 mM, or about 20 to about 90 mM). Examples of suitable amines include MEA-HCl (e.g., at a concentration of about 0.1 to about 150 mM, about 0.1 to about 40 mM, or about 60 to about 90 mM) and MEA (e.g., at a concentration of about 0.1 to about 300 mM, about 0.1 to about 50 mM, or about 60 to about 90 mM). Examples of suitable surfactants include Pluronic F68 (e.g., at a concentration of about 0.001% (w/v) to about 10% (w/v), about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.5% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v) or about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 (e.g., at a concentration of about 0.001% (w/v) to about 2% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), 0.04% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the stable aqueous adalimumab formulation without buffer has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00517] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 200 mg/mL, such as about 90 to about 120 mg/mL, about 160 to 190 mg/mL, about 40 to about 60 mg/mL, about 50 mg/mL, about 100 mg/mL, or about 170 mg/mL, and one or more excipients selected from the group consisting of proline at a concentration of about 0.1 to about 450 mM (e.g., about 50 to about 300 mM or about 60 to

about 300 mM), PEG 600 at a concentration of about 0.1% (w/v) to about 30% (w/v) (e.g., about 1.2% (w/v) to about 14.5% (w/v)), PEG 200 at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 0.6% (w/v) to about 4.8% (w/v)), calcium chloride at a concentration of about 1 to about 150 mM (e.g., about 5 to about 50 mM, about 10 to about 30 mM, about 20 to about 40 mM, about 30 to about 50 mM, about 40 to about 80 mM, about 20 to about 100 mM, about 50 to about 100 mM, or about 25 mM), sodium chloride at a concentration of about 10 to about 100 mM (e.g., about 60 to about 90 mM, about 15 to about 50 mM, and/or about 35 mM), MSA at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 50 mM or about 20 to about 90 mM), MEA-HCl at a concentration of about 0.1 to about 150 mM (e.g., about 0.1 to about 40 mM or about 60 to about 90 mM), MEA at a concentration of about 0.1 to about 300 mM (e.g., about 0.1 to about 50 mM or about 60 to about 90 mM), sorbitol at a concentration of about 0.1% (w/v) to about 10% (w/v) (e.g., about 3% (w/v) to about 5% (w/v), and/or about 4% (w/v)), sucrose at a concentration of about 0.1% (w/v) to about 15% (w/v) (e.g., about 4% (w/v) to about 10% (w/v), about 4% (w/v) to about 9% (w/v), about 6.5% (w/v) to about 7.3% (w/v), about 6.5% (w/v), about 6.8% (w/v), about 6.9% (w/v), about 9% (w/v)), Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.5% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.01% (w/v), about 0.05% (w/v), and/or about 0.1% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v)), and Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.03% (w/v) to about 0.1% (w/v), 0.04% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Optionally, the stable aqueous adalimumab formulation without buffer has a pH of about 4.8 to about 5.7, for example, about 4.9 to about 5.6, about 5.0 to about 5.5, about 5.1 to about 5.4, about 5.1 to about 5.3, about 5.1 to about 5.2, about 5.2 to about 5.3, and/or about 5.2. Optionally, the pH of the stable aqueous adalimumab formulation is adjusted using a strong acid and/or a strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

[00518] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, MSA at a concentration of about 10 to about

30 mM, and proline at a concentration of about 250 to about 350 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA or NaOH.

[00519] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 8% (w/v) to about 10% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00520] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 6.5% (w/v) to about 7.3% (w/v), PEG 200 at a concentration of about 0.3% (w/v) to about 1% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00521] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 4% (w/v) to about 5% (w/v), PEG 200 at a concentration of about 1.5% (w/v) to about 2.1% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00522] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 0.9% (w/v) to about 1.5% (w/v), PEG 200 at a concentration of about 2.5% (w/v) to about 3.5% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00523] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 200 at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about

5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00524] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 6.9% (w/v) to about 7.7% (w/v), proline at a concentration of about 40 to about 80 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00525] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 5% (w/v) to about 6% (w/v), proline at a concentration of about 90 to about 150 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00526] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 2% (w/v) to about 3% (w/v), proline at a concentration of about 150 to about 210 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00527] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, proline at a concentration of about 200 to about 300 mM, calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00528] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sorbitol at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00529] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, sorbitol at a concentration of about 3.5% (w/v) to about 4.5% (w/v), calcium chloride at a concentration of about 20 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.2% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00530] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sorbitol at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00531] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, sorbitol at a concentration of about 3.5% (w/v) to about 4.5% (w/v), calcium chloride at a concentration of about 20 to about 30 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00532] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sorbitol at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00533] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sorbitol at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00534] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sorbitol at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00535] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sorbitol at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00536] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 5% (w/v) to about 8% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00537] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 6.1% (w/v) to about 6.9% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00538] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, sucrose at a concentration of about 6.3% (w/v) to about 6.7% (w/v), calcium chloride at a concentration of about 20 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.2% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00539] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 6.1%

(w/v) to about 6.9% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00540] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 110 mg/mL, sucrose at a concentration of about 6.3% (w/v) to about 6.7% (w/v), calcium chloride at a concentration of about 20 to about 30 mM, and Pluronic F68 at a concentration of about 0.03% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00541] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 6.1% (w/v) to about 6.9% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00542] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 6.1% (w/v) to about 6.9% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 80 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00543] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 6.1% (w/v) to about 6.9% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Polysorbate 20 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00544] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 6.1% (w/v) to about 6.9% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and

Polysorbate 20 at a concentration of about 0.01% (w/v) to about 0.1% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl, NaOH, CaCl₂, MEA, and/or MSA.

[00545] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, proline at a concentration of about 200 to about 250 mM, calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00546] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 11% (w/v) to about 15% (w/v), calcium chloride at a concentration of about 20 to about 40 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00547] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 160 to about 190 mg/mL, sucrose at a concentration of about 5% (w/v) to about 8% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00548] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sucrose at a concentration of about 6.9% (w/v) to about 7.7% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00549] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 200 at a concentration of about 4.5% (w/v) to about 5.1% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about

5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00550] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, sorbitol at a concentration of about 3% (w/v) to about 5% (w/v), calcium chloride at a concentration of about 15 to about 35 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with HCl.

[00551] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 13% (w/v) to about 16% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00552] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 90 to about 120 mg/mL, PEG 600 at a concentration of about 3% (w/v) to about 3.6% (w/v), calcium chloride at a concentration of about 10 to about 30 mM, proline at a concentration of about 150 to about 210 mM, and Pluronic F68 at a concentration of about 0.05% (w/v) to about 0.5% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00553] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL and PEG 600 at a concentration of about 10% (w/v) to about 11% (w/v), and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00554] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, PEG 600 at a concentration of about 8% (w/v) to about 9% (w/v), and calcium chloride at a concentration of about 15 to about 35 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00555] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, PEG 600 at a concentration of about 6% (w/v) to about 7% (w/v), and calcium chloride at a concentration of about 40 to about 60 mM, and has

a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00556] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, PEG 600 at a concentration of about 3.4% (w/v) to about 4% (w/v), and calcium chloride at a concentration of about 65 to about 85 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00557] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL and calcium chloride at a concentration of about 80 to about 120 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00558] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL and proline at a concentration of about 250 to about 350 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00559] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, proline at a concentration of about 200 to about 250 mM, and calcium chloride at a concentration of about 15 to about 35 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00560] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, proline at a concentration of about 120 to about 180 mM, and calcium chloride at a concentration of about 40 to about 60 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00561] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, proline at a concentration of about 60 to about 90 mM, and calcium chloride at a concentration of about 65 to about 85 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00562] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, proline at a concentration of about 200 to about 300 mM, MEA at a concentration of about 40 to about 80 mM, and MSA at a concentration of about 40 to about 80 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00563] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, proline at a concentration of about 150 to about 210 mM, MEA at a concentration of about 40 to about 80 mM, and MSA at a concentration of about 40 to about 80 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00564] In an embodiment, the stable aqueous adalimumab formulation includes adalimumab at a concentration of about 40 to about 60 mg/mL, proline at a concentration of about 90 to about 150 mM, MEA at a concentration of about 70 to about 110 mM, and MSA at a concentration of about 70 to about 110 mM, and has a pH of about 5.1 to 5.3. Optionally, the pH of the formulation is adjusted within this range with MEA and/or MSA.

[00565] Exemplary aqueous adalimumab formulations are provided in Table J. Each formulation in Table J may optionally include Pluronic F68 at a concentration of about 0.001% (w/v) to about 10% (w/v) (e.g., about 0.005% (w/v) to about 1% (w/v), about 0.01% (w/v) to about 0.1% (w/v), about 0.01% (w/v) to about 1% (w/v), about 0.05% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.4% (w/v), about 0.01% (w/v), about 0.05% (w/v) to about 0.5% (w/v), about 0.1% (w/v) to about 2% (w/v), about 0.2% (w/v) to about 1% (w/v), about 0.05% (w/v), about 0.1% (w/v), and/or about 0.4% (w/v)), Polysorbate 20 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.02% (w/v) to about 0.1% (w/v), and/or about 0.05% (w/v) to about 0.2% (w/v)), or Polysorbate 80 at a concentration of about 0.001% (w/v) to about 2% (w/v) (e.g., about 0.002% (w/v) to about 0.01% (w/v), about 0.005% (w/v) to about 0.1% (w/v), about 0.005% (w/v) to about 0.05% (w/v), about 0.02% (w/v) to about 0.1% (w/v), about 0.03% (w/v) to about 0.1% (w/v), 0.04% (w/v) to about 0.1% (w/v), about 0.05% (w/v) to about 0.2% (w/v), about 0.03% (w/v), about 0.04% (w/v), and/or about 0.1% (w/v)). Each formulation in Table J has a pH of about 5.0 to about 5.5, e.g., about 5.1 to about 5.3 and/or about 5.2. Optionally, the pH of each formulation

in Table J is adjusted using a strong acid and/or strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

Table J

Protein conc.	Excipient(s)
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂

[00566] Exemplary aqueous adalimumab formulations are provided in Table K. Each formulation in Table K has a pH of about 5.0 to about 5.5, e.g., about 5.1 to about 5.3 and/or about 5.2. Optionally, the pH of each formulation in Table K is adjusted using a strong acid and/or strong base including, but not limited to, hydrochloric acid, sodium hydroxide, calcium hydroxide, MSA, and/or MEA.

Table K

Protein conc.	Excipient(s)	Surfactant
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	0.1% (w/v) Pluronic F68
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	0.1% (w/v) Pluronic F68
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	0.05% (w/v) Pluronic F68
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	0.05% (w/v) Pluronic F68
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	0.1% (w/v) Polysorbate 80
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	0.1% (w/v) Polysorbate 80
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	0.05% (w/v) Polysorbate 80
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	0.05% (w/v) Polysorbate 80
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	0.1% (w/v) Polysorbate 20
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	0.1% (w/v) Polysorbate 20
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	0.05% (w/v) Polysorbate 20
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	0.05% (w/v) Polysorbate 20

[00567] Exemplary aqueous adalimumab formulations are provided in Table L.

Table L

Protein conc.	Excipient(s)	pH Adjusting Agent	Surfactant	pH
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Pluronic F68	5.2
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Pluronic F68	5.2
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Pluronic F68	5.2
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 80	5.2
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 80	5.2
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 80	5.2

100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 20	5.2
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.1% (w/v) Polysorbate 20	5.2
100 mg/mL	4% (w/v) sorbitol 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 20	5.2
100 mg/mL	6.5% (w/v) sucrose 25 mM CaCl ₂	HCl/NaOH, HCl/Ca(OH) ₂ , HCl/MEA, MSA/Ca(OH) ₂ , or MSA/MEA	0.05% (w/v) Polysorbate 20	5.2

[00568] In an embodiment, a lyophilized form of any one of the foregoing adalimumab formulations without buffer is provided.

Methods of Treatment

[00569] The invention provides for methods of treating a patient suffering from a TNF- α associated disease or disorder comprising administering to the patient any of the stable aqueous adalimumab formulations of the invention (or lyophilized formulations thereof once reconstituted, e.g., with sterile water for injection). The TNF- α diseases and disorders include, but are not limited to, inflammatory diseases and disorders, intestinal diseases and disorders, autoimmune diseases and disorders, eye diseases and disorders, pulmonary diseases and disorders, and infectious diseases and disorders. The term “patient” includes humans and non-human animal subjects.

[00570] The invention also provides for compositions comprising any of the stable aqueous or lyophilized adalimumab formulations of the invention for the treatment of a TNF- α associated disease or disorder, such as inflammatory diseases and disorders, intestinal diseases and disorders, autoimmune diseases and disorders, eye diseases and disorders, pulmonary diseases and disorders, and infectious diseases and disorders.

[00571] The invention further provides for use of the stable aqueous or lyophilized adalimumab formulations of the invention for the preparation of a medicament for the treatment of TNF- α associated diseases or disorders, such as inflammatory diseases and disorders, intestinal diseases and disorders, autoimmune diseases and disorders, eye diseases and disorders, pulmonary diseases and disorders, and infectious diseases and disorders.

[00572] Inflammatory diseases and disorders include, but are not limited to, arthritis, adult and juvenile rheumatoid arthritis, juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, osteoarthritis including erosive osteoarthritis and non-erosive osteoarthritis, plaque psoriasis, general pustular psoriasis, nail and scalp psoriasis, hidradenitis suppurativa, ankylosing spondylitis, interstitial cystitis, spondyloarthritis including peripheral spondyloarthritis and axial spondyloarthritis, spondylarthropathy, pulmonary inflammation disorder, allergy, uveitis, chronic pulmonary inflammation disease, vascular inflammation, enthesitis related arthritis, enthesopathy, coronary atherosclerosis, inflammatory bone disorders, bone resorption disease, hepatitis including alcoholic hepatitis, chronic pouchitis, inflammatory bowel disease, adult and pediatric Crohn's disease, ulcerative colitis, scleritis, sarcoidosis, cutaneous sarcoidosis, Netherton syndrome, and giant cell arteritis.

[00573] Intestinal diseases and disorders include, but are not limited to, chronic pouchitis, inflammatory bowel disease, adult and pediatric Crohn's disease, ulcerative colitis, small bowel lesions, anal squamous intraepithelial lesions, anal fissures, and intestinal Behçet's disease.

[00574] Autoimmune diseases and disorders include, but are not limited to, adult and juvenile rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, plaque psoriasis, general pustular psoriasis, nail and scalp psoriasis, psoriasis vulgaris, psoriasis arthropica, psoriatic arthritis, pyoderma gangrenosum, gouty arthritis, allergy, multiple sclerosis, autoimmune diabetes, autoimmune uveitis, nephrotic syndrome, diabetic ulcers, and graft vs. host disease

[00575] Eye diseases and disorders include, but are not limited to, uveitis, anterior uveitis, intermediate uveitis and posterior uveitis, refractory diabetic retinopathy, choroid diseases, choroidal neovascularization, macular degeneration including age-related macular degeneration, albinism, Behçet's syndrome, Hermanski-Pudluk syndrome, panuveitis, pars planitis, retinal degeneration, uveal diseases, retinal vascular disorders, and scleritis.

[00576] Infectious diseases and disorders include, but are not limited to, malaria, acquired immune deficiency (AIDS), cytomegalovirus infection and influenza.

[00577] Pulmonary disease and disorders include, but are not limited to, adult respiratory distress syndrome, asthma, refractory asthma, pulmonary inflammation disorder, shock lung, chronic pulmonary inflammatory disease, pulmonary sarcoidosis, pulmonary fibrosis and silicosis.

[00578] Other TNF- α associated diseases and disorders include, but are not limited to, mucopolysaccharidosis including mucopolysaccharidosis type I, mucopolysaccharidosis type II, mucopolysaccharidosis type IV, cancers, cachexia, ischemia of the heart, coagulation disturbances, acute disc prolapse, sleep apnea, anaplastic thyroid cancer and focal segmental glomerulosclerosis.

[00579] Stable aqueous adalimumab formulations of the invention (or lyophilized formulations thereof once reconstituted, e.g., with sterile water for injection) may be administered subcutaneously, intravenously, parenterally, intradermally, intramuscularly, and/or intraperitoneally using standard techniques. For example, the stable aqueous adalimumab formulations of the invention may be prepared to be subcutaneously administered using a pre-filled syringe. Specifically, any of the formulations of the invention may be administered once every week or 6 to 8 days or 7 to 10 days, or every other week or every two weeks or 12 to 16 days or 7 to 14 days or 13 to 15 days, or every three weeks or 19 to 23 days, or every month or 26 to 30 days or 29 to 31 days, or every five weeks or 33 to 34 days, or every six weeks or 40 to 44 days, or every seven weeks or 47 to 51 days, or every two months or 54 to 58 days subcutaneously, intravenously, parenterally, intradermally, intramuscularly, and/or intraperitoneally at a therapeutically effective dosage and in the formulations described herein for an indefinite period of time for the treatment of the diseases and conditions described above.

[00580] Administration and dosage regimens of stable aqueous adalimumab formulations of the invention (or lyophilized formulations thereof once reconstituted, e.g., with sterile water for injection) can be adjusted to provide an effective amount for an optimum therapeutic response. For example, a single bolus can be administered, two or more divided doses can be administered over time or the dose can be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. For example, a unit dose can be administered over two consecutive days every two weeks. Unit dosing refers to a physically discrete amount of adalimumab or a biosimilar thereof suited as unitary dosages for the patients to be treated; each unit contains a

predetermined quantity of active biopharmaceutical calculated to produce a desired therapeutic effect.

[00581] The dosing regimen of stable aqueous adalimumab formulations of the invention (or lyophilized formulations thereof once reconstituted, e.g., with sterile water for injection) may comprise administering a dose given on Day one, followed by the administration of the same dose every other week. For example, a dose of 40 mg adalimumab or biosimilar thereof is administered every other week in patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. For patients suffering from juvenile idiopathic arthritis that are 10 kg (22 lbs) to less than 15 kg (33 lbs), a dose of 10 mg adalimumab or biosimilar thereof is administered every other week, for example. For patients suffering from juvenile idiopathic arthritis that are 15 kg (33 lbs) to less than 30 kg (66 lbs), a dose of 20 mg adalimumab or biosimilar thereof is administered every other week, for example. For patients suffering from juvenile idiopathic arthritis that are greater or equal to 30 kg (66 lbs), a dose of 40 mg adalimumab or biosimilar thereof is administered every other week, for example. This dosing regimen may also include administering methotrexate (MTX), other non-biologic DMARDS, glucocorticoid, nonsteroidal anti-inflammatory drugs (NSAIDS) and/or analgesics throughout the administration or for a portion of the time of administration of any of the stable aqueous adalimumab formulations of the invention.

[00582] The dosing regimen of stable aqueous adalimumab formulations of the invention may (or lyophilized formulations thereof once reconstituted, e.g., with sterile water for injection) comprise administering an initial dose given on day one or split over two consecutive days, followed by the administration of the same or a reduced dose two weeks later (Day 15), e.g. the initial dose reduced by half. The dosing regimen may further comprise administration of the same or further reduced dose two weeks later (Day 29); e.g. a dose that is a fourth of the initial dose which will be continued as a maintenance dose every two weeks. For example, for patients suffering from adult Crohn's disease or ulcerative colitis, an initial dose of 160 mg adalimumab or biosimilar thereof is administered on Day 1, a second dose of 80 mg adalimumab or biosimilar thereof is administered two weeks later (Day 15), followed by a maintenance dose of 40 mg adalimumab or biosimilar thereof administered two weeks later (Day 29) that is continued every other week. For patients suffering from pediatric Crohn's disease that are 17 kb (37 lbs) to less than 40 kg (88 lbs), an initial dose of 80 mg adalimumab or biosimilar thereof is administered on

Day 1, a second dose of 40 mg adalimumab or biosimilar thereof is administered two weeks later (Day 15), followed by a maintenance dose of 20 mg adalimumab or biosimilar thereof administered two weeks later (Day 29) that is continued every other week, for example. For patients suffering from pediatric Crohn's disease that are greater than 40 kg (88 lbs), an initial dose of 160 mg adalimumab or biosimilar thereof is administered on Day 1, a second dose of 80 mg adalimumab or biosimilar thereof is administered two weeks later (Day 15), followed by a maintenance dose of 40 mg adalimumab or biosimilar thereof administered two weeks later (Day 29) that is continued every other week, for example. This dosing regimen may also include administering aminosalicylates and/or corticosteroids, azathioprine, 6-mercaptopurine (6-MP) or MTX throughout the administration or for a portion of the time of administration of any of the stable aqueous adalimumab formulations of the invention.

[00583] The dosing regimen of stable aqueous adalimumab formulations of the invention (or lyophilized formulations thereof once reconstituted, e.g., with sterile water for injection) may comprise administering an initial dose given on Day one or split over two consecutive days, followed by the administration of the same or a reduced dose two weeks later (Day 15), e.g. an initial dose reduced by half. The dosing regimen may further comprise administration of the same or further reduced dose two weeks later (Day 29), e.g. a dose that is a fourth of the initial dose. For example, an initial dose of 160 mg adalimumab or biosimilar thereof is administered on Day 1, a second dose of 80 mg adalimumab or biosimilar thereof is administered two weeks later (Day 15), and a third dose of 40 mg adalimumab or biosimilar thereof is administered on Day 29 followed by administration of 40 mg adalimumab or biosimilar thereof every week. This dosing regimen may be administered to patients suffering from hidradenitis suppurativa.

[00584] The dosing regimen of stable aqueous adalimumab formulations of the invention (or lyophilized formulations thereof once reconstituted, e.g., with sterile water for injection) may comprise administering an initial dose given on Day one or split over two consecutive days, followed by the administration of the same or a reduced dose one week after the initial dose e.g. an initial dose reduced by half and continued administration every other week.. For example, an initial dose of 80 mg adalimumab or biosimilar thereof, followed by administration of 40 mg adalimumab or biosimilar thereof every other week starting one week after the initial dose. This dosing regimen may be administered to patients suffering from plaque psoriasis or uveitis.

[00585] The invention provides for a method of preparing a stable aqueous adalimumab formulations of the invention, comprising combining an aqueous solution comprising one or more excipients and an therapeutically effective amount of adalimumab using techniques standard in the art. The invention further provides for a method of preparing the stable lyophilized adalimumab formulations of the invention, comprising lyophilizing an aqueous adalimumab formulation comprising one or more excipients and a therapeutically effective amount of adalimumab using techniques standard in the art.

[00586] The foregoing detailed description is not intended to define every aspect of the invention, and other features and advantages of the present disclosure will be apparent to those skilled in the art. The present disclosure is intended to be related as a unified document, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features are not found together in the same sentence, paragraph, or section of this disclosure. In addition, the disclosure includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations specifically mentioned above. With respect to aspects of the disclosure described or claimed with “a” or “an,” it should be understood that these terms mean “one or more” unless context unambiguously requires a more restricted meaning. With respect to elements described as one or more within a set, it should be understood that all combinations within the set are contemplated. If aspects of the disclosure are described as “comprising” a feature, embodiments also are contemplated “consisting of” or “consisting essentially of” the feature. Additional features and variations of the disclosure will be apparent to those skilled in the art from the entirety of this application, and all such features are intended as aspects of the disclosure.

[00587] The present disclosure will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended to be limiting.

EXAMPLES

[00588] The following Examples describe formulations of the present disclosure.

[00589] General Materials: In the following examples, an adalimumab biosimilar as described in Velayudhan et al., BioDrugs 30:339-351 (2016) (i.e., ABP 501) was used.

[00590] General Analytical Methods: Cation-exchange high-performance liquid chromatography (CEX-HPLC) and size-exclusion high-performance liquid chromatography (SE-

HPLC) were used to assess stability. CEX-HPLC examines changes in charge, mainly due to deamidation, which is measured as pre-peak or acidic growth, and SE-HPLC is used to resolve and measure soluble aggregation, also known as high molecular weight species (HMWS), which is determined as a growth in pre-peak area. To be considered significant, changes in degradation should be greater than the intermediate precision of the assays: the standard deviation is ± 0.16 for the CEX-HPLC method and ± 0.032 for the SE-HPLC method. CEX-HPLC was performed using, a Pro Pac WCX-10 analytical column, 4.0 mm X 250 mm (Dionex, 054993) for the charge separation of protein in a gradient mobile phase. Mobile Phase A was 20 mM sodium phosphate, pH 6.8 and Mobile Phase B was 20 mM sodium phosphate, 0.5 M NaCl, pH 6.8. Samples were injected onto the column at a 50 μ g mass load and detected at a wavelength of 230 nm. SE-HPLC was performed using an Agilent 1200 system. A TSK-GEL G3000SWXL column, 5 μ m particle size, 7.8 X 300 nm (Tosoh Bioscience, 08541) to separate protein by size. A UV detector with a wavelength of 220 nm was used to detect samples injected at a mass load of 35 μ g. The mobile phase which allows for separation on the column was 100 mM sodium phosphate, 250 mM sodium chloride, pH 6.8.

[00591] Opalescence measurement was also used to assess stability. Opalescence examines physical instability of a formulation due to the presence of aggregates. Opalescence was measured in a 2100 AN Turbidimeter, using 13 cm x 100 mm glass tubes and a 13 mm sample tube adapter. Samples of at least 2.5 mL were used for each measurement. A standard curve was generated using Stablcal® turbidity standard (Hach Company) prepared to expected turbidimetry readings of 3, 6, 18 and 30 nephelometric turbidity units (NTUs) by diluting a stock standard in water.

[00592] Transport stress studies were also used to assess stability. Frozen formulations were thawed statically at room temperature protected from light using a TempTale® temperature monitor to monitor temperature conditions in the cold room during the thaw. After fully thawing, the cap on the bottle was tightened to avoid leakage. The bottle was placed on its side and rolled gently for 4-6 minutes to ensure thorough mixing. The bottle was then placed at -30°C for 8 hours to re-freeze. Freezing was confirmed visually. The freeze-thaw process was repeated for a total of 3 cycles. Next, the formulation was mixed with an overhead mixer for 15 minutes to simulate shear from a mixing operation, and then filtered at 2-8°C under pressure using a 0.2 μ m PVDF filter. The formulation was sterile-filtered a second time prior to filling

into syringes followed by stoppering. The formulations were pressure-filtered through a 0.2 μm PVDF filter, then hand-filled into syringes or vials. The hand-filled syringes were stoppered using an ASPU (autoclavable stopper placement unit) system. The filled and stoppered syringes were placed in a laminar air flow hood at room temperature for 3 days to mimic room temperature and light exposure stresses expected during manufacturing. Temperature was recorded using a TempTale® temperature monitor, and UV and visible light levels were recorded using a photometer. A portion of the filled syringes were subjected to simulated air and ground transportation stresses. Air and ground simulated transport stress studies were carried out for a total duration of 91.5 hours, with air transportation vibration of 48 hours and truck transportation vibration for 43.5 hours. Samples were also subjected to the International Safe Transit Association (ISTA 3A) drop test sequence six times which included drops 1 thru 9 prior to the 91.5 hour air and ground vibrational simulation and drops 10 thru 17 after the air and ground vibrational transport simulation. The syringes were stored for 2 weeks at 40°C. Stability was assessed by SE-HPLC, CEX-HPLC, and micro-flow imaging (MFI). MFI measures the presence of sub-visible particles by passing a sample through a visual flow cell, counting particles as they pass through the cell, and categorizing into different bins based on size. An aspect ratio is applied to resolve silicone oil, if present, from proteinaceous particles. MFI (Micro-Flow Imaging) was performed on MFI 5200 systems. The size range of particles measured was from 1 to 70 μm . The sample volume measured was 1 mL, with pre filled syringes pooled into a clean glass vial to allow for adequate volume of at least 1 mL for measurement. Between each measurement, the system was flushed and a baseline established before proceeding. For each sample measurement, a digital camera is used to magnify, record the size, shape and morphology of visible particles.

[00593] Conductivity is the ability of an aqueous solution to conduct an electric current between two electrodes. Because a current flows via ion transport, the more ions in a particular solution, the higher the conductivity. Conductivity of the formulations described herein was assessed on a Model CDM83, Thermo Orion 4 or Model S230 Seven Compact, Mettler Toledo instrument, using a conductivity cell. At minimum of at least 20 mL sample (Thermo Orion) or 3 mL sample (Mettler Toledo) was used for each measurement. The cell was rinsed with water and dried between sample measurements. Conductivity measurements were performed at ambient room temperature, and is reported using the standard SI unit of siemens per meter (S/m).

[00594] Osmolality is the concentration of a solution in terms of amount of solute quantity of solvent. For example, serum has an osmolality ranging from about 270-300 mOsM. Osmolality of the formulations described herein can be determined using, for example, Freezing Point Depression Osmometry.

EXAMPLE 1

Effect of Buffer Composition on Formulation Stability

[00595] Adalimumab biosimilar was prepared in a target formulation buffer by centrifuge concentration using a 30kD MW cutoff filter tube. 2 mL of adalimumab biosimilar was diluted with the target formulation buffer to a volume of 15 mL, followed by a centrifuge concentration step to a final volume of around 2 mL before repeating the dilution and centrifuge concentration step three times. Around 3 mL were collected after the last centrifuge concentration step, which was diluted with the desired formulation buffer to 100 mg/mL, sterile filtered and aliquoted into 5cc glass vials. Following the filling step, samples were placed at 40°C and examined for stability at approximately 1 week, 2 weeks and 4 weeks.

[00596] The formulation buffers used for the centrifuge concentration step contained various buffers, with the pH of the buffer adjusted to 5.2 ± 0.1 using either NaOH or monoethanolamine (MEA). Each buffer contained isotonic proline as an additional excipient. Formulations without buffer were prepared by adjusting the pH of methane sulfonic acid (MSA) to $\text{pH } 5.2 \pm 0.1$ with MEA or NaOH. The composition of the formulation buffer, and the pH and antibody (Ab) concentration of the formulations are provided in Table 1.

Table 1

Ref.	Buffer	Excipient	pH adjusting agent	pH	Ab conc. (mg/mL)
1A	20 mM benzoate	300 mM proline	MEA	5.2	73
1B	20 mM benzoate	300 mM proline	NaOH	5.2	109
1C	20 mM glutamate	300 mM proline	MEA	5.2	105
1D	20 mM glutamate	300 mM proline	NaOH	5.1	111
1E	20 mM glycolate	300 mM proline	MEA	5.2	110
1F	20 mM glycolate	300 mM proline	NaOH	5.2	108
1G	20 mM lactate	300 mM proline	MEA	5.1	109
1H	20 mM lactate	300 mM proline	NaOH	5.1	104
1I	---	20 mM MSA 300 mM proline	MEA	5.3	100
1J	---	20 mM MSA 300 mM proline	NaOH	5.3	107

[00597] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 6, 13, and 28 days at 40°C. As shown in FIG. 1, the formulations containing lactate or glycolate buffers demonstrated less acidic peak growth over time compared to the formulations containing benzoate or glutamate buffers. The formulations without buffer, but including MSA, demonstrated stability comparable to the buffered formulations and improved compared to the benzoate and glutamate-buffered formulations at the 28 day time point.

[00598] Stability also was assessed by measuring high molecular weight species (HMWS) by SE-HPLC after 0, 6, 13, and 28 days at 40°C. As shown in FIG. 2, the formulations containing lactate demonstrated significantly less HMWS growth over time compared to the other formulations. Compared to glycolic acid, lactic acid has a structure that differs only by including an additional methyl group. As shown in FIG. 2, HMWS were surprisingly lower for the formulations containing lactate compared to the formulations containing glycolate. The formulations without buffer, but including MSA, demonstrated stability comparable to the buffered formulations.

EXAMPLE 2

Effect of PEG, Dextran, and Calcium Chloride on Formulation Stability

[00599] Adalimumab biosimilar solution at a concentration of 220 mg/mL (“UF DF stock”) was prepared by ultrafiltration/diafiltration (UF DF) into a buffer of 20 mM glutamate, pH 5.1 using a Cogent μ Scale tangential flow filtration (TFF) system with a delta pressure set to about 23 psi. A Millipore Pellicon 3 Ultracell 30 kD 0.11m² cassette was used as the exchange filter. The resulting material was then further concentrated to 220 mg/mL to obtain the UF DF stock.

[00600] Stock 2X excipient solutions were prepared, and were then diluted into UF DF stock adalimumab biosimilar solution. Upon final dilution and mixing in of the 2X excipients, the adalimumab biosimilar concentration was adjusted to about 100 mg/mL. If needed, the pH was adjusted to 5.2 ± 0.2 using NaOH or HCl. The composition of the formulation buffer, and the pH and antibody concentration of the formulations are provided in Table 2. Following sterile filtration, aliquots were filled into 5cc glass vials and stored at -30°C, 4°C, and 40°C.

Table 2

Ref.	Buffer	Excipient(s)	pH	Ab conc. (mg/mL)
2A	20 mM glutamate	7% PEG 3350	5.4	114
2B	20 mM glutamate	7% PEG 3350 45 mM calcium chloride	5.3	114

2C	20 mM glutamate	10% dextran	5.1	128
2D	20 mM glutamate	10% dextran 45 mM calcium chloride	5.2	119
2E	20 mM glutamate	1% PEG 200	5.1	110
2F	20 mM glutamate	1% PEG 200 40 mM calcium chloride	5.1	115
2G	20 mM glutamate	2% PEG 600	5.1	110
2H	20 mM glutamate	2% PEG 600 40 mM calcium chloride	5.1	109

[00601] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 7, 14, and 28 days at 40°C. As shown in FIG. 3, the formulations containing calcium chloride and one of PEG 200, PEG 600, PEG 3350, or dextran demonstrated less acidic peak growth over time compared to otherwise similar formulations without calcium chloride. In addition, the formulations containing PEG 200 or PEG 600 demonstrated less acidic peak growth over time compared to the formulations containing PEG 3350 or dextran.

[00602] Stability also was assessed by measuring HMWS by SE-HPLC after 0, 7, 14, and 28 days at 40°C. As shown in FIG. 4, the formulations containing PEG 200, PEG 600, or PEG 3350 (alone or in combination with calcium chloride) demonstrated less HMWS growth over time compared to the formulations containing dextran.

EXAMPLE 3

Effect of Proline, PEG, MSA, TEA, and Calcium Chloride on Frozen Stability

[00603] Stock 2X excipient solutions in 20 mM glutamate buffer, pH 5.2 were added to the UF DF stock adalimumab biosimilar solution described in Example 2 to a final protein concentration of 100 mg/mL. If needed, the pH was adjusted to 5.2 ± 0.2 using NaOH or HCl. The final formulations were sterile filtered and placed into 5 cc glass vials for subsequent tests.

[00604] Three free thaw (F/T) cycles were executed, with room temperature thaws of samples stored at -30°C at each cycle. After the freeze thaw cycles, each formulation was then analyzed for stability and the remainder of the material stored at -30°C for long term storage stability. The composition of the formulation buffer, and the pH and antibody concentration of the formulations are provided in Table 3.

Table 3

Ref.	Buffer	Excipient(s)	pH	Ab conc. (mg/mL)
3A	20 mM glutamate	250 mM proline	5.1	119
3B	20 mM glutamate	1% PEG 3350	5.4	114
2A	20 mM glutamate	7% PEG 3350	5.4	114

2B	20 mM glutamate	7% PEG 3350 45 mM calcium chloride	5.3	114
2E	20 mM glutamate	1% PEG 200	5.1	110
2F	20 mM glutamate	1% PEG 200 40 mM calcium chloride	5.1	115
2G	20 mM glutamate	2% PEG 600	5.1	109
2H	20 mM glutamate	2% PEG 600 40 mM calcium chloride	5.1	109
3C	20 mM glutamate	100 mM MSA 50 mM TEA	5.2	109

[00605] Stability was assessed by measuring HMWS by SE-HPLC after 0 days, after 3 F/T cycles, and after 83 days at -30°C. As shown in FIG. 5, the formulations containing proline demonstrated almost no HMWS growth over time.

[00606] Stability was also assessed by measuring HMWS by SE-HPLC after 0 days, after 3 F/T cycles, after 35 days at -30°C, and after 56 days at -30°C. As shown in FIG. 6, the formulations containing PEG 600 and a formulation with MSA and triethanolamine (TEA) demonstrated a small decrease in HMWS growth upon F/T stress and storage at -30°C compared to the formulations containing PEG 200.

EXAMPLE 4

Effect of Salts on Formulation Stability

[00607] The UF DF stock adalimumab biosimilar solution described in Example 2 was diluted to 170 mg/mL with 20 mM glutamate, pH 5.2 buffer and various salts were added directly by weight until dissolved at a final concentration of 75 mM. A stock concentrated solution of proline in the 20 mM glutamate, pH 5.2 buffer was also added to achieve a final concentration of 100 mM. After preparing the protein solutions, the pH was adjusted if needed with either HCl or NaOH to 5.2 ± 0.4 . The composition of the formulation buffer, and the pH and antibody concentration of the formulations are provided in Table 4. Following sterile filtration, aliquots were filled into 5cc glass vials and stored at -30°C, 4°C, and 40°C.

Table 4

Ref.	Buffer	Excipient(s)	pH	Ab conc. (mg/mL)
4A	20 mM glutamate	75 mM sodium borate 100 mM proline	5.6	175
4B	20 mM glutamate	75 mM sodium bicarbonate 100 mM proline	5.2	180
4C	20 mM glutamate	75 mM sodium sulfate 100 mM proline	5.2	183

4D	20 mM glutamate	15 mM calcium sulfate 100 mM proline	5.1	178
4E	20 mM glutamate	75 mM ammonium sulfate 100 mM proline	5.2	175
4F	20 mM glutamate	75 mM calcium chloride 100 mM proline	5.1	172
4G	20 mM glutamate	75 mM sodium chloride 100 mM proline	5.2	167
4H	20 mM glutamate	75 mM magnesium chloride 100 mM proline	5.1	193

[00608] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 7, 14, and 28 days at 40°C. As shown in FIG. 7, the formulations containing calcium chloride or magnesium chloride demonstrated less acidic peak growth over time compared to the formulations containing sodium borate, sodium bicarbonate, sodium sulfate, calcium sulfate, ammonium sulfate, or sodium chloride.

[00609] Stability also was assessed by measuring HMWS by SE-HPLC after 0, 7, 14, and 28 days at 40°C. As shown in FIG. 8, the formulations containing calcium sulfate, ammonium sulfate, calcium chloride, sodium chloride, or magnesium chloride demonstrated less HMWS growth over time compared to the formulations containing sodium borate, sodium bicarbonate, or sodium sulfate.

EXAMPLE 5

Effect of MEA on Formulation Stability

[00610] The UF DF stock adalimumab biosimilar solution described in Example 2 was diluted with 20 mM glutamate buffer, pH 5.0 and 2M MEA in volumes needed to generate the final MEA concentrations shown in Table 5. After preparing the protein solutions, the pH was adjusted if needed with either HCl or NaOH to 5.2. The composition of the formulation buffer, and the pH and antibody concentration of the formulations are provided in Table 5. Following sterile filtration, aliquots were filled into 5cc glass vials and stored at 4°C or 40°C.

Table 5

Ref.	Buffer	Excipient(s)	pH	Ab conc. (mg/mL)
5A	20 mM glutamate	30 mM MEA	5.2	182
5B	20 mM glutamate	80 mM MEA	5.2	182
5C	20 mM glutamate	115 mM MEA	5.2	185
5D	20 mM glutamate	160 mM MEA	5.2	177

[00611] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 7, 14, and 28 days at 40°C. As shown in FIG. 9, the formulations containing higher concentrations of MEA (e.g., 160 mM MEA) demonstrated less acidic peak growth over time compared to the formulations containing lower concentrations of MEA (e.g., 30 mM MEA). The ratio of % acidic peak after 28 days to the % acidic peak at 0 days was 2.23 for formulation 5A, 2.17 for formulation 5B, 2.11 for formulation 5C, and 2.09 for formulation 5D.

[00612] Stability also was assessed by measuring HMWS by SE-HPLC after 0, 7, 14, and 28 days at 40°C. As shown in FIG. 10, the formulations containing higher concentrations of MEA (e.g., 160 mM MEA) demonstrated slightly less HMWS growth over time compared to the formulations containing lower concentrations of MEA (e.g., 30 mM MEA).

EXAMPLE 6

Effect of Excipients on Formulation Stability

[00613] The UF DF stock adalimumab biosimilar solution described in Example 2 was diluted to around 105 mg/mL once excipients were added. In each formulation, 2X stock excipient solutions in 20 mM glutamate buffer, pH 5.2 were added to a final protein concentration of around 105 mg/mL. The pH was adjusted to 5.2 ± 0.1 with HCl or NaOH if needed. The final formulations were sterile filtered and placed into 5 cc glass vials for subsequent tests. The composition of the formulation buffer, and the pH and antibody concentration of the formulations are provided in Table 6.

Table 6

Ref.	Buffer	Excipient(s)	pH	Ab conc. (mg/mL)
6A	20 mM glutamate	1.4% ethanol	5.1	102
6B	20 mM glutamate	0.5% ethanol 40 mM calcium chloride	5.2	106
6C	20 mM glutamate	0.5% ethanol 1% PEG 3350 40 mM calcium chloride	5.2	108
6D	20 mM glutamate	150 mM TEA 40 mM calcium chloride	5.2	107
6E	20 mM glutamate	30 mM TEA 75 mM calcium chloride	5.2	105
6F	20 mM glutamate	0.5% ethanol	5.2	106
6G	20 mM glutamate	0.5% ethanol 2% PEG 200	5.2	106
6H	20 mM glutamate	0.25% ethanol 2% PEG 200	5.2	102
6I	20 mM glutamate	0.5% ethanol	5.1	105

		100 mM MSA		
6J	20 mM glutamate	0.5% ethanol 0.5% poly(vinylpyrrolidone) (PVP) 10K 100 mM MSA	5.2	105
6K	20 mM glutamate	0.5% ethanol 100 mM MEA	5.2	101

[00614] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 7, 14, and 28 days at 40°C. As shown in FIG. 11, the formulations containing ethanol with calcium chloride, ethanol with calcium chloride and PEG 3350, TEA with calcium chloride, and ethanol with MEA demonstrated less than 30% of acidic peak after 4 weeks at 40°C. The formulations containing 1.4% ethanol with no additional excipients demonstrated stability comparable to the formulations containing 0.5% ethanol with no additional excipients at the 4 week time point.

[00615] Stability also was assessed by measuring HMWS by SE-HPLC after 0, 7, 14, and 28 days at 40°C. As shown in FIG. 12, the formulation containing 1.4% ethanol with no additional excipients demonstrated less than 1% of HMWS after 4 weeks at 40°C. The formulations containing 0.5% ethanol, ethanol in combination with calcium chloride, ethanol in combination with calcium chloride and PEG 3350, ethanol in combination with PEG 200, and ethanol in combination with MEA demonstrated less than 1.5% of HMWS at the 4 week time point.

EXAMPLE 7

Effect of Amino Acids on Formulation Stability

[00616] Adalimumab biosimilar was prepared in a buffer containing 15 mM glutamate, pH 5.2 using a Cogent µScale TFF system with a 30kD Millipore cassette and a pressure difference of about 23 psi. The protein was concentrated to 114 mg/mL, and the resulting material in 15 mM glutamic acid, pH 5.2 buffer was then concentrated by centrifugation concentration to 186 mg/mL. In each formulation, 2X stock excipient solutions in 15 mM glutamate buffer, pH 5.2 were added to the starting material, resulting in a final protein concentration of around 90-100 mg/mL. The pH was adjusted to 5.2 with HCl or NaOH if needed. The final formulations were sterile filtered and placed into 5 cc glass vials for subsequent tests. The composition of the formulation buffer, and the pH and antibody concentration of the formulations are provided in Table 7.

Table 7

Ref.	Buffer	Excipient(s)	pH	Ab conc. (mg/mL)
7A	15 mM glutamate	100 mM alanine 45 mM calcium chloride	5.2	92
7B	15 mM glutamate	100 mM asparagine 45 mM calcium chloride	5.2	95
7C	15 mM glutamate	100 mM isoleucine 45 mM calcium chloride	5.2	96
7D	15 mM glutamate	100 mM serine 45 mM calcium chloride	5.2	98
7E	15 mM glutamate	20 mM aspartic acid 80 mM proline 45 mM calcium chloride	5.2	96
7F	15 mM glutamate	25 mM creatine 75 mM proline 45 mM calcium chloride	5.2	96
7G	15 mM glutamate	50 mM glutamine 50 mM proline 45 mM calcium chloride	5.2	97
7H	15 mM glutamate	50 mM leucine 50 mM proline 45 mM calcium chloride	5.2	97
7I	15 mM glutamate	50 mM phenylalanine 50 mM proline 45 mM calcium chloride	5.2	97
7J	15 mM glutamate	25 mM tryptophan 75 mM proline 45 mM calcium chloride	5.2	90

[00617] To assess stability, the % acidic peak was measured by CEX-HPLC after 0 and 7 days at 40°C. As shown in FIG. 13, the formulations containing alanine, serine, proline in combination with glutamine, or proline in combination with creatine, for example, demonstrated 18-19% of acidic peak after 7 days incubation at 40°C, in comparison to the formulation containing proline in combination with phenylalanine, which demonstrated almost 20% of acidic peak after 7 days.

[00618] Stability also was assessed by measuring HMWS by SE-HPLC after 0 and 7 days at 40°C. As shown in FIG. 14, the formulations containing alanine, asparagine, isoleucine, serine, proline in combination with aspartic acid, proline in combination with creatine, proline in combination with glutamine, and proline in combination with tryptophan demonstrated about 0.5% or less of HMWS after 7 days at 40°C.

EXAMPLE 8

Effect of Nonionic, Anionic, or Cationic Surfactants on Formulation Stability

[00619] Adalimumab biosimilar was prepared using a Cogent μ Scale TFF system with a 30kD Millipore cassette and a pressure difference of about 23 psi in a buffer containing 20 mM acetate, 45 mM calcium chloride, and 100 mM arginine, with a final pH of 5.2. The resulting protein was concentrated to greater than 143 mg/mL. The material was then used for the addition of stock surfactant solutions to the final concentrations of surfactant and protein listed in Table 8. Final pH adjustment to 5.2 was accomplished with NaOH or HCl. For accelerated stability tests, aliquots were filled into 5 cc glass vials and examined for stability at 40°C. For shaking stress studies, 36 mL of each formulation in 50 cc containers was subjected to continued shaking stress at room temperature. The composition of the formulation buffer, and the pH and antibody concentration of the formulations are provided in Table 8.

Table 8

Ref.	Buffer	Surfactant	Excipient(s)	pH	Ab conc. (mg/mL)
8A	20 mM acetate	0.1% Polysorbate 20	45 mM calcium chloride 100 mM arginine-HCl	5.2	140
8B	20 mM acetate	0.1% Polysorbate 80	45 mM calcium chloride 100 mM arginine-HCl	5.2	140
8C	20 mM acetate	0.1% Pluronic F68	45 mM calcium chloride 100 mM arginine-HCl	5.2	140
8D	20 mM acetate	0.01% Docusate sodium	45 mM calcium chloride 100 mM arginine-HCl	5.2	140
8E	20 mM acetate	0.1% benzalkonium chloride	45 mM calcium chloride 100 mM arginine-HCl	5.2	140
8F	20 mM acetate	0.1% Span 40	45 mM calcium chloride 100 mM arginine-HCl	5.2	140
8G	20 mM acetate	0.1% Triton X-100	45 mM calcium chloride 100 mM arginine-HCl	5.2	140
8H	20 mM acetate	---	45 mM calcium chloride 100 mM arginine-HCl	5.2	140

[00620] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 3, and 7 days at 40°C. As shown in FIG. 15, the formulations containing nonionic, anionic, or cationic surfactants demonstrated similar amounts of acidic peak after 7 days at 40°C, in comparison to a formulation without surfactant.

[00621] Stability also was assessed by measuring HMWS by SE-HPLC after 0, 3, 7, and 14 days at 40°C. As shown in FIG. 16, the formulations containing nonionic, anionic, or cationic surfactants demonstrated similar amounts of HMWS after 14 days at 40°C, in comparison to a formulation without surfactant.

[00622] Stability was further assessed after subjecting the formulations to shaking stress. The % acidic peak was measured by CEX-HPLC after continuous shaking at room temperature for 0 and 158 hours. As shown in FIG. 17, the formulations containing surfactants demonstrated around 0.3% or less of acidic peak after continuous shaking at room temperature for 158 hours, in comparison to a formulation without surfactant. HMWS were measured by SE-HPLC after continuous shaking at room temperature for 0 and 158 hours. As shown in FIG. 18, the formulation containing benzalkonium chloride demonstrated about twice the percentage of HMWS, in comparison to the formulations containing other surfactants and a formulation without surfactant.

EXAMPLE 9

Effect of Nonionic, Anionic, or Cationic Surfactants on Formulation Stability

[00623] Adalimumab biosimilar in a buffer consisting of 20 mM acetate, with 45 mM calcium chloride and 100 mM arginine, with a final pH set at 5.2 was used to assess stability upon stirring stress. The final formulation pH was adjusted to 5.2 using NaOH or HCl. Surfactants were chosen and selected at low, medium and high levels to assess stirring stability with adalimumab biosimilar at a final concentration of approximately 140 mg/mL. Stock surfactant solutions were made and diluted with the starting material to achieve the final surfactant concentrations as shown in Table 9. For each formulation condition, 30 mL were prepared, transferred to 50 cc containers and stirred continuously for 5 days at room temperature.

Table 9

Ref.	Buffer	Surfactant	Excipient(s)	pH	Ab conc. (mg/mL)
9A	20 mM acetate	0.005% Polysorbate 80	45 mM calcium chloride 100 mM arginine-HCl	5.2	137

9B	20 mM acetate	0.01% Polysorbate 80	45 mM calcium chloride 100 mM arginine-HCl	5.2	135
9C	20 mM acetate	0.05% Polysorbate 80	45 mM calcium chloride 100 mM arginine-HCl	5.2	138
9D	20 mM acetate	0.005% Polysorbate 20	45 mM calcium chloride 100 mM arginine-HCl	5.2	138
9E	20 mM acetate	0.01% Polysorbate 20	45 mM calcium chloride 100 mM arginine-HCl	5.2	136
9F	20 mM acetate	0.05% Polysorbate 20	45 mM calcium chloride 100 mM arginine-HCl	5.2	136
9G	20 mM acetate	0.005% Triton X-100	45 mM calcium chloride 100 mM arginine-HCl	5.2	134
9H	20 mM acetate	0.01% Triton X-100	45 mM calcium chloride 100 mM arginine-HCl	5.2	139
9I	20 mM acetate	0.05% Triton X-100	45 mM calcium chloride 100 mM arginine-HCl	5.2	138
9J	20 mM acetate	0.05% Pluronic F68	45 mM calcium chloride 100 mM arginine-HCl	5.2	139
9K	20 mM acetate	0.1% Pluronic F68	45 mM calcium chloride 100 mM arginine-HCl	5.2	139
9L	20 mM acetate	0.4% Pluronic F68	45 mM calcium chloride 100 mM arginine-HCl	5.2	134

[00624] To assess stability, the % acidic peak was measured by CEX-HPLC after stirring at room temperature for 0, 1, 2, and 5 days. The results are shown in FIG. 19. With the exception of the 0.005% Polysorbate 80 formulation (9A), which had a slightly higher level of % acidic peak, there was no meaningful difference due to the level of surfactant in the range tested on stability as measured by CEX-HPLC.

[00625] Stability also was assessed by measuring HMWS by SE-HPLC after stirring at room temperature for 0, 1, 2, and 5 days. The results are shown in FIG. 20. No meaningful differences in the amount of HMWS were observed in the concentration range of surfactants examined.

[00626] Stability additionally was assessed by measuring opalescence after stirring at room temperature for 0, 1, 2, and 5 days. As shown in FIG. 21, the formulations containing low levels of Polysorbate 20 or Polysorbate 80 demonstrated the highest opalescence of the formulations tested after stirring at room temperature for 5 days. In comparison, the formulations containing Pluronic F68 demonstrated the lowest opalescence of the formulations tested after stirring at room temperature for 5 days.

EXAMPLE 10

Effect of Nontraditional Surfactants on Formulation Stability

[00627] Adalimumab biosimilar was prepared in a buffer containing 15 mM glutamate, 300 mM proline, pH 5.2 using the Cogent μ Scale TFF system described in Example 2. Surfactant stock solutions were then added to obtain a final protein concentration close to 110 mg/mL. The pH was adjusted to 5.2 using NaOH or HCl if needed. Aliquots were then filled into 5cc glass vials for evaluation of stability at accelerated temperature. The composition of the formulation buffer, and the pH and antibody concentration of the formulations are provided in Table 10.

Table 10

Ref.	Buffer	Surfactant	Excipient(s)	pH	Ab conc. (mg/mL)
10A	15 mM glutamate	0.01% benzalkonium chloride	300 mM proline	5.2	109
10B	15 mM glutamate	0.01% guanidine HCl	300 mM proline	5.2	109
10C	15 mM glutamate	0.01% lecithin	300 mM proline	5.2	109
10D	15 mM glutamate	0.01% oleic acid	300 mM proline	5.2	109
10E	15 mM glutamate	0.01% Polysorbate 80	300 mM proline	5.2	109
10F	15 mM glutamate	0.1% polyvinyl alcohol 205K	300 mM proline	5.2	100
10G	15 mM glutamate	0.1% polyvinyl alcohol 31K	300 mM proline	5.2	100
10H	15 mM glutamate	0.01% PVP	300 mM proline	5.2	109
10I	15 mM glutamate	0.01% protamine sulfate	300 mM proline	5.2	109

[00628] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 7, 14, and 28 days at 40°C. The results are shown in FIG. 22. The amount of acidic peak formed after storage at 40°C for 28 days was found to be similar. Meaningful differences were not observed.

[00629] Stability also was assessed by measuring HMWS by SE-HPLC after 0, 7, 14, and 28 days at 40°C. The results are shown in FIG. 23. The formulations containing benzalkonium

chloride and protamine sulfate (10A and 10I) appeared to have the lowest amount of HMWS after 28 days at 40°C.

EXAMPLE 11

Effect of PEG, Proline, and Calcium Chloride on Formulation Stability

[00630] Adalimumab biosimilar frozen in a buffer with 20 mM glutamic acid, pH 5.2 was thawed and subjected to dialysis using dialysis tubing into one of the following buffers: 20 mM calcium chloride; 10 mM lactate; 4.2% mannitol; and 14.4 mM sodium phosphate with 7.7 mM citrate, 105 mM sodium chloride and 1.2% mannitol. Stock excipient solutions were then added to achieve the final concentrations as shown in Table 11. If needed, the pH was adjusted to 5.2 ± 0.1 with MEA or MSA. Comparative formulations were also prepared and adjusted to $pH\ 5.2 \pm 0.1$ with NaOH or HCl as needed. The final formulation compositions, pH, and antibody concentration are listed in Table 11.

Table 11

Ref.	Buffer/pH Adjusting Agent	Excipient(s)	Surfactant	pH	Ab conc. (mg/mL)	Osmolality (mOsm/kg)
Comp. 1A	---/HCl, NaOH	4.2% mannitol	0.1% polysorbate 80	5.2	102	271
Comp. 2A	7.7 mM citrate, 14.1 mM sodium phosphate	105 mM NaCl 1.2% mannitol	0.1% polysorbate 80	5.1	110	309
11A	---/ MEA, MSA	9% PEG 600 20 mM calcium chloride	0.1% Pluronic F68	5.1	105	383
11B	---/ MEA, MSA	6.9% PEG 600 0.6% PEG 200 20 mM calcium chloride	0.1% Pluronic F68	5.1	97	367
11C	---/ MEA, MSA	4.5% PEG 600 1.8% PEG 200 20 mM calcium chloride	0.1% Pluronic F68	5.1	104	321
11D	---/ MEA, MSA	1.2% PEG 600 3% PEG 200 20 mM calcium chloride	0.1% Pluronic F68	5.1	112	349
11E	---/ MEA, MSA	4% PEG 200 20 mM calcium chloride	0.1% Pluronic F68	5.1	99	321

Ref.	Buffer/pH Adjusting Agent	Excipient(s)	Surfactant	pH	Ab conc. (mg/mL)	Osmolality (mOsm/kg)
11F	---/ MEA, MSA	7.3% PEG 600 60 mM proline 20 mM calcium chloride	0.1% Pluronic F68	5.2	114	439
11G	---/ MEA, MSA	5.5% PEG 600 120 mM proline 20 mM calcium chloride	0.1% Pluronic F68	5.1	107	404
11H	---/ MEA, MSA	2.5% PEG 600 180 mM proline 20 mM calcium chloride	0.1% Pluronic F68	5.2	105	410
11I	---/ MEA, MSA	240 mM proline 20 mM calcium chloride	0.1% Pluronic F68	5.1	109	367
11J	10 mM lactate	8.4% PEG 600	0.1% Pluronic F68	5.1	107	379
11K	10 mM lactate	4% PEG 600 1.6% PEG 200	0.1% Pluronic F68	5.1	102	307
Comp. 1B	---/HCl, NaOH	4.2% mannitol	0.1% polysorbate 80	5.2	173	301
Comp. 2B	7.7 mM citrate 14.1 mM sodium phosphate	105 mM NaCl 1.2% mannitol	0.1% polysorbate 80	5.1	174	317
11L	10 mM lactate	8.4% PEG 600	0.1% Pluronic F68	5.2	177	488
11M	10 mM lactate	4% PEG 600 1.6% PEG 200	0.1% Pluronic F68	5.2	178	413
11N	10 mM lactate	3.8% PEG 200	0.1% Pluronic F68	5.2	182	310
11O	10 mM lactate	220 mM proline	0.1% Pluronic F68	5.2	170	389

[00631] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 2, and 4 weeks at 40°C and at 25°C. The results are shown in FIG. 24 and FIG. 25. At 25°C, meaningful differences were not observed. After storage at 40°C, the formulations labeled 2A and 2B

appeared to have higher growth of the % acidic peak, however the other formulations tested did not show apparent differences that could be considered meaningful.

[00632] Stability also was assessed by measuring HMWS by SE-HPLC after 0, 2, and 4 weeks at 40°C and at 25°C. The results are shown in FIG. 26 and FIG. 27. In formulations at a protein concentration of around 170 mg/mL, the formulation buffered with lactate and containing proline had superior stability, both at 25°C and at 40°C. In formulations containing PEG 200 or PEG 600, stability was worse than the other formulations at 170 mg/mL. Formulations at approximately 100 mg/mL also showed a preference for proline in that the amount of HMWS was reduced as the proline concentration increased, a trend which was most apparent at 40°C and to a lesser extent at 25°C.

[00633] Stability was assessed after freeze/thaw cycling as described in Example 3. The percentage of HMWS was measured by SE-HPLC after 0 days and after 3 F/T cycles. The results are shown in FIG. 28. In general, at around 100 mg/mL, the comp 1A and comp 2A formulations appeared to have the largest increase in HMWS compared to the other formulations examined. At 170 mg/mL, the formulation with PEG 600 and PEG 200 (11M) appeared to have the largest increase in HMWS.

EXAMPLE 12

Effect of Sorbitol, Sucrose, Proline, PEG, and Calcium Chloride on Formulation Stability

[00634] Adalimumab biosimilar starting material was prepared using a Cogent µScale TFF with a 30kD Millipore cassette and a pressure difference of about 23 psi in the following buffers: 4.2% mannitol; 14.4 mM sodium phosphate with 7.7 mM citrate, 105 mM sodium chloride and 1.2% mannitol; 7.3% sucrose with 20 mM calcium chloride; 20 mM calcium chloride; 4% sorbitol with 25 mM calcium chloride; 320 mM proline with 20 mM calcium chloride; 10 mM lactate with 225 mM proline and 20 mM calcium chloride; 10 mM lactate with 20 mM calcium chloride; 10 mM acetate with 9% sucrose. The pH was adjusted as shown in Table 12. The resulting protein was concentrated to achieve the concentration provided in Table 12, with the exception of Comp 3A which was diluted to 100 mg/mL with buffer from a bulk preparation at 170 mg/mL. The formulations are provided in Table 12. The formulations were stored at -30°C.

Table 12

Ref.	Buffer/pH Adjusting Agent	Excipient(s)	Surfactant	pH	Ab conc. (mg/mL)
Comp. 3A	---	4.2% mannitol	0.1% Polysorbate 80	5.2	100
Comp. 3B	---	4.2% mannitol	0.1% Polysorbate 80	5.2	170
Comp. 4	14.1 mM sodium phosphate 7.7 mM citrate	105 mM NaCl 1.2% mannitol	0.1% Polysorbate 80	5.2	50
12A	---/ MSA, MEA	7.3 % sucrose 20 mM calcium chloride	0.1% Pluronic F68	5.2	100
12B	---/ MSA, MEA	4.8% PEG 200 20 mM calcium chloride	0.1% Pluronic F68	5.2	100
12C	---/ HCl	4% sorbitol, 25 mM calcium chloride	0.1% Pluronic F68	5.2	100
12D	---/ MSA, MEA	14.5% PEG 600 20 mM calcium chloride	0.1% Pluronic F68	5.2	100
12E	10 mM histidine/ MSA, MEA	320 mM proline 20 mM calcium chloride	---	6.8	100
12F	10 mM lactate/ MSA, MEA	225 mM proline 20 mM calcium chloride	0.1% Pluronic F68	5.2	170
12G	10 mM lactate/ MSA, MEA	13% PEG 600 20 mM calcium chloride	0.1% Pluronic F68	5.2	170
12H	10 mM acetate/ MSA, MEA	9% sucrose	0.1% Polysorbate 80	5.2	170

[00635] To assess stability, the % acidic peak was measured by CEX-HPLC after 0 days, after transport, and after storing the transported sample at 40°C for 2 weeks. The results are shown in FIG. 29. After 2 weeks at 40°C, the lowest amount of % acidic peak was found in the formulation buffered with lactate and containing calcium chloride (12F). Otherwise, formulations buffered with histidine, containing PEG 600 at a high concentration or the formulation buffered with sodium phosphate were less stable (12E, 12D, Comp 4). The antibody

concentration of each formulation, i.e. whether at 50, 100 or 170 mg/mL did not appear to influence the amount of % acidic peak.

[00636] Stability also was assessed by measuring HMWS by SE-HPLC after 0 days, after transport, and after storing the transported sample at 40°C for 2 weeks. The results are shown in FIG. 30. The lower the concentration, the lower the amount of HMWS. This is shown in comparing Comp 3B, Comp 3A and Comp 4 in which as the concentration changes from 170 mg/mL to 100 mg/mL to 50 mg/mL the HMWS is correspondingly reduced. For the other formulations tested, at 170 mg/mL, there are differences in the amount of HMWS after two weeks at 40°C. The lowest amount of HMWS was measured for the acetate formulation with sucrose (12H), followed by the lactate buffered formulation with proline (12F) and finally the formulation with the high amount of PEG 600 (12G). In formulations at 100 mg/mL, the lowest HMWS was found in the self-buffering formulation with sorbitol and calcium chloride (12C). The addition of PEG 200 resulted in more HMWS at 100 mg/mL (12B).

[00637] Stability was further assessed by MFI. The results are shown in FIGs. 31-36. High particle counts at 5 µM were measured in the formulation containing proline and calcium chloride after transport stress (12E). In general, particle counts were higher at 100 mg/mL than at 170 mg/mL at the 5 µM particle size. At 100 mg/mL, formulation Comp 3A and the self-buffered formulation with sorbitol had lower particle counts at 5 µM post transport than the other formulations tested at this concentration (compare 12C and Comp 3A to 12A, 12B, 12D and 12E). The particle count trends observed at 5 µM were also observed at the 10 µM particle size. The lowest particle counts at 10 µM were measured at 170 mg/mL. At 100 mg/mL, a low particle count increase post transport was also observed in the self-buffered formulation with sorbitol (12C) and in Comp 3A. Finally, the particle count trends reported for the 5 µM and 10 µM particle sizes were also observed at 25 µM. The lowest particle counts were again at the 25 µM size. At 100 mg/mL, the lowest particle counts post transport were measured in formulations Comp 3A, 12A and 12C.

EXAMPLE 13

Effect of PEG, Proline, and Calcium Chloride on Formulation Stability

[00638] Adalimumab biosimilar starting material at 200 mg/mL was diluted to 180 mg/mL and then subjected to dialysis using 3kD cutoff dialysis tubing in the following buffers: 20 mM calcium chloride, pH adjusted with MSA or MEA; 14.4 mM sodium phosphate with 7.7 mM

citrate, 105 mM sodium chloride and 1.2% mannitol, pH adjusted with HCl or NaOH to a final pH of 4.8; 10 mM lactate with 20 mM calcium chloride, pH adjusted with MSA or MEA; and 4.2% mannitol, pH adjusted with MSA or MEA. Stock excipient solutions were then added to achieve the final concentrations as shown in Table 13 and the pH was adjusted to 5.2 if needed. The formulations are provided in Table 13.

Table 13

Ref.	Buffer/pH Adjusting Agent	Excipient(s)	Surfactant	pH	Ab conc. (mg/mL)
Comp. 5A	---/HCl, NaOH	4.2% mannitol	0.1% Polysorbate 80	5.2	100
Comp. 6A	14.1 mM sodium phosphate 7.7 mM citrate/ HCl, NaOH	105mM NaCl 1.2% mannitol	0.1% Polysorbate 80	5.2	100
13A	---/ MSA, MEA	9% PEG600 20 mM calcium chloride	0.1% Pluronic F68	5.2	100
13B	---/ MSA, MEA	6.9% PEG600 0.6% PEG200 20 mM calcium chloride	0.1% Pluronic F68	5.2	100
13C	---/ MSA, MEA	4.5% PEG600 1.8 % PEG200 20 mM calcium chloride	0.1% Pluronic F68	5.2	100
13D	---/ MSA, MEA	1.2% PEG600 3% PEG200 20 mM calcium chloride	0.1% Pluronic F68	5.2	100
13E	---/ MSA, MEA	4% PEG200 20 mM calcium chloride	0.1% Pluronic F68	5.2	100
13F	---/ MSA, MEA	7.3% PEG600 20 mM calcium chloride 60 mM proline	0.1% Pluronic F68	5.2	100
13G	---/ MSA, MEA	5.5% PEG600 20 mM calcium chloride 120 mM proline	0.1% Pluronic F68	5.2	100
13H	---/ MSA, MEA	2.5% PEG600	0.1% Pluronic F68	5.2	100

Ref.	Buffer/pH Adjusting Agent	Excipient(s)	Surfactant	pH	Ab conc. (mg/mL)
		20 mM calcium chloride 180 mM proline			
13I	---/ MSA, MEA	20 mM calcium chloride 240 mM proline	0.1% Pluronic F68	5.2	100
13J	10 mM lactate/ MSA, MEA	20 mM calcium chloride 8.4% PEG 600	0.1% Pluronic F68	5.2	100
13K	10 mM lactate/ MSA, MEA	20 mM calcium chloride 4% PEG 600, 1.6% PEG 200	0.1% Pluronic F68	5.2	100
Comp. 5B	---/HCl, NaOH	4.2% mannitol	0.1% Polysorbate 80	5.2	170
Comp. 6B	14.1 mM sodium phosphate 7.7 mM citrate/ HCl, NaOH	105mM NaCl 1.2% mannitol	0.1% Polysorbate 80	5.2	170
13L	10 mM lactate/ MSA, MEA	8.4% PEG600 20 mM calcium chloride	0.1% Pluronic F68	5.2	170
13M	10 mM lactate/ MSA, MEA	4% PEG600 1.6% PEG200 20 mM calcium chloride	0.1% Pluronic F68	5.2	170
13N	10 mM lactate/ MSA, MEA	3.8% PEG200 20 mM calcium chloride	0.1% Pluronic F68	5.2	170
13O	10 mM lactate/ MSA, MEA	20 mM calcium chloride 220 mM proline	0.1% Pluronic F68	5.2	170

[00639] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 2, and 4 weeks at 40°C and at 25°C. The results are shown in FIG. 37 and FIG. 38. At 25°C, after 4 weeks, the lowest % acidic peak was found in the formulation containing proline and calcium chloride (13I) and the formulation with PEG 200 and PEG 600 and calcium chloride (13D). Lower growth was also observed in formulations with a mixture of PEG 600, proline and calcium chloride (13H) and in the formulation buffered with sodium phosphate (Comp 6A). In

formulations at a concentration of 170 mg/mL, the lowest % acidic peak after storage for 4 weeks at 25°C was found in the lactate buffer formulation with proline (13O) and in the sodium phosphate buffered formulation (Comp 6B). After 4 weeks at 40°C, meaningful differences between formulations were not as apparent. The highest amount of % acidic peak found after 4 weeks at 40°C were in the formulations buffered with sodium phosphate at both 100 and 170 mg/mL (Comp 6A, Comp 6B respectively.)

[00640] Stability was assessed by measuring HMWS by SE-HPLC after 0, 2, and 4 weeks at 40°C and at 25°C. The results are shown in FIG. 39 and FIG. 40. At 25°C, after 4 weeks, the formulation with proline and calcium chloride had the lowest HMWS (13I). Otherwise, increasing concentrations of PEG 600 and lower proline levels in formulations resulted in higher amounts of HMWS (compare 13I, 13H, 13G and 13F). In formulations at 170 mg/mL stored for 4 weeks at 25°C, the proline formulation with calcium chloride was again superior in having the lowest HMWS (13O). At 40°C, similar trends to those observed at 25°C were noted. The proline formulations had the lowest amount of HMWS at both 100 mg/mL and 170 mg/mL (13I, 13O). At 4°C, stability was assessed by measuring HMWS by SE-HPLC after 0, 4, and 8 weeks. The results are shown in FIG. 41. Minimal growth of HMWS is observed at 4°C in most formulations. At time zero, the lowest HMWS in the 100 mg/mL formulation is found in the proline formulation with calcium chloride (13I). Likewise, at 170 mg/mL, HMWS is minimized in the lactate buffer formulation with proline at time zero (13O). Finally, stability was assessed by measuring HMWS by SE-HPLC after 0 weeks, after 3 F/T cycles, and after 8 weeks at -30°C. The results are shown in FIG. 42. In agreement with the results obtained at 4°C, the proline formulation at 100 and 170 mg/mL (13I, 13O) had the lowest amount of HMWS and no meaningful change in HMWS after the freeze thaw cycles. Most formulations did not show meaningful change upon repeated freezing and thawing at -30°C. The lone exception appears to be the Comp 5A formulation, in which HMWS increased upon repeated freezing and thawing and after 8 weeks at -30°C.

EXAMPLE 14

Effect of PEG, Proline, MEA, MSA and Calcium Chloride on Formulation Stability

[00641] Adalimumab biosimilar starting material at 50 mg/mL was prepared using 3.5 kD cutoff dialysis tubing in the following buffers: 5 mM MEA with 5 mM MSA, pH adjusted using MSA or MEA to a final pH of 4.8; 14.4 mM sodium phosphate with 7.7 mM citrate, 105 mM

sodium chloride and 1.2% mannitol, pH adjusted with HCl or NaOH to a final pH of 4.8; 4.2% mannitol, pH adjusted with HCl or NaOH to a final pH of 4.8; 10 mM acetate with 9% sucrose, pH adjusted with HCl or NaOH to a final pH of 4.8. Stock excipient solutions were then added to achieve the final concentrations as shown in Table 14 and the pH was adjusted to 5.2 if needed. The formulations are provided in Table 14.

Table 14

Ref.	Buffer	Excipient(s)	pH Adjusting Agent	pH	Ab conc. (mg/mL)
Comp. 7	14.1 mM sodium phosphate 7.7 mM citrate	105 mM NaCl 1.2% mannitol	HCl, NaOH	5.2	50
Comp. 8	---	4.2% mannitol	HCl, NaOH	5.2	50
14A	10 mM acetate	9% sucrose	HCl, NaOH	5.2	50
14B	---	10.4% PEG600	MSA, MEA	5.2	50
14C	---	8.5% PEG600 25 mM calcium chloride	MSA, MEA	5.2	50
14D	---	6.4% PEG600 50 mM calcium chloride	MSA, MEA	5.2	50
14E	---	3.7% PEG600 75 mM calcium chloride	MSA, MEA	5.2	50
14F	---	100 mM calcium chloride	MSA, MEA	5.2	50
14G	---	300 mM proline	MSA, MEA	5.2	50
14H	---	225 mM proline 25 mM calcium chloride	MSA, MEA	5.2	50
14I	---	150 mM proline 50 mM calcium chloride	MSA, MEA	5.2	50
14J	---	75 mM proline 75 mM calcium chloride	MSA, MEA	5.2	50
14K	---	240 mM proline 60 mM MEA 60 mM MSA	MSA, MEA	5.2	50
14L	---	180 mM proline 60 mM MEA 60 mM MSA	MSA, MEA	5.2	50
14M	---	120 mM proline	MSA, MEA	5.2	50

Ref.	Buffer	Excipient(s)	pH Adjusting Agent	pH	Ab conc. (mg/mL)
		90 mM MEA 90 mM MSA			

[00642] To assess stability, the % acidic peak was measured by CEX-HPLC after 0, 2, and 4 weeks at 40°C and after 0, 2, 4, and 8 weeks at 25°C. The results are shown in FIG. 43 and FIG. 44. At 25°C, after 8 weeks, lower amounts of HMWS were measured in the formulation with proline and high MEA and MSA (14M) and in the formulations with the higher concentrations of calcium chloride (14E, 14F and 14J). As is shown by comparing formulations 14B, 14C, 14D, 14E and 14F, the level of HMWS increased as the concentration of PEG 600 increased after 8 weeks at 25°C. Similar trends were observed at 40°C that had been apparent at 25°C. Increasing levels of calcium chloride were beneficial in minimizing the formation of HMWS. PEG 600 was not preferred for stability at 40°C. Low HMWS was observed in the formulation containing proline and high MEA and MSA after 4 weeks at 40°C. Stability was assessed by measuring acidic peak by CEX-HPLC after 0, 4 and 8 weeks at 4°C. The results are shown in FIG. 45. Minor differences were measured in the % acidic peak at time zero and after storage for 8 weeks at 4°C. These differences were not considered meaningful. Stability was assessed by measuring acidic peak by CEX-HPLC after 0 days, after 3 F/T cycles, and after 4 weeks at -30°C. The results are shown in FIG. 46. Consistent with the results obtained at 4°C, differences between formulations were minor and apparent growth of the % acidic peak was not observed after multiple freeze thaws and 8 weeks storage at -30°C.

[00643] Stability also was assessed by measuring HMWS by SE-HPLC after 0 days and after 3 F/T cycles. The results are shown in FIG. 47. For most formulations, multiple freezing and thawing did not result in growth of HMWS, with the exception of formulation Comp 8. Several formulations, although not showing an increase in HMWS after multiple freeze thaw steps, did grow in HMWS after storage at -30°C following the freeze thaw steps (formulations Comp. 8, self-buffered, and 14M, containing high amounts of MEA and MSA). Stability was assessed by measuring HMWS by SE-HPLC after 0 and 2 weeks at 40°C and at 25°C. The results are shown in FIG. 48 and FIG. 49. After storage at 40°C for 4 weeks, HMWS growth appeared to be higher in formulations containing PEG 600 or higher amounts of calcium chloride and in the formulation buffered with sodium phosphate (Comp 7, 14B, 14C, 14D, 14E, 14F). Overall, the

highest amount of HMWS at >3% was measured in the formulation with higher MEA and MSA (14M). Low amounts of HMWS were observed in the formulation buffered with acetate and the proline formulation (14A, 14G). Similar trends were observed at 25°C as were found at 40°C. Low HMWS were apparent in formulations 14A and 14G, with PEG 600 not preferred for stability, along with high levels of MEA and MSA. Finally, stability was also assessed at 4°C by SE-HPLC after 0, 4 and 8 weeks. The results are shown in Figure 50. Meaningful growth of HMWS at 4°C was not observed in most formulations, with the exception of the formulations containing higher amounts of PEG 600 (14B, 14C). As discussed previously, at time zero the highest HMWS was observed in the formulation containing high levels of MEA and MSA.

EXAMPLE 15

Stability of Self-Buffered, Lactate Buffered, and Acetate Buffered Formulations

[00644] Three adalimumab formulations were prepared, as shown in Table 15.

Table 15

Ref.	Buffer/pH Adjusting Agent	Excipients	Surfactant	pH	Ab conc. (mg/mL)	Conductivity
15A	--/HCl, Ca(OH) ₂	4% sorbitol, 30 mM calcium chloride	0.05% Pluronic F68	5.2	100	4.7 mS/cm
15B	10 mM Lactate/HCl, Ca(OH) ₂	6% sucrose, 30 mM calcium chloride	0.006% Pluronic F68	5.1	100	4.78 mS/cm
15C	10 mM Acetate/HCl, NaOH	6% sucrose, 45 mM NaCl	0.1% Polysorbate 80	5.2	100	4.05 mS/cm

[00645] To assess stability, the % acidic peak was measured by CEX-HPLC at 0 days, 1 week, 2 weeks, 1 month, and 2 months, at 2-8°C, and at 0 days, 1 week, 2 weeks, 1 month, and 2 months at 25°C. The results are shown in FIG. 51 (2-8°C) and FIG. 52 (25°C). All three formulation (formulations 15A-C) exhibited similar stability with respect to acidic species at 2-

8°C. At 25°C, formulation 15C (acetate buffer with sodium chloride) had the highest amount of % acidic peak.

[00646] Stability also was assessed by measuring HMWS by SE-HPLC after 0 days, 1 week, 2 weeks, 1 month, and 2 months at 2-8°C, and after 0 days, 1 week, 2 weeks, 1 month, and 2 months at 25°C. The results are shown in FIGs. 53 (2-8°C) and 54 (25°C). At time zero, the highest HMWS was measured in the self-buffered formulation, followed by the acetate buffer formulation with sodium chloride and the lactate buffer formulation with calcium chloride, respectively. This trend was maintained at 4°C over time, with the lactate buffer formulation having the least amount of HMWS. Likewise, at 25°C, the lactate buffer formulation exhibited the least growth of HMWS. At the 1 and 2 month time point, the rate of degradation also slowed down compared to the earlier time points at 25°C. This trend was observed for all formulations at 25°C. At 4°C, the rate of growth of HMWS were similar for each formulation, with a minor increase observed in all formulations after time zero and up to two weeks, followed by a leveling off of the rate after the two week time point. The lactate buffer formulation also had the lowest amount of HMWS at time zero.

[00647] Stability also was assessed by measuring the count of 5 µM, 10 µM, and 25 µM sub-visible particles by MFI in non-transported and transported samples at 2-8°C for 1, 2, and 4 weeks. The particles exhibited an equivalent circular diameter of at least 5.000 and an aspect ratio of less than 0.700. The results are shown in FIGs. 55-57. All formulations at ≤ 25 µM had low particle counts. For the 10 µM sub-visible counts, the acetate formulation (formulation 15B) showed the lowest amount of sub-visible particles. For the non-spherical ≤ 5 µM particle counts, the self-buffered and lactate buffer formulations (formulations 15A and 15C) showed higher particle counts at t=0 (pre-transport) and at later time points compared to the acetate formulation with sodium chloride. In general, for ≤ 5 µM particle counts, each formulation showed an increase in particles post-transport, followed by a trend of lower particle counts at the 1 week, 2 week and 4 week time points.

EXAMPLE 16

Effect of Surfactant and Salt on Formulation Stability

[00648] Several adalimumab formulations (formulations 16A-16L) were prepared, as shown in Table 16.

Table 16

Ref.	Buffer/pH Adjusting Agent	CaCl ₂ (mM)	Excipient	Surfactant	pH	Ab conc. (mg/mL)	Conductivity Osmolality Viscosity
16A	--/--	0	4% sorbitol	0.09% Polysorbate 20	5.21	97.89	0.76 mS/cm 241 mOsm 2.54 mPa·s
16B	--/60 μ L Ca(OH) ₂	15	4% sorbitol	0.09% Polysorbate 20	5.09	99.37	3.01 mS/cm 283 mOsm 2.59 mPa·s
16C	--/40 μ L Ca(OH) ₂	30	4% sorbitol	0.03% Polysorbate 20	5.06	103.47	4.98 mS/cm 317 mOsm 2.62 mPa·s
16D	--/40 μ L Ca(OH)	15	4% sorbitol	0.03% Polysorbate 20	5.1	99.99	3.07 mS/cm 283 mOsm 2.46 mPa·s
16E	--/60 μ L Ca(OH) ₂	30	4% sorbitol	0.09% Polysorbate 20	5.03	103.77	4.97 mS/cm 316 mOsm 2.54 mPa·s
16F	10 mM Lactate/--	0	6% sucrose	0.10% Pluronic F68	5.25	97.68	0.744 mS/cm 219 mOsm 2.82 mPa·s
16G	10 mM Lactate/--	15	6% sucrose	--	5.09	111.79	2.99 mS/cm 268 mOsm 3.03 mPa·s
16H	10 mM Lactate/--	15	6% sucrose	0.08% Pluronic F68	5.09	106.72	2.97 mS/cm 266 mOsm 3.00 mPa·s
16I	10 mM Lactate/--	15	6% sucrose	0.02% Pluronic F68	5.06	109.35	2.99 mS/cm 268 mOsm 2.93 mPa·s
16J	10 mM Lactate/--	30	6% sucrose	0.2% Pluronic F68	5.04	101.79	4.99 mS/cm 305 mOsm 2.75 mPa·s
16K	10 mM Lactate/--	30	6% sucrose	0.08% Pluronic F68	5.05	102.27	5.03 mS/cm 309 mOsm 2.70 mPa·s
16L	10 mM Lactate/--	30	6% sucrose	0.03% Pluronic F68	5.04	104.89	5.06 mS/cm 308 mOsm 2.68 mPa·s

[00649] To assess stability, the % acidic peak was measured by CEX-HPLC in non-transported samples and transported samples at 0, 1, and 2 weeks at 4°C, 25°C, and 40°C. The results are shown in FIGs. 58-63. No meaningful differences in the % acidic peak were exhibited at time 0 for all twelve formulations. The lack of meaningful differences between

formulations was also apparent after 1 month at 4°C for both transport stressed and non-transport stressed conditions. At 25°C, and 40°C, as a general trend, formulations without calcium chloride (16A and 16F) had the highest amount of % acidic peak after 1 month. In addition, differences between transported stressed and non-transported stressed formulations were not apparent at 25°C. At 40°C, the non-transported formulations that were self-buffered and containing calcium chloride (16B – 16E) had lower rates of growth of % acidic peak compared to the identical formulations that were transport stressed. Otherwise, the presence of calcium chloride appears to reduce the formation of the acidic peak at both 25°C and at 40°C.

[00650] Stability also was assessed by measuring HMWS by SE-HPLC after 0 days, after transport, and after storing the non-transported and transported samples at 4°C, 25°C, or 40°C for 1, 2, and 4 weeks. The results are shown in FIGs. 64-69. The formulations having the combination of lactate buffer and calcium chloride (e.g., formulations 16G-16L), versus self-buffered and formulations with sorbitol (formulations 16A-E), exhibited the lowest amount of HMWS at time 0. Formulations having lactate buffer exhibited better stability than formulations without lactate buffer at 25°C. Formulations having 15 mM of calcium chloride (formulations 16G-16I) exhibited better stability than formulations having 0 mM or 30 mM of calcium chloride. This trend was more apparent in the self-buffered formulations (16A – 16E) in which 15 mM calcium chloride was superior for stability at 25°C compared to self-buffered formulations with 30 mM calcium chloride. Overall, formulations having the combination of lactate buffer and calcium chloride exhibited surprisingly superior stability at 25°C. After storage for 1 month at 40°C, the growth of HMWS appeared to increase faster in the lactate buffer formulations compared to the self-buffered formulations, however the amount of HMWS formed did not exceed that of the HMWS measured in the self-buffered formulations at this same temperature and time point. In general, formulations having the combination of lactate buffer and 15 mM calcium chloride exhibited the lowest amount of HMWS, in part, because they initially had the lowest amount of HMWS.

[00651] Stability also was assessed by measuring the count of 5 µM, 10 µM, and 25 µM sub-visible particles by MFI in non-transported and transported samples at 4°C, 25°C, or 40°C for 1, 2, and 4 weeks. The particles exhibited an equivalent circular diameter of at least 5.000 and an aspect ratio of less than 0.700. The results are shown in FIGs. 70-72. For the 5 µM size particles, the lactate buffered formulation with 0.25% Pluronic F68 had the highest number of

particles following transport and at later time points. In the self-buffered formulations, the absence of calcium chloride resulted likewise in a high 5 μ M particle count initially and over time. These results were not expected, especially with the higher level of Pluronic F68 in the lactate buffer formulation associated with high particle counts. In the lactate buffer formulations in general at 5 μ M, 0.13% Pluronic F68 appeared best at minimizing particles in formulations with either 15 mM or 30 mM calcium chloride. FIGs. 70A-B. At the 10 μ M particle level, a similar trend to that observed for the 5 μ M results was observed. The lactate buffer formulation with 0.13% Pluronic F68 was effective in reducing the number of particles compared to higher Pluronic F68 at 0.25%. FIGs. 71A-B. Finally, at 25 μ M, Pluronic F68 at 0.13% minimized particle growth in lactate buffer formulations. Calcium chloride at concentrations of either 15 or 30 mM minimized particle growth in self-buffered formulations in the presence of PS 20. FIGs. 72A-B.

EXAMPLE 17

Effect of Calcium Chloride Concentration on the Stability of Lactate Buffer Formulations

[00652] Several adalimumab formulations (formulations 17A-17E) were prepared, as shown in Table 17.

Table 17

Ref.	Buffer/pH Adjusting Agent	CaCl ₂ (mM)	Excipient	Surfactant	pH	Ab conc. (mg/mL)	Conductivity Osmolality
17A	10 mM Lactate/HCl, Ca(OH) ₂	5	8.3% sucrose	0.03% Pluronic F68	5.11	100	1.339 mS/cm 292 mOsm
17B	10 mM Lactate/HCl, Ca(OH) ₂	10	7.8% sucrose	0.03% Pluronic F68	5.12	100	2.125 mS/cm 304 mOsm
17C	10 mM Lactate/HCl, Ca(OH) ₂	15	7.4% sucrose	0.03% Pluronic F68	5.10	100	2.792 mS/cm 304 mOsM
17D	10 mM Lactate/HCl, Ca(OH) ₂	20	6.9% sucrose	0.03% Pluronic F68	5.13	100	3.527 mS/cm 302 mOsM
17E	10 mM Lactate/HCl, Ca(OH) ₂	-- mM	8.8% sucrose	0.03% Pluronic F68	5.23	100	0.534 mS/cm 314 mOsM

[00653] To assess stability, the % acidic peak was measured by CEX-HPLC after 0 days, after transport, and after 1 week, 2 weeks and 4 weeks at 4°C, 25°C and 40°C. The results are shown in FIGs. 73-78. At time zero, the % acidic peak was similar either with or without transport stress, with only minor variability observed. After 1 month at 25°C, the rate of growth was similar in all formulations, with the level of calcium chloride in the range evaluated in this study having minor to no impact, tested in both transport stressed and non-transport stressed samples. In formulations stored at 40°C, a smaller amount of % acidic peak was observed as the level of calcium chloride increased after 1 month's storage. This trend was observed for both the transport and non-transport stressed formulations. Otherwise, transport stress did not appear to result in higher rates of degradation.

[00654] Stability also was assessed by measuring HMWS by SE-HPLC after 0 days, after transport, and after storing the non-transported and transported samples at 4°C, 25°C, or 40°C for 1, 2, and 4 weeks. The results are shown in FIGs. 79-84. At time zero, a very minor increase in HMWS was observed as the calcium chloride level increased. This is most likely not meaningful, considering assay variability. Formulations that were transport stressed did not appear to have higher HMWS than non-transport stressed formulations. After one month at 25°C and at 40°C, it is difficult to detect a correlation in formulations with a higher amount of HMWS and increasing amounts of calcium chloride. These results suggest that levels of calcium chloride in the range tested do not adversely affect stability with respect to the formation of HMWS.

[00655] Stability also was assessed by measuring the count of 5 µM, 10 µM, and 25 µM sub-visible particles by MFI in non-transported and transported samples. The particles exhibited an equivalent circular diameter of at least 5.000 and an aspect ratio of less than 0.700. The results are shown in FIGs. 85-87. In formulations tested for particle counts at ≤ 5 µm, counts appeared to spike after transport stress, however the particle counts dropped at all time points and temperature conditions thereafter. High temperature exposure (25°C, 40°C) resulted in only a modest increase in particles. There was a less apparent spike in particles ≤ 10 µm in most formulations that had been transport stressed, but the counts were also reduced at the 1 month time point at all temperatures tested. A modest particle count increase was also observed in samples stored after 1 month at 25°C and 40°C. MFI results measured for particles in the range ≤ 25 µm did not show an apparent trend, as the number of particles was low or not detected.

[00656] All publications, patents and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this disclosure that certain changes and modifications may be made thereto without departing from the spirit or scope of the disclosed embodiments.

CLAIMS

WHAT IS CLAIMED:

1. A stable aqueous formulation comprising about 180 mg/mL adalimumab, about 20 mM glutamate, and about 160 mM monoethanolamine (MEA), wherein the formulation has a pH of about 5.2, and demonstrates less than about a 2.1-fold increase in acidic species as measured by cation-exchange high-performance liquid chromatography (CEX-HPLC) after storage for 28 days at 40°C.

FIG. 1






FIG. 2



3/90

FIG. 3



4/90

FIG. 4




FIG. 5





FIG. 6



7/90

FIG. 7






FIG. 8



9/90

FIG. 9



10/90

FIG. 10





FIG. 11



12/90

FIG. 12






FIG. 13




14/90

FIG. 14




15/90

FIG. 15




16/90

FIG. 16




17/90

FIG. 17




18/90

FIG. 18



19/90

FIG. 19



20/90

FIG. 20






FIG. 21




22/90

FIG. 22




23/90

FIG. 23



24/90

FIG. 24



25/90

FIG. 25





FIG. 26



27/90

FIG. 27






FIG. 28




29/90

FIG. 29



30/90

FIG. 30



31/90

FIG. 31




FIG. 32






FIG. 33




34/90

FIG. 34




35/90

FIG. 35




36/90

FIG. 36




37/90

FIG. 37




38/90

FIG. 38




39/90

FIG. 39




40/90

FIG. 40



41/90

FIG. 41



42/90

FIG. 42






FIG. 43




44/90

FIG. 44




45/90

FIG. 45



46/90

FIG. 46



47/90

FIG. 47






FIG. 48




49/90

FIG. 49




50/90

FIG. 50




51/90

FIG. 51




52/90

FIG. 52




53/90

FIG. 53




54/90

FIG. 54




55/90

FIG. 55




56/90

FIG. 56




57/90

FIG. 57




58/90

FIG. 58




59/90

FIG. 59




60/90

FIG. 60




61/90

FIG. 61




62/90

FIG. 62




63/90

FIG. 63




64/90

FIG. 64




65/90

FIG. 65




66/90

FIG. 66




67/90

FIG. 67




68/90

FIG. 68



69/90

FIG. 69



70/90

FIG. 70A




FIG. 70B




FIG. 71A




FIG. 71B






FIG. 72A




75/90

FIG. 72B



76/90

FIG. 73



77/90

FIG. 74






FIG. 75



79/90

FIG. 76



80/90

FIG. 77




FIG. 78




FIG. 79




FIG. 80




FIG. 81




FIG. 82




FIG. 83




FIG. 84




FIG. 85






FIG. 86



90/90

FIG. 87



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/067723

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/395 A61K9/00 A61K9/08 C07K16/24
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2014/039903 A2 (COHERUS BIOSCIENCES INC [US]) 13 March 2014 (2014-03-13) the whole document	1
A	US 2015/110799 A1 (RAMASUBRAMANYAN NATARAJAN [US] ET AL) 23 April 2015 (2015-04-23) the whole document	1
A	WO 2015/177057 A1 (ARES TRADING SA [CH]) 26 November 2015 (2015-11-26) the whole document	1
A	WO 2016/128564 A1 (SANOFI SA [FR]) 18 August 2016 (2016-08-18) the whole document	1
	----- -/--	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 February 2018

Date of mailing of the international search report

22/03/2018

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Irion, Andrea

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/067723

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2016/120413 A1 (MABXIENCE S A [UY]; MABXIENCE RES S L [ES]) 4 August 2016 (2016-08-04) the whole document -----	1
A	WO 2016/103093 A1 (PFIZER [US]) 30 June 2016 (2016-06-30) the whole document -----	1
A	WO 2016/066688 A1 (RICHTER GEDEON NYRT [HU]) 6 May 2016 (2016-05-06) the whole document -----	1
A	WO 2016/162819 A1 (LUPIN LTD [IN]) 13 October 2016 (2016-10-13) the whole document -----	1
A	SEJAL GANDHI ET AL: "Elucidation of Degradants in Acidic Peak of Cation Exchange Chromatography in an IgG1 Monoclonal Antibody Formed on Long-Term Storage in a Liquid Formulation", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 29, no. 1, 16 August 2011 (2011-08-16), pages 209-224, XP019993274, ISSN: 1573-904X, DOI: 10.1007/S11095-011-0536-0 the whole document -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/067723

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2014039903	A2	13-03-2014	AR 092470 A1 22-04-2015
		AU 2013312300 A1 16-04-2015	
		CA 2884182 A1 13-03-2014	
		CL 2015000574 A1 23-10-2015	
		CN 104768576 A 08-07-2015	
		DO P2015000051 A 31-05-2015	
		EA 201590518 A1 31-05-2016	
		EP 2892550 A2 15-07-2015	
		HK 1210601 A1 29-04-2016	
		JP 2015527402 A 17-09-2015	
		KR 20150047140 A 04-05-2015	
		PE 09642015 A1 25-07-2015	
		SG 10201705668X A 30-08-2017	
		SG 11201501715Q A 28-05-2015	
		TW 201424749 A 01-07-2014	
		US 2014186361 A1 03-07-2014	
		US 2015182626 A1 02-07-2015	
		US 2015190512 A1 09-07-2015	
		US 2015190513 A1 09-07-2015	
		US 2015191538 A1 09-07-2015	
		US 2015191539 A1 09-07-2015	
		US 2016031982 A1 04-02-2016	
		US 2016039926 A1 11-02-2016	
		US 2016256545 A1 08-09-2016	
		US 2016256546 A1 08-09-2016	
		US 2016256547 A1 08-09-2016	
		US 2016263226 A1 15-09-2016	
		US 2016303233 A1 20-10-2016	
		US 2016303234 A1 20-10-2016	
		US 2016303235 A1 20-10-2016	
		US 2016304599 A1 20-10-2016	
		US 2016304600 A1 20-10-2016	
		US 2016304601 A1 20-10-2016	
		US 2017072054 A1 16-03-2017	
		US 2017312361 A1 02-11-2017	
		US 2018021433 A1 25-01-2018	
		US 2018028653 A1 01-02-2018	
		US 2018028654 A1 01-02-2018	
		US 2018028655 A1 01-02-2018	
		US 2018028656 A1 01-02-2018	
		US 2018028657 A1 01-02-2018	
		US 2018043018 A1 15-02-2018	
		US 2018043019 A1 15-02-2018	
		UY 35351 A 29-08-2014	
		WO 2014039903 A2 13-03-2014	
US 2015110799	A1	23-04-2015	US 2015110799 A1 23-04-2015
			US 2015132801 A1 14-05-2015
			US 2015140006 A1 21-05-2015
			US 2015166650 A1 18-06-2015
			US 2015259410 A1 17-09-2015
			US 2016194390 A1 07-07-2016
			US 2017158758 A1 08-06-2017
WO 2015177057	A1	26-11-2015	AU 2015263340 A1 03-11-2016
			CA 2946953 A1 26-11-2015
			CN 106456538 A 22-02-2017
			DK 2946765 T3 31-10-2016

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/067723

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		EP 2946765 A1	25-11-2015	
		EP 3050557 A1	03-08-2016	
		EP 3145487 A1	29-03-2017	
		ES 2600488 T3	09-02-2017	
		HR P20161311 T1	02-12-2016	
		HU E029849 T2	28-04-2017	
		JP 2017516846 A	22-06-2017	
		KR 20170005864 A	16-01-2017	
		LT 2946765 T	25-11-2016	
		PL 2946765 T3	31-08-2017	
		PT 2946765 T	10-11-2016	
		SG 11201608745Q A	29-11-2016	
		US 2017196974 A1	13-07-2017	
		WO 2015177057 A1	26-11-2015	

WO 2016128564	A1	18-08-2016	AU 2016217806 A1	05-10-2017
			CA 2976298 A1	18-08-2016
			CN 107635581 A	26-01-2018
			EP 3256160 A1	20-12-2017
			KR 20170117166 A	20-10-2017
			SG 11201706505P A	28-09-2017
			TW 201632203 A	16-09-2016
			US 2018008707 A1	11-01-2018
			WO 2016128564 A1	18-08-2016

WO 2016120413	A1	04-08-2016	AR 103544 A1	17-05-2017
			EP 3250598 A1	06-12-2017
			TW 201636047 A	16-10-2016
			US 2018016333 A1	18-01-2018
			UY 36542 A	31-08-2016
			WO 2016120413 A1	04-08-2016

WO 2016103093	A1	30-06-2016	CA 2916035 A1	23-06-2016
			EP 3237000 A1	01-11-2017
			JP 2016117732 A	30-06-2016
			US 2017360929 A1	21-12-2017
			WO 2016103093 A1	30-06-2016

WO 2016066688	A1	06-05-2016	CA 2989930 A1	06-05-2016
			DE 202015009016 U1	24-06-2016
			DE 202015009509 U1	18-01-2018
			EP 3212667 A1	06-09-2017
			US 2017252437 A1	07-09-2017
			WO 2016066688 A1	06-05-2016

WO 2016162819	A1	13-10-2016	NONE	
